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    Summary of the thesis 
 
Glucose has been considered the major, if not the exclusive, energy substrate for the brain. 
But under certain physiological and pathological conditions other substrates, namely 
monocarboxylates (lactate, pyruvate and ketone bodies), can contribute significantly to satisfy 
brain energy demands. These monocarboxylates need to be transported across the blood-brain 
barrier or out of astrocytes into the extracellular space and taken up into neurons. It has been 
shown that monocarboxylates are transported by a family of proton-linked transporters called 
monocarboxylate transporters (MCTs). In the central nervous system, MCT2 is the 
predominant neuronal isoform and little is known about the regulation of its expression. 
Noradrenaline (NA), insulin and IGF-1 were previously shown to enhance the expression of 
MCT2 in cultured cortical neurons via a translational mechanism. Here we demonstrate that 
the well known brain neurotrophic factor BDNF enhances MCT2 protein expression in 
cultured cortical neurons and in synaptoneurosome preparations in a time- and concentration- 
dependent manner without affecting MCT2 mRNA levels. We observed that BDNF induced 
MCT2 expression by activation of MAPK as well as PI3K/Akt/mTOR signaling pathways. 
Furthermore, we investigated the possible post-transcriptional regulation of MCT2 expression 
by a neuronal miRNA. Then, we demonstrated that BDNF enhanced MCT2 expression in the 
hippocampus in vivo, in parallel with some post-synaptic proteins such as PSD95 and AMPA 
receptor GluR2/3 subunits, and two immediate early genes Arc and Zif268 known to be 
expressed in conditions related to synaptic plasticity. In the last part, we demonstrated in vivo 
that a downregulation of hippocampal MCT2 via silencing with an appropriate lentiviral 
vector in mice caused an impairment of working memory without reference memory deficit. 
In conclusion, these results suggest that regulation of neuronal monocarboxylate transporter 
MCT2 expression could be a key event in the context of synaptic plasticity, allowing an 
adequate energy substrate supply in situations of altered synaptic efficacy. 
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   Résumé du travail de thèse 
 
Le glucose représente le substrat énergétique majeur pour le cerveau. Cependant, dans 
certaines conditions physiologiques ou pathologiques, le cerveau a la capacité d’utiliser des 
substrats énergéiques appartenant à la classe des monocarboxylates (lactate, pyruvate et corps 
cétoniques) afin de satisfaire ses besoins énergétiques. Ces monocarboxylates doivent être 
transportés à travers la barrière hématoencéphalique mais aussi hors des astrocytes vers 
l’espace extracellulaire puis re-captés par les neurones. Leur transport est assuré par une 
famillle de transporteurs aux monocarboxylates (MCTs). Dans le système nerveux central, les 
neurones expriment principalement l’isoforme MCT2 mais peu d’informations sont 
disponibles concernant la régulation de son expression. Il a été montré que la noradrénaline, 
l’insuline et l’IGF-1 induisent l’expression de MCT2 dans des cultures de neurones corticaux 
par un mécanisme traductionnel. Dans cette étude nous démontrons dans un premier temps 
que le facteur neurotrophique BDNF augmente l’expression de MCT2 à la fois dans des 
cultures de neurones corticaux et dans les préparations synaptoneurosomales selon un décours 
temporel et une gamme de concentrations propre. Aucun changement n’a été observé 
concernant les niveaux d’ARNm de MCT2. Nous avons observé que le BDNF induisait 
l’expression de MCT2 par l’activation simultanée des voies de signalisation MAPK et 
PI3K/Akt/mTOR. De plus, nous nous sommes intéressés à une potentielle régulation par les 
micro-ARNs de la synthèse de MCT2. Ensuite, nous avons démontré que le BDNF induit 
aussi l’expression de MCT2 dans l’hippocampe de la souris en parallèle avec d’autres 
protéines post-synaptiques telles que PSD95 et GluR2/3 et avec deux « immediate early 
genes » tels que Arc et Zif268 connus pour être exprimés dans des conditions de plasticité 
synaptique. Dans un dernier temps, nous avons démontré qu’une diminution d’expression de 
MCT2 induite par le biais d’un siRNA exprimé via un vecteur lentiviral dans l’hippocampe de 
souris générait des déficits de mémoire de travail sans affecter la mémoire de référence. En 
conclusion, ces résultats nous suggèrent que le transporteur aux monocarboxylates neuronal 
MCT2 serait essentiel pour l’apport énergétique du lactate pour les neurones dans des 
conditions de haute activité neuronale comme c’est le cas pendant les processus de plasticité 
synaptique. 
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Chapter 1 
 
Introduction 
 
 
 
The brain is a complex organ which is composed of around 100 billions of cells. The two 
principal cell types found in the brain are neurons and glial cells. Neurons are highly 
polarized cells and specialized for information transmission. They are interconnected by 
synapses. Among glial cells, astrocytes which are up to five times more numerous than 
neurons (in certain human brain areas) constitute half of the brain volume and are involved in 
many functions such as synthesis of neuroactive substances, neurotransmitter recycling, 
synaptic activity modulation, immune roles and trophic as well as energetic support.  
 
This thesis work focused on the regulation of one particular transporter in neurons under 
conditions purported to reflect synaptic plasticity. This neuronal transporter, called MCT2 
(monocarboxylate transporter 2) is involved in the transport of monocarboxylates such as 
lactate, principally produced by astrocytes from glucose and proposed to be a major energy 
substrate for active neurons.  
 
In this context, it is essential to describe the processes involved in cerebral energetic 
metabolism, as well as the specific roles of the monocarboxylate transporter family and their 
regulations at the cellular level to understand the potential role of MCT2 in synaptic plasticity.  
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1.1  Brain energy metabolism: an overview 
 
1.1.1 Glucose metabolism in the brain 
 
For more than 50 years, glucose has been considered as the major energetic substrate for the 
brain (McIlwain, 1956). Sokoloff and colleagues have shown that the adult brain consumes 
around 50% of the oxygen and 10% of the glucose provided via blood vessels, corresponding 
respectively to 20% and 25% of the organism total consumption (Sokoloff, 1960). Glucose 
transport takes place across the BBB via specific transporters expressed by endothelial cells 
forming capillaries (GLUT1 55KDa), as well as on cerebral cells like astrocytes (GLUT1 
45kDa) and neurons (GLUT3) (Maher et al., 1994). After entry into the brain, glucose is 
almost completely oxidized to CO2 and H2O via glycolysis and the TCA cycle (Review 
Magistretti, 1999). 
Glycolysis is the energy producing process by which intracellular glucose is metabolized to 
pyruvate, resulting in the net formation of two ATP molecules per glucose. Glycolysis 
account only for a minor part of the ATPs produced from glucose. The largest amount is 
produced by the mitochondrial oxidative phosphorylation cascade which oxidizes pyruvate 
into CO2 and H2O and leads to the production of about 30 molecules of ATP per molecule of 
glucose. Because of its higher ATP yield, oxidative phosphorylation represents the source of 
most of the energy needed for neuronal signalling (Raichle and Mintum 2006). Nevertheless, 
glycolysis has advantages when energetics needs to be increased rapidly: it is independent of 
oxygen and can produce cytosolic ATP faster than oxidative phosphorylation. In such case 
however, pyruvate must be converted into lactate to generate NAD+ and maintain glycolysis 
rate, leading to transient lactate accumulation (Raichle and Mintun 2006). Even if glycolysis 
produces far less energy than oxidative phosphorylation, it can be of strategic importance in 
particular circumstances as we will see below. 
 
Apart from ATP, another form of energy which is important for cerebral function is carried by 
nicotinamide adenine dinucleotide phosphate (NADPH). NADPH represents a source of 
reducing equivalents and is produced predominantly by the processing of glucose through the 
pentose phosphate pathway. Metabolic energy in the form of reducing equivalents is required 
for biosynthetic reactions in which the precursors are in a more oxidized state than the 
products (e.g. the reductive synthesis of fatty acids from acetyl-CoA which are components of 
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myelin and of neural cell plasma membranes) as well as for scavenging of reactive oxygen 
species (ROS) which are highly damaging to cells (Magistretti 2003). 
 
1.1.2 Energy consuming processes in the brain 
 
The cerebral processes consuming the major part of the energy are the maintenance and the 
regeneration of the ionic gradient across the plasma membrane. In particular for Na+ and K+ 
which are important for neuronal excitability. These gradients are predominantly maintained 
by the Na+/K+-ATPase which is located in both neurons and astrocytes and is fuelled by ATP. 
It was demonstrated that these pumps account for about 50% of basal glucose oxidation in the 
nervous system (Erecinska and Dagani 1990). The contribution of different energy consuming 
processes in the rodent brain (grey matter) has been estimated and reviewed by Attwell and 
Laughlin (Attwell and Laughlin, 2001).  
 
In this review, they simplified the model by treating all neurons as glutamatergic because 
excitatory neurons are the major class of neurons in the brain and 90% of synapses release 
glutamate. According to this study, it exists a definite hierarchy of energy usage devoted to 
signalling. Brain grey matter has an energy usage of 33 to 50 µmol of ATP/g/min when 
considering the neocortex whereas the energy usage of the whole brain is on average of 21 
µmol of ATP/g/min. This phenomenon could be explained by the high signalling-related 
energy demand in grey matter. Attwell and Laughlin have predicted that the most energy 
demanding processes were both action potentials and postsynaptic potentials that represent 
47% and 34% of brain energy expenditures respectively. However recently these values have 
been revisited by Alle and colleagues (reviewed by Magistretti 2009). Indeed, the excitatory 
postsynaptic potentials mediated by glutamate involve six times more charge transfert than 
that underlying action potentials (96 versus 15pC, respectively) (Alle et al., 2009). 
Maintenance of resting potentials in both neurons and glial cells (13%) represents a smaller 
fraction of energy expenses. Presynaptic calcium entry and neurotransmitter recycling (3% 
each) account for even less. It is noteworthy that, apart from signalling mechanisms, protein 
synthesis consumes only 2% of the rat brain’s total ATP consumption. Similarly, the turnover 
of oligonucleotides and lipids represents approximately 5% of the total rate for the whole 
brain (Attwell and Laughlin 2001). It is interesting also to note that earlier reports based on 
heat production considered action potentials as a very poor energy consuming process (0.3 to 
3%) (Creutzfeldt 1975). 
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Concerning human brain energy consumption, there are still very few data but some studies 
based upon positron emission tomography (PET) and nuclear magnetic resonance (NMR) 
spectroscopy are attempting to fill in the gap. These techniques permit to monitor alterations 
in glucose utilization and metabolism, oxygen consumption and blood flow during activation 
of specific brain areas. Positron emission tomography (PET) can measure blood flow, oxygen 
consumption and glucose use associated with neuronal activity; the degree of blood 
oxygenation is currently thought to contribute to the signal detected with functional magnetic 
resonance imaging, while magnetic resonance spectroscopy (MRS) identifies the spatio-
temporal pattern of the activity-dependent appearance of certain metabolic intermediates such 
as glucose or lactate (Magistretti and Pellerin, 1999). Energy expenditures in human brain are 
similar than those from rodent brain. Indeed, several studies using magnetic resonance 
spectroscopy measurements in a variety of experimental settings have shown that the resting 
brain accounts for up to 80% of the total energy consumption to support events associated 
with neuronal activity (energetic consequences of electrical activity associated with cycling of 
neurotransmitters glutamate and GABA) (Shulman et al., 2004). 
 
 
1.1.3 Brain energy metabolism at the cellular level: The neuron-astrocyte-capillary 
metabolic unit 
 
At the cellular level, there are three main partners concerned about brain energy metabolism: 
The neurons, the astrocytes and the vascular endothelial cells forming capillaries. It is well 
established that neurons represent, at most, 50% of the cerebral cortical volume and that a 
ratio of ~ 5-10 astrocytes for 1 neuron is a feature of some brain regions (Tsacopoulos and 
Magistretti 1996). Astrocytes are particularly well situated to actively participate in the 
distribution of energy substrates from blood circulation to neurons. Astrocytes are polarized 
cells with one process contacting the endothelial cells forming capillaries and many processes 
contacting neurons. Indeed, astrocytes are stellate cells composed of multiple specialized 
processes, like those that surround brain capillaries called endfeet (Kacem et al., 1998). Thus, 
astrocytes are ideally positioned to provide coupling between neuronal activity and glucose 
uptake, even more so as the specific 45kDa glucose transporter GLUT1 is abundantly 
expressed on endfeet (Morgello et al.,1995). This cytoarchitectural arrangement implies that 
astrocytes form the first cellular barrier that glucose entering the brain parenchyma 
encounters, and it makes astrocytes a likely site of primary glucose uptake (Figure1.1) 
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Figure1.1. Schematic representation of the organization and cooperation between neurons, astrocytes and blood vessels 
(taken from Kuffler and Nicholl; “neuron to brain; A cellular approach to the function of the nervous system”, 1976). 
 
 
In addition to perivascular endfeet, other astrocyte processes are wrapped around synaptic 
contacts. At these sites, astrocyte processes possess receptor and reuptake sites for a variety of 
neurotransmitters (e.g. glutamate) (Magistretti and Pellerin 1999). Another important feature 
of astrocytes is that they form an extensive network interconnected by gap junctions 
(Benarroch 2005). The astrocytic gap junctions are permeable to small molecules and permit 
cell-cell communication, allowing astrocytes to form a functional syncytium through which 
energy metabolites, among others, can circulate (Benarroch 2005) (Figure1.2). 
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Figure1.2. Metabolic polarity of the astrocytic syncytium. Astrocytes have various processes that make contact either with 
capillaries, neuronal perikaryon, or synapses. In addition, they are connected with each other at gap junctions; through these 
junctions small molecules (MW < 1000) can be exchanged. These properties endow the astrocytic syncytium with the 
capacity to ensure the transfer of metabolic intermediates from areas of production to areas of demand. Glu, Glutamate; Gln, 
glutamine. (Picture from Magristretti et al., 1995) 
 
 
 
The aforementioned characteristics are of critical importance for astrocytes to exert their main 
functions. These include the removal of excess glutamate and potassium from the synaptic 
cleft upon neuronal stimulation and to provide neurons with metabolic support (Magistretti 
and Pellerin 1996). Astrocytes also possess the largest energy reserve of the brain in the form 
of glycogen. Glycogen has been considered as a metabolic buffer during physiological 
activity and its turnover as well as overall levels seem tightly coordinated with synaptic 
activity (Hevor 1994; Magistretti 2003). Altogether, these features suggest that astrocytes play 
a key role in regulating the distribution of energy substrates from their site of entry in the 
brain parenchyma (the capillaries) to their site of utilization (active synapses). 
 
 
1.2  Monocarboxylates in the CNS 
 
During adulthood, in normal conditions, the entry of energetic substrates other than glucose is 
low (Stone 1938; Klein and Olsen, 1947; McIlwain, 1953). However, glucose can be partially 
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substituted by other metabolic intermediates under particular conditions such as starvation 
(hypoglycaemia), diabetes or breast-feeding in neonates. Indeed, it was shown that these 
particular conditions lead to increased plasmatic levels of the ketone bodies acetoacetate and 
D-3-hydroxybutyrate which can be used as metabolic substrates by the brain (Sokoloff 1989) 
(Figure1.3). Lactate and pyruvate are also possible energetic substrates for the developing and 
adult brain and can sustain synaptic activity in vitro (McIlwain and Bachelard, 1985; Schurr et 
al., 1988). Ketone bodies, lactate and pyruvate are molecules belonging to the 
monocarboxylate group which are charaterized by the presence of only one carboxyl group (-
COOH) in their structure (Figure1.4). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Oxidative metabolism of glucose and other substrates in brain cells. LDH: lactate dehydrogenase (Picture adapted 
from Brain energy metabolism course, Prof. Luc Pellerin, University of Lausanne, 2006) 
 
 
 
 
 
 
 
 
 
Figure1.4 Chemical structures of the main 
monocarboxylates: pyruvate, L lactate, 
acetoacetate and D-hydroxybutyrate. 
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 1.2.1 Perinatal utilization of monocarboxylates 
 
Birth is a period of dramatic changes in body nutrient utilization.  During gestation, the foetus 
is continuously supplied with substrates coming from the placental circulation. This stable 
situation changes with birth which imposes changes in metabolic environment to the 
newborn. Studies in the rat showed that the very early neonatal period is always associated 
with profound hypoglycemia. Indeed, glucose levels are usually between 2.5 and 3.5mM at 
birth and drop to approximately 1mM at one hour of postnatal life. This low glucose level is 
accompanied by a low concentration of ketone bodies (around 0.2-0.4mM). Immediately after 
birth, the principal source of energy for the newborn brain becomes lactate which is present at 
high concentrations in the blood during the presuckling period (Dombrowski et al., 1989; 
Vicario et al., 1991). However, the majority of this pool of lactate is consumed during the first 
two hours after birth, just before the onset of suckling. 
 
It is well known that during the normal development of both human and rodent brain, there is 
a switch in fuel utilization from a combination of glucose, lactate, and ketone bodies (beta-
hydroxybutyrate and acetoacetate) in the immature brain to a total reliance on glucose in the 
adult (Cremer 1982; Nehlig 1997). With the onset of suckling and the ingestion of the high-fat 
milk diet, rat pups become hyperketonemic and remain so during the suckling period (Nehlig 
and Pereira de Vasconcelos, 1993). Whereas cerebral glucose utilization is relatively low in 
the newborn rat brain (Nehlig et al., 1988; Vannucci et al., 1994), rates of beta-
hydroxybutyrate uptake and utilization actually peak during the second and third postnatal 
weeks before declining to low adult levels after weaning (Cremer et al., 1982; Hawkins et al., 
1986; Nehlig et al., 1991). In the rat pup, these two ketone bodies (beta-hydroxybutyrate and 
acetoacetate) are formed by hepatic oxidation in the liver of fat contained in maternal milk 
(Hawkins et al., 1971; Cremer 1982) before to be used as significant sources of energy. The 
high fat content of both human milk and rodent milk generates circulating ketone body 
concentrations sufficient to contribute to the energetic and synthetic needs of early cerebral 
maturation (Edmond et al., 1985; Nehlig 1997; Nehlig and Pereira de Vasconcelos 1993). 
 
It was shown that ketone bodies can account for at least 30% of the total energy metabolism 
balance in suckling rats (Cremer 1982). However, lactate, beta-hydroxybutyrate and 
acetoacetate do not cross the BBB easily and require a transport system to reach the brain 
parenchyma. It was demonstrated that these monocarboxylates share a common transport 
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system: the monocarboxylate transporters (MCTs) (Cremer et al., 1979; Cremer et al., 1982; 
Pellerin et al., 1998a). Then, during the suckling period, the MCTs as well as the enzymes for 
ketone body utilization are up-regulated and permit the effective utilization of these 
alternative substrates by the brain (Pellerin et al. 1998b). There is a 7-fold increase in cerebral 
beta-hydroxybutyrate permeability during the suckling period and an equivalent decrease after 
the weaning period (Nehlig 2004). At the end of the suckling period, the high level of ketone 
bodies in blood tends to decrease and the rate of cerebral glucose utilization concomitantly 
increases (Hawkins et al., 1971). It was demonstrated that in the 15 days old rat, glucose 
become the predominant energy substrate (57%) and the beta-hydroxybutyrate and lactate 
represent respectively 20 and 23% of the total energy supply of the brain. 
 
1.2.2 Adult brain utilization of monocarboxylates 
 
Under specific conditions, monocarboxylates can be used as alternative substrates for adult 
brain energy metabolism (Sokoloff 1989). For example under starvation, diabetes, 
hypoglycaemia or intense exercise. All of these situations lead to an increase of ketone bodies 
acetoacetate and D-3-hydroxybutyrate or lactate in the plasma, all used by the brain as 
metabolic substrates (Sokoloff 1989). Owen and colleagues (Owen et al. 1967) showed that 
beta-hydroxybutyrate and acetoacetate replace glucose as brain’s primary fuel during 
starvation in obese patients. Similarly, it was shown by quantitative autoradiography that the 
brain of starved and diabetic rats increase their capacity to use ketone bodies by up to 50%-
60% in such conditions (Hawkins et al.,1986). In the rat under hypoglycemia, cerebral uptake 
of beta-hydroxybutyrate was shown to be greatly increased as well as the transport capacity of 
ketone bodies through the BBB (Ghajar et al., 1982; Nehlig 1997). In human adults, during 
cardiopulmonary resuscitation, arteriovenous differences indicate that lactate is consumed by 
the brain (Rivers et al., 1991). The same results were observed during exercice in human brain 
(Ide et al., 1999; Ide et al., 2000; Dalsgaard 2006 ; Dalsgaard and Secher 2007). In the mouse, 
lactate injection was shown to reduce cerebral glucose utilization, to induce an increase in 
lactate uptake from plasma and an increase in brain oxidation under insulin-induced 
hypoglycemia or acute stress conditions (Thurston et al., 1983; Thursten and Hauhart 1989). 
Measurements made using microdialysis or lactate-sensitive microelectrodes have shown that 
lactate utilization is enhanced upon electrical or behavioural activation (Fellows et al., 1993; 
Hu and Wilson 1997), or following brief hypoxic episodes in the rats (Jones et al., 2000). 
Thanks to NMR spectroscopy, it was further demonstrated that lactate is efficiently 
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metabolized by the brain. A (13C)MR spectroscopy study using intravenous injection of 
radiolabelled lactate permitted to confirm in the rat that lactate crosses the BBB and is 
metabolized in the brain, in a manner analogous to glucose (Qu et al., 2000). Moreover, these 
studies demonstrated that lactate is prominently metabolized in neurons (Bouzier et al., 2000; 
Hassel and Brathe 2000; Qu et al., 2000).  
 
In parallel, in human, PET has permitted to monitor alterations in glucose utilization, oxygen 
consumption and blood flow during the activation of specific brain area. By this technique, 
Fox and Raichle observed an uncoupling between oxygen consumption on one hand and 
glucose use or blood flow changes on the other in the visual cortex of human subjects during 
intense visual stimulation (Figure1.5) (Fox and Raichle 1986; Fox et al., 1988). Indeed, they 
observed a 30 to 40% increase in glucose utilization whereas oxygen consumption only 
increased by 6%, indicating that the additional glucose utilized during neuronal activation is 
processed primarily through glycolysis rather than through the TCA cycle (mitochondrial 
tricarboxylic acid cycle). In this case, if glucose is processed through glycolysis and does not 
enter the TCA cycle, lactate will be produced and at least accumulate transiently into the 
brain. 
  
 
Figure 1.5.  Stimulation of the human visual cortex with a reversing annular checkerboard when compared with a simple 
fixation crosshair (a) produces dramatic increases in blood flow and glucose use in the visual cortex that are unaccompanied 
by similar increases in oxygen use (b). The result is an increase in the local oxygen availability (b) because the increased 
supply of oxygen by flowing blood exceeds the increased local demand for oxygen. (picture taken from Raichle and Mintun 
2006). 
 
 
 20 
To confirm this hypothesis, studies using MRS technique were performed. For instance, MRS 
in humans has revealed that a transient lactate peak is observed in the primary visual cortex 
during physiological activation of the visual system (Prichard et al., 1991). In addition, 
Mintun and colleagues have shown an increase of the lactate/pyruvate ratio in parallel with 
blood flow in physiologically activated human brain using a combination of PET and 
functional MRI (Mintun et al., 2004). These observations support the view that during 
activation, some brain cells may transiently resort to aerobic glycolysis while others may use 
lactate as preferential oxidative substrate (Magistretti and Pellerin 1999; Schurr 2006; Smith 
D, 2003; Wyss et al., 2011). 
 
  1.2.3 Monocarboxylate utilization at the cellular level 
 
A) Lactate: another neuronal substrate? 
 
The idea that lactate could be a satisfactory alternative substrate for the brain did not easily 
gain success as it was considered that substrates other than glucose do not readily enter the 
brain (Stone 1938; Klein 1947; McIlwain 1953). Several studies have appeared confirming 
that lactate was efficiently oxidized to CO2 by brain tissue and particularly by neurons. 
Indeed, lactate oxidation rate equals or is even greater than glucose utilization and it reduced 
glucose oxidation to CO2 in such in vitro preparations including cultured neurons (Vicario et 
al.,1991; Tabernero et al., 1996; McKenna et al.,2001), synaptoneurosomal preparation 
(McKenna et al.,1993; 1994; 1998) and brain slices (Ide et al.,1969; Fernandez and Medina 
1986). In addition, lactate was shown to be able to fully substitute for glucose in order to 
maintain respiration rate of cultured cortical neurons as measured by mitochondrial 
dehydrogenase activity (Pellerin et al.,1998a). Other evidences were provided  from some 
structures associated with the peripheral nervous system further suggesting lactate utilization 
by brain cells. Indeed, lactate conversion to CO2 was shown to be more rapid than glucose 
oxidation to CO2 in the vagus nerve (Vega et al.,1998). Then it was shown that lactate is a 
better energy substrate than glucose for photoreceptors in the retina (Poitry-Yamate et 
al.,1995) and that lactate was extensively oxidized to CO2 in the chick sympathetic ganglia 
(Larrabee 1996).  Further evidence that lactate is a prominent energy substrate in neurons has 
been provided ultimately by Zielke et al., showing that lactate was readily oxidized by brain 
cells in vivo including neurons (Zielke et al., 2007). 
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Another confirmation that lactate was efficiently metabolized by neurons, was made with 
Nuclear Magnetic Resonance Spectroscopy (NMR). Thanks to its application to biology, 
some studies on cultured glutamatergic and GABAergic neurons have shown that lactate was 
metabolized through the TCA cycle in both, leading to labeling of TCA cycle intermediates as 
well as several amino acids derived from these (Schousboe et al.,1997; Waagepetersen et al., 
2000). From these studies, lactate can be considered equivalent to glucose considering its 
accessibility to the TCA cycle (Waagepetersen et al., 1998a). Note that lactate could serve as 
a precursor for the synthesis of the neurotransmitters GABA, glutamate and aspartate 
(Waagepetersen et al., 1998b). In a recent report, Boumezbeur et al. (2010) demonstrated 
using intravenous infusions of 13C-lactate, combined with in vivo 13C magnetic resonance 
spectroscopy (MRS), that neurons metabolized 80% of the radiolabeled lactate, i.e., 
approximately four times more than glial cells in human brain (Boumezbeur et al., 2010; 
Figley 2011). Furthermore, in presence of both glucose and lactate, as it is the case 
physiologically, it was shown that lactate is largely preferred as an oxidative energy substrate 
over glucose by neurons (Itoh et al., 2003; Bouzier-Sore et al., 2003; 2006). Taken together, 
evidences suggest that lactate can be used by neurons as another efficient energetic substrate 
in addition to glucose. 
 
 
B) Functional evidence for the role of lactate as supplementary substrate 
for neurons 
 
The pioneering work conducted by McIlwain revealed that brain tissue is able to efficiently 
utilize monocarboxylates (such as lactate) as alternative energy substrates. Indeed, it was 
demonstrated that lactate could sustain electrical activity of the nervous tissue (McIlwain 
1953) and could maintain synaptic activity in hippocampal slices (Schurr et al., 1988). Several 
studies demonstrated that lactate was not only neuroprotective and preserved morphological 
integrity of tissue upon glucose deprivation but was also able to maintain synaptic function 
and allowed the induction of long-term potentiation (Fowler 1993; Izumi et al., 1994; 1997a; 
1997b; Schurr et al.,1999a; Cater et al.,2001). Other studies showed that lactate, not glucose, 
was a necessary substrate for neurons following recovery from an hypoxic episode in 
hippocampal slices (Schurr et al., 1997a,b,c), supporting its neuroprotective effect. 
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However, these results must be moderated as some other studies had previously found that 
evoked granule cell field potentials were only partially preserved when glucose was replaced 
by lactate (Cox and Bachelard 1988). In contrast to the results of Schurr (Schurr et al.,1999a), 
it was reported that lactate was unable to sustain NMDA activation and maintain K+ 
homeostasis in absence of glucose (Chih et al.,2001). In addition, long-term potentiation as 
evidenced by the enhancement of population spike was reduced following glucose 
replacement by lactate. More recent results showing that neuronal activity was diminished in 
presence of lactate were obtained by the analysis of 14C-labelled energy substrate oxidation 
using young adult organotypic slice cultures (Gilber and Bergold, 2005). In contrast, a recent 
study in neonatal hippocampal slices shows that lactate effectively covers energy demands 
during neuronal network activity (Ivanov et al., 2011). But quite importantly, this last study 
points out to a possible caveat in previous studies on hippocampal slices that were not able to 
show the capacity of lactate to sustain neuonal activity. In fact, slices oxygenation seems to 
play a critical role in the capacity of lactate to sustain neuronal network activity. Thus, despite 
some divergent results that might find a technical explanation, it seems that most studies on 
hippocampal slices have highlighted the fact that lactate not only allows to maintain energy 
status of the tissue as well as insure survival of brain cells, but it can also sustain neuronal 
activity.  
 
In addition to studies on hippocampal slices mentioned before, several studies suggest that 
lactate could support neuronal functions. It is the case in the rat optic nerve where it was 
shown that the evoked compound action potential can be fully supported when replacing 
glucose by lactate (Brown et al., 2001). More recently, Bliss and colleagues demonstrated that 
overexpression of MCT2 in hippocampal neuron cultures increased lactate utilization 
following glutamate treatment and significantly decreased the neurotoxicity of glutamate 
(Bliss et al., 2004). In cultured cortical neurons, lactate was shown to be equivalent to glucose 
for sustaining synaptic vesicle turnover during activity (Morgenthaler et al., 2006). Moreover, 
a study of Aubert et al., based on a mathematical model of brain lactate kinetics, showed that 
the kinetic properties of monocarboxylate transporter isoforms strongly suggest that neurons 
represent the most likely compartment for activation-induced lactate uptake. They also 
demonstrated that neuronal lactate utilization occurring early after activation onset is 
responsible for the initial dip in brain lactate levels observed in both animals and humans 
(Aubert et al., 2005). Using measurable levels and kinetic properties of GLUT (Glucose 
transporter) of capillary endothelial cells, astrocytes, and neurons, along with corresponding 
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kinetic properties of the MCTs, Simpson and colleagues have successfully modeled brain 
glucose and lactate levels as well as lactate transients in response to neuronal stimulation 
(Reviewed by Simpson et al., 2007). However, their conclusions were apparently at odds with 
the idea of lactate transfer from astrocytes to neurons. In contrast, more recent studies using 
distinct mathematical approaches and based on in vitro and in vivo data strongly support the 
idea of a neuron-glia compartmentalization in energy metabolism (Aubert and Costalat 2007, 
Aubert et al., 2007, Jolivet et al., 2009, 2010). Authors have shown that a significant part of 
glucose is taken up by astrocytes while oxygen is mostly consumed within the neuronal 
population. They found that this bias tends to increase with the level of activation (Jolivet et 
al., 2009). These results rather support the view of an activity-related transfer of glucose-
derived metabolites from astrocytes to neurons.  
          
   C) The astrocyte - neuron lactate shuttle 
 
Walz and Mukerji were the first to demonstrate the capacity of astrocytes to produce large 
amounts of lactate (Walz and Mukerji 1988a,b). Few years later, some reports independently 
proposed that astrocytes might export lactate as energy substrate for neurons. Two of them 
suggested that lactate, as a consequence of glycogen breakdown, would be transferred to 
neurons (Dringen et al., 1993a,b; Magistretti et al.,1993), while a third one simply proposed 
an exchange between the two cell types based upon their difference in lactate formation vs 
oxidation (McKenna et al.,1993). Indeed, it was later shown that astrocytic glycogen provide 
a source of lactate to support axonal function during intense stimulation (Shulman et al., 
2001; Brown et al., 2003; 2004; 2005) and during glucose deprivation (Wender et al.,2000). 
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Figure 1.6. Schematic of the mechanism for glutamate-induced glycolysis in astrocytes during physiological activation (taken 
from Pellerin and Magistretti 1994). 
 
 
Based on a series of in vitro experiments, Pellerin and Magistretti proposed an original model 
to explain the coupling between synaptic activity and glucose utilization (Pellerin and 
Magistretti 1994) (Figure1.6). They challenged the conventional scheme of brain energetics 
which states that neuronal energy metabolism is fuelled by glucose oxidation and introduced 
the astrocyte-neuron lactate shuttle hypothesis (ANLSH) (Figure1.6) (Pellerin and Magistretti 
1994; 2003a; Magistretti et al., 1999; Bouzier-Sore et al., 2002; Pellerin 2003, 2007, 2008).  
 
In this model, glutamate that is released as a neurotransmitter by neurons is primarily taken up 
into astrocytes via specific sodium-dependent transporters: glutamate aspartate transporter 
(GLAST) and glutamate transporter 1 (GLT1) (Danbolt et al., 1998; Gegelashvili and 
Schousboe 1998). These transporters carry one glutamate, three Na+, and one H+ inward while 
one K+ is moved out of the cell. Thus, the simultaneous entry of glutamate and sodium 
increases the intracellular concentration of sodium as measured by cellular imaging (Chatton 
et al., 2000). As a consequence of raised intracellular Na+ concentration, Na+/K+ ATPase 
activity will increase to restore ionic balance, while glutamine synthesis from glutamate will 
take place at the expense of two ATPs per glutamate, leading to enhanced glucose utilization 
and lactate production (Pellerin and Magistretti 1997; Pellerin et al., 2007; Pellerin and 
Magistretti 1994). Interestingly, it was shown that a stimulation of the glutamate transporter 
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GLAST in cultured astrocytes causes a translocation of the Na+/K+ ATPase gamma subunit to 
the plasma membrane that modulates the activity of the Na+/K+ ATPase (Gegelashvili et al., 
2007; Rose et al., 2009). It was also shown that the α2 subunit of Na+/K+ ATPase is 
responsible for enhanced glycolysis induced by glutamate via its uptake by specific 
transporters (Pellerin and Magistretti 1997). Further observations at the electron microscopic 
levels have indicated that the subunit of the α2 Na+/K+ ATPase colocalized with glial 
glutamate transporters in thin astrocytic processes surrounding glutamatergic synapses 
(Cholet et al., 2002). Some studies showed a decreased metabolic response to synaptic 
activation (i.e. enhancement of glucose uptake) in both GLAST and GLT1 deficient mice 
compared to wildtype mice (Voutsinos-Porche et al., 2003, Cholet et al., 2001; Herard et al., 
2005). The implication of glial glutamate transporters in this metabolic response was further 
demonstrated in vivo by monitoring lactate production using microdialysis. Indeed, lactate 
production was measured during specific behavioural task and was prevented by use of 
glutamate transporter inhibitors (Fray et al., 1996; Demestre et al., 1997, Uehara et al., 2007). 
Taken together, these data show that glutamate stimulates aerobic glycolysis in astrocyte, i.e. 
glucose transport and glucose utilization and lactate production in presence of oxygen. This 
observation was also confirmed by others (Takahashi et al., 1995; Keller et al., 1996; Hamai 
et al., 1999; Loaiza et al., 2003; Porras et al., 2004, 2008; Bittner et al., 2010).  
 
In the ANLSH, much of the fuel for increased energy demands of neurons is supplied by 
lactate from surrounding astrocytes. As a result, metabolism of astrocytes is largely glycolytic 
while that of neurons is largely oxidative. This concept is supported by numerous studies. 
First, a transcriptome analysis carried out on both astrocytes and neurons isolated from the 
brain of adult animals confirmed the fact that astrocytes have a prominent expression of 
glycolytic enzymes as compared with neurons (Lovatt et al., 2007; Rossner et al., 2006; 
Cahoy et al., 2008). In addition, a differential expression of the two lactate dehydrogenase 
(LDH) isoforms was found between astrocytes and neurons (Bittar et al., 1996; Laughton et 
al., 2007; Pellerin et al., 2005; O’Brien et al., 2007). Moreover, glycolytic activity is more 
important in astrocytes than in neurons (Itoh et al., 2003; Bouzier-Sore et al., 2006) even if 
neurons do exhibit glycolytic activity (Bittner et al., 2010).  
 
The idea of a metabolic compartmentalization between astrocyte and neurons was further 
supported by an important finding from Ramos and colleagues. They demonstrated that 
astrocytes lack an important component in mitochondria for the recycling of NADH to NAD 
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(Ramos et al., 2003; Xu et al., 2007). In order to maintain the glycolytic rate, the cofactor 
nicotinamide adenine dinucleotide (NAD) must be regenerated.  This could be done in 
mitochondria, involving the malate / aspartate shuttle. In astrocyte mitochondria, it was 
recently found that the activity of this shuttle was low, showing a weak activity of aspartate / 
glutamate transporter (Berkich et al., 2007). In astrocytes, the regeneration of NAD and 
maintenance of high glycolytic activity can thus be obtained predominantly by conversion of 
pyruvate into lactate by the LDH.  
 
By the use of a method combining immunocytochemistry with high-resolution 
microautoradiography, Nehlig and colleagues established in vivo that half of all glucose 
utilization occurs in astrocytes under resting conditions (Nehlig et al., 2004). Furthermore, 
using a different technique in cerebellar slices, it was recently shown a more important 
glucose utilization in Bergmann glial cells than in neighboring neurons (Barros et al., 2009). 
Finally, a critical demonstration of the preferential glucose utilization by astrocytes following 
synaptic activation was recently provided in vivo (Chuquet et al., 2010). It was shown that 
whisker stimulation leads to enhanced glucose utilization in astrocytes of the somatosensory 
cortex as revealed by accumulation of the fluorescent deoxyglucose analog 6-NBDG with 
relatively little changes in neighboring neurons (Chuquet et al., 2010). These observations 
complement the previous demonstration that astrocytes have a prominent glycolytic activity 
while neurons are more oxidative. 
 
The ANLSH has also been proposed for other support cell-neuron energetic interactions such 
as those between Schwann cells and peripheral neurons (Vega et al., 1998), as well as in the 
retina between Müller glial cells and photoreceptors (Poitry-Yamate et al., 1995; Poitry et al., 
2000). Xu and colleagues showed even an absence of the aspartate / glutamate carrier in the 
retina Müller cells, supporting the idea of a compartmentalized metabolism between Müller 
cells and photoreceptors (Xu et al., 2007). Thus, as astrocytes exhibit the same type of 
metabolic characteristics as Müller cells, it reinforces the view that a process such as the 
ANLS probably exists in various brain regions. 
 
In conclusion, many studies confirmed that monocarboxylates such as lactate can at least 
partially substitute for glucose. However, these energy substrates do not cross easily the BBB 
as well as other cell membranes, and thus require a transport system. Indeed, it has been 
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shown that monocarboxylates are transported by a family of proton-linked transporters called 
monocarboxylate transporters (MCTs). 
 
1.3  The monocarboxylate transporter (MCTs) family: identification, functional 
characteristics and distribution  
 
Lactate plays an important role in metabolism, not only in cerebral metabolism but also in 
most cells. It is produced by cells which have an important glycolytic metabolism, generating 
two molecules of lactate for one molecule of glucose consumed. Lactate must be exported to 
maintain the glycolytic rate and an adequate cytosolic pH. Other cells use lactate as an 
oxidative or a gluconeogenic (liver) substrate. The transport of L-lactate across plasma 
membranes is of considerable importance to almost all mammalian cells. In most cells, a 
specific H+-monocarboxylate cotransporter is largely responsible for this process. In order to 
support the high rate of production or utilization of L-lactate, the capacity of this carrier must 
be very high. Evidence for a family of monocarboxylate transporters came initially from 
kinetic studies of lactate transport in various tissues (Poole and Halestrap 1993) and has been 
confirmed by the cloning and expression of the first two MCT isoforms, namely, MCT1 and 
MCT2. L-lactate is the monocarboxylate which has the highest transport rate across 
membranes, but MCTs are also essential for the transport of pyruvate, as well as ketone 
bodies such as acetoacetate and beta-hydroxybutyrate. Monocarboxylate transporters have 
been studied in a variety of cell preparations, e.g. erythrocytes, hepatocytes, tumour cells, 
cardiac myocytes, skeletal muscle cells, as well as in brain astrocytes and neurons. 
 
Up to now, the monocarboxylate transporter family (part of the solute carrier SLC16 gene 
family) is composed of 14 members based on sequence homologies, identified as MCT1-9, 
MCT11-14 and T-Type amino-acid transporter-1 (TAT1) (Halestrap and Meredith 2004). 
Other proteins called sMCT1 (SLC5A8) and sMCT2 have been identified as sodium-coupled 
MCT transporter (Ganapathy et al., 2005; Martin et al., 2006; Scrinivas et al., 2005). Among 
the SLC16 family of monocarboxylate transporters, only four MCTs (MCT1-4) have been 
functionally characterized. Each isoform possesses unique biochemical properties such as 
kinetic constants and sensitivity to known MCT inhibitors. In addition, MCT expression is 
tissue-specific (Reviewed by Pierre and Pellerin, 2005) (table 1.1; Figure1.7; Figure 1.8)  
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Figure 1.7. MCT2 expression in cultured astrocytes and neurons. A) Double immunolabelling of primary cultures of mouse 
cortical astrocytes after 14 days in vitro with antibodies directed against MCT2 (green) and GFAP (red). B) Double 
immunolabelling of primary cultures of mouse cortical neurons after 7 days in vitro with antibodies against MCT2 (green) 
and microtubule-associated protein 2 (MAP2) (red). (Picture from Pierre K and Pellerin L, unpublished) 
 
 
 
One difficulty in the characterization of monocarboxylate transport in cultured cells is the 
simultaneous expression of multiple isoforms with very similar substrate specificity. 
Moreover, several changes in MCT expression may be evoked by modifying physiological 
conditions. The molecular mechanisms underlying the regulation of MCTs are poorly 
understood and remain to be clarified. In the past few years, our lab has studied 
monocarboxylate transporter expression in the brain, notably for MCT1, MCT2 and MCT4 
(see point 1.3.2). 
MCT2GFAP GFAP & MCT2
MCT2MAP2 MAP2 & MCT2
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Table 1.1 Regional distribution and cellular localization of monocarboxylate transporters (MCTs) in the adult rodent central 
nervous system (Table taken from Pierre and Pellerin 2005) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 1.8 A schematic representation of the cellular localization of glucose transporter (GLUTs) and monocarboxylate 
(Taken from Simpson et al., 2007) 
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1.3.1 Structure and functional characteristics of MCTs 
 
The secondary structure of MCTs was determined based on hydrophobicity by standard 
algorithms, predicting the number of transmembrane segments (TM). By this technique, it 
was found that MCT1, MCT2, MCT3, MCT7 and MCT8 possess 12 TM while between 10 
and 12 were predicted for the other MCTs. Thus, it seems probable that there are 12 TM 
domains with the N- and C- termini located within the cytoplasm for most MCTs, as 
illustrated in Figure 1.9 for MCT1. A study using proteolytic digestion of the MCT1 protein 
led to a topological model of the transporter with these 12 segments separated between TM 6 
and TM 7 by a large hydrophilic loop and an extended hydrophilic C-terminal tail (Figure 
1.9). The 12-TM helix topology is shared by many other plasma-membrane transporters such 
as the GLUT family (Baldwin 1993; Gould and Holman 1993). It has been proposed that the 
N-terminal domain is important for energy coupling, membrane insertion and correct structure 
maintenance, whereas the C-terminal domain may be more important for the determination of 
substrate specificity.  
 
For expression at the membrane, MCTs require ancillary proteins. CD147 (also known as 
basigin), a widely distributed cell surface glycoprotein, enables the proper expression and 
function of MCT1 and MCT4 at the cell surface. Without CD147, proteins accumulate in the 
endoplasmic reticulum or the Golgi apparatus (Kirk et al.,2000). Similarly, gp70 (also known 
as embigin) is required for the translocation and catalytic activity of MCT2 (Wilson et al., 
2005) 
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Figure1.9. Proposed membrane topology of the MCT family. The sequence shown is that of human MCT1. (Figure taken and 
modified from Halestrap and Price 1999) 
 
 
1.3.2 Distribution of the MCTs in the periphery and in the CNS 
 
The existence of several different MCT isoforms must bear a physiological significance that is 
related either to their unique properties or to their regulation. In either case, their tissue 
distribution should give some clues as to their role. The mRNA distribution of different MCT 
isoforms was achieved by Northern-blot analysis. But it was also important to directly detect 
MCT proteins. Several techniques such as Immunocytochemistry, immunogold electron 
microscopy and Western-blotting allowed to detect MCT1-4 protein expression. As 
mentioned before, each MCT has been shown to be expressed in specific tissues depending on 
the species studied (Table 1.1). 
 
 In the periphery, MCT1, in humans and rodents is present in almost all tissues 
including muscle, kidney, heart, liver, and brain, in many cases with specific locations within 
each tissue (Fishbein et al., 2002; Bonen et al., 2006). In contrast, it was originally thought 
that MCT2 expression was more limited, with high level of expression in tissues such as 
testis, liver, stomach and kidney, and lower levels in lung and brain. It was also considered 
that MCT2 distribution was much more species specific than MCT1 and important differences 
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in tissue distribution was observed between rat, mouse and hamster (Jackson et al., 1997; 
Merezhinskaya and Fishbein 2009). In mouse tissues, MCT2 was expressed both in kidney 
and in liver (Pierre and Pellerin 2005). MCT3 is found exclusively in the retinal pigment 
epithelium and choroid plexus epithelia in both chicken and rat (Yoon et al.,1997; Philp et 
al.,1998). MCT4 is expressed particularly strongly in skeletal muscle, and is also the major 
MCT isoform in white blood cells and some mammalian cell lines. In addition, MCT4 is 
expressed in cancer-associated fibroblasts, and its expression is induced by oxidative stress 
(Whitaker-Menezes et al., 2011). This has led to propose that it may be of particular 
importance in tissues that rely on high levels of glycolysis to meet their energy needs, and 
hence require rapid lactic acid efflux (Wilson et al., 1998). In addition, MCT4 is expressed on 
various mammalian cell lines (COS, ETL, and NBL-1 cells), in the rat neonatal heart and in 
the placenta (Halestrap and Meredith 2004). 
 
 In the central nervous system, the MCTs that are expressed in the brain are: MCT1, 
MCT2 and MCT4. They exhibit a cell-specific distribution throughout the brain. 
 
a) MCT1 
MCT1 is expressed in the whole rodent brain, both at the mRNA and protein levels. In situ 
hybridization studies demonstrated that MCT1 mRNA is abundant in the hippocampus, in the 
cortex and in the cerebellum of young (15 days-old) and adult rodent brain (Pellerin et al., 
1998a). It was shown that during the suckling period, the endothelial cells forming capillaries 
expressed MCT1 mRNA and expression decreased at the adult stage. The same observations 
were obtained in rat brain. Indeed, the MCT1 mRNA was strongly expressed from postnatal 
day 7 to 21 and was gone at day 27 (Vannucci and Simpson 2003). MCT1 protein is highly 
expressed in endothelial cells forming microvessels and ependymocytes lining the four brain 
ventricles in both young and adult rodent brain (Gerhart et al., 1997, 1998; Hanu et al., 2000; 
Pierre et al., 2000; Baud et al., 2003). Experiments using light and electron microscopy 
revealed the presence of MCT1-positive glial end-feet surrounding capillaries and of MCT1 
on glial-like processes (Gerhart et al., 1997; Leino et al., 1999). Confocal microscopy using 
double labellings with glial markers such as glial fibrillary acidic protein (GFAP) or S100β 
confirmed the association in vitro and in vivo between astrocytic processes and MCT1 
immunoreactivity (Hanu et al., 2000; Pierre et al., 2000; Ainscow et al., 2002; Debernardi et 
al., 2003). In cultured astrocytes, MCT1 protein expression was observed in both soma and 
processes of astrocytes (Broer et al., 1997; Hanu et al., 2000; Debernardi et al., 2003). 
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Experiments based on chronic administration of nicotine in rat brain have shown an 
overexpression of MCT1 within endothelial cells and astrocytes of treated animals (Canis et 
al., 2009a).  
 
A low MCT1 expression level was found in some cultured neurons (Debernardi et al., 2003). 
In addition, MCT1 expression was enhanced by 6 weeks of high fat diet in mouse brain 
neurons (Pierre et al., 2007) and after chronic hyperglycemia in rat brain (Canis et al., 2009b). 
Some subpopulations of neurons in vivo expressed MCT1 protein; it is the case for CA1 
pyramidal neurons of the hippocampus (Tseng et al., 2003) and for specific neuronal 
populations in the hypothalamus (Ainscow et al., 2002). MCT1 was even found in the 
cerebral cortex (Leino et al., 1999). In addition it was shown that neurons express transiently 
MCT1 during specific embryonic stages both in rat and in human (Baud et al., 2003; Fayol et 
al., 2004).  
 
Other cell types in which MCT1 protein were detected are microglial cells and 
oligodendrocytes. Indeed, in a rat ischemia model, MCT1 expression was increased in 
microglial cells after 48h of reperfusion (Moreira et al., 2009). Moreover, in cultured slices of 
developing cerebral cortex from mice MCT1 is expressed in both oligodendrocytes and 
myelin (Rinholm et al., 2011). Authors have demonstrated that L-lactate can support 
oligodendrocyte development and myelination through MCT1.  
 
 
b) MCT4 
In the rodent brain, MCT4 was shown to be expressed exclusively in astrocytes. Immunogold 
electron microscopy revealed that MCT4 is localized in the membrane of astrocytes in adult 
cerebellum (Bergersen et al., 2001, 2002). The same localization was observed in the 
developing rat brain. Indeed, MCT4 expression is very low at birth and is enhanced at P14 in 
the hippocampus, in the cerebellum and in the spinal cord (Rafiki et al., 2003). Finally, in the 
adult rat brain, MCT4 protein expression is intense in various regions of the brain, such as the 
cerebral cortex, the hippocampus, the paraventricular nucleus in the hypothalamus, and the 
capsula internalis (Pellerin et al., 2005). Very few data on its regulation are available. It was 
described that mice fed with a high fat diet during 6 weeks display an increased expression of 
MCT4 in neurons (Pierre et al., 2007). In cultures of cortical astrocytes, MCT4 is expressed at 
very low levels, but a recent study shows that MCT4 mRNA and MCT4 protein were induced 
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in astrocytes by NO donors (Marcillac et al., personal communication). However, up to now, 
specific mechanisms of regulation as well as specific modulators of MCT4 expression remain 
to be identified. 
 
c) MCT2  
In 1995, Garcia et al., screened a cDNA library from hamster liver and found a cDNA 
encoding MCT2, a monocarboxylate transporter 60% identical to hamster MCT1. The 
functional properties of the two MCTs were compared by expression in Sf9 insect cells using 
recombinant baculovirus vectors (Garcia et al., 1995). MCT2 is predicted to contain 484 
amino acids plus 5’- and 3’-UTRs (of 118 and 496 base pairs respectively) and has a 
molecular weight of 52,839 Da. However, on blotted polyacrylamide gel, MCT2 has an 
apparent molecular weight of about 43,000 Da. MCT2 has now been cloned and sequenced 
from human, rat and mouse. 
 
MCT2 catalyses the proton-linked transport of a variety of monocarboxylates as shown by 
expression of rat MCT2 in Xenopus laevis oocytes, but with a considerably higher affinity 
than other MCTs. The Km value for L-lactate is about 0.7mM and the Vmax value of MCT2 is 
as much as 20 times lower than MCT1 (Broer et al., 1999) (Table 1.2). It was also 
demonstrated by expression in Xenopus laevis oocytes that the human MCT2 is a high affinity 
pyruvate transporter with an apparent Km value of 25µM. Thus, MCT2 has been considered a 
primary pyruvate transporter in humans (Lin et al., 1998). Functional studies were also 
performed in Sf9 insect cells in which the hamster MCT2 was expressed. The Km values 
found were 0.8mM and 8.7mM for pyruvate and lactate respectively (Garcia et al., 1995). 
MCT2 can be inhibited by CHC (alpha-cyano-4-hydroxycinnamate), anion-channel inhibitors 
and flavonoids (Broer et al., 1999). 
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Table 1.2. Table 1 Comparison of kinetic constants of MCT1 and MCT2 (taken from Broer et al., 1999) 
 
 
As previously mentioned, in the periphery MCT2 is only expressed in kidney and in liver 
(Pierre et al., 2005). More specifically, MCT2 is localized to basolateral membranes of 
epithelial cells lining the nephron (Becker HM et al., 2010). Moreover MCT2 was also found 
in the small intestine, in the epithelium of gastrointestinal tract reindeer (Koho N et al., 2005). 
In the central nervous system MCT2 is widely expressed and is considered as the predominant 
neuronal monocaroboxylate transporter.  Considering its putative importance for neuronal 
energetics, we will devote the next section to describe in details what is known about MCT2 
and the central nervous system. 
 
1.3.3 The predominant neuronal monocarboxylate transporter MCT2 
 
a) Distribution of MCT2 
 
MCT2 is considered as the major neuronal monocarboxylate transporter. MCT2 mRNA is 
abundant in the cortex, the hippocampus and in the cerebellum of mouse brain as shown by 
northern blot and in situ hybridization studies (Broer et al., 1997; Koehler-Stec et al., 1998; 
Pellerin et al., 1998a; Debernardi et al., 2003; Vannucci and Simpson 2003). At the cellular 
level, the MCT2 mRNA had a predominantly neuronal pattern of expression in young as well 
as in adult rodent brain (Pellerin et al., 1998a; Vanucci and Simpson 2003). Northern blot 
analysis on primary cultures of mouse cortical astrocytes and neurons indicated a prominent 
expression of MCT2 mRNA in neuronal cultures (Broer et al., 1997; Debernardi et al., 2003). 
The demonstration that MCT2 is the major neuronal monocarboxylate transporter was finally 
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obtained by immunohistochemistry in adult mouse brain (Pierre et al., 2002). Expression of 
the MCT2 protein follows the distribution pattern of its mRNA, as it is strongly expressed in 
the cortex, the hippocampus and the cerebellum of rodent brain (Bergersen et al., 2001; 
Bergersen et al., 2002; Pierre et al., 2002; Rafiki et al., 2003). MCT2 expression was found to 
be particularly abundant in the neuropil as well as on several fiber tracts. It was usually absent 
from neuronal cell bodies with the exception of Purkinje cells in the cerebellum. Cortical 
neurons in culture exhibited MCT2 immunoreactivity at the surface and in the cytoplasm of 
their cell bodies and neurites (Debernardi et al., 2003; figure 1.7). MCT2 immunoreactivity in 
vivo revealed that MCT2 labeling occurred predominantly in the neuropil of most structures 
including the neocortex, caudate-putamen, and hippocampus (Pierre et al., 2002). Authors 
have shown that MCT2-positive elements in the neuropil were associated with neuronal cell 
processes. Thus, MCT2 appears to be present on many axonal projections, supporting a 
putative role in lactate transfer into axons to fuel action potential propagation (Brown et al., 
2003). It was particularly visible on sensory fibers in the brainstem as well as on facial and 
trigeminal nerves (Pierre et al., 2002). Except in some astrocytes of the white matter, MCT2 
protein expression was never detected in glial-like cells of the mouse brain parenchyma, 
whereas it could be visible in some endothelial cells forming brain capillaries (Pierre et al., 
2000; Pierre et al., 2002). In contrast, in the rat brain, MCT2 was present in astrocytes both in 
vitro (Hanu et al., 2000) and in vivo (Gerhart et al., 1998). 
 
Observations that MCT2 is expressed on membrane of dendrites in vitro and in vivo suggested 
that part of MCT2 expression is associated with synapses. Thus, double immunofluorescent 
labellings with the presynaptic marker synaptophysin and MCT2 revealed a parallel 
distribution of these proteins in developing cultured neurons (Debernardi et al., 2003). A close 
apposition without colocalization between MCT2 and presynaptic elements was observed, 
suggesting a postsynaptic localization for MCT2. Similarly, in the mouse brain, double 
immunostaining for MCT2 and PSD95 (postsynaptic density protein) indicated a partial 
colocalization (Pierre et al., 2002). By electron microscopy, Bergersen et al., showed that 
MCT2 was associated with postsynaptic δ2-glutamate receptors in the cerebellum (Bergersen 
et al., 2001, 2002). Several years later, using immunogold staining, Bergersen and colleagues 
demonstrated that MCT2 and AMPA receptor GluR2/3 subunits have a similar postsynaptic 
distribution at glutamatergic synapses with high levels expressed within the postsynaptic 
density (Bergersen et al., 2005; Pierre et al., 2009). The MCT2 protein is not only present in 
dendrites but it is also specifically associated with spines, where it was found to be expressed 
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in the postsynaptic density as well as on vesicle-like structures forming an intracellular pool 
(Bergersen et al, 2005). MCT2 was recently found to interact with a specific subset of 
postsynaptic proteins (Pierre et al, 2009). This is particularly the case with GluR2, a subunit 
of the glutamatergic AMPA receptor subtype. It was shown that MCT2 seems not only to 
determine the subcellular localization of GluR2 in neural cells but also to regulate its 
expression levels (Maekawa et al, 2009). In addition, it was observed that MCT2 together 
with GluR2 undergoes a trafficking process between the plasma membrane and an 
intracellular pool under conditions inducing synaptic plasticity (Pierre et al, 2009). 
 
b) Regulation of MCT2 expression in the brain 
 
The brain is capable of adjusting its supply of monocarboxylates to meet specific energy 
requirements, under physiological (Cremer 1982; Dombrowski et al., 1989; Vicario et al., 
1991) as well as pathological conditions (Hawkins et al., 1986; Schurr et al., 1999b, 2001a). 
For example, during the early postnatal development, monocarboxylate uptake increases 
during this period (Cremer et al., 1976; Cornford et al., 1982; Edmond et al., 1985; Cornford 
and Cornford 1986; Nehlig et al., 1991; Nehlig and Pereira de Vasconcelos 1993). 
Furthermore, it was shown that during development, a peak in the expression of both MCT2 
and MCT1 mRNA occurs during the suckling period around postnatal day 15, followed by a 
rapid decline after weaning to reach at postnatal day 30 levels observed in adults (Pellerin et 
al., 1998a). MCT2 expression was shown to be also induced by 6 weeks of high fat diet in 
mouse brain neurons as MCT1 and MCT4 (Pierre et al., 2007).  
 
MCT2 was shown to be expressed by mouse cultured cortical neurons. It was found that the 
level of MCT2 expression correlated with increased expression of synaptophysin, a 
presynaptic protein along days in vitro, suggesting a relationship between synaptic 
development and energy substrate requirements (Debernardi et al., 2003). Recent observations 
have shown that MCT2 expression can be regulated in primary neuronal cultures. Indeed, it 
was found that noradrenaline, insulin, and insulin-like growth factor-1 (IGF-1) increase 
MCT2 protein expression in neurons through a translational mechanism (Pierre et al., 2003; 
Chenal and Pellerin, 2007; Chenal et al, 2008). Interestingly, each of these neuroactive 
substances is known to induce long-term changes in synaptic transmission (Kobayashi and 
Yasoshima, 2001; Trejo et al, 2007; van der Heide et al, 2006). Thus, evidences suggest that 
changes of MCT2 expression could participate in the process of synaptic plasticity induced by 
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noradrenaline, insulin, or IGF-1. Up to now, no direct demonstration was provided of a 
putative link between the regulation of MCT2 and synaptic plasticity processes.  
 
1.4 Metabolic plasticity in the brain 
 
1.4.1 BDNF: synaptic plasticity and learning/memory  
 
Brain derived neurotrophic factor is a neurotrophin whose status as a regulator of survival, 
growth, and differentiation of neurons during development (Barde et al., 1994; Wang et al., 
1995) has matured to include the adult nervous system. Indeed, it is now known that BDNF 
functions to translate activity into synaptic and cognitive plasticity in the adult animal. BDNF 
is able to modulate the efficacy of neurotransmitter release (Kang and Schuman, 1995; Bolton 
et al., 2000), stimulate the synthesis of vesicle-associated proteins (Lu and Chow, 1999; 
Schinder and Poo, 2000), and regulate transcription factors (Finkbeiner et al., 1997; Tully, 
1997). In the hippocampus, BDNF is capable of inducing a rapid potentiation of glutamate-
mediated synaptic transmission (Lessmann and Heumann, 1998) and a long-lasting 
potentiation of perforant path-dentate gyrus connections in vivo (Messaoudi et al., 1998). 
Learning and memory (Falkenberg et al., 1992) and long-term potentiation (LTP), considered 
an electrophysiological correlate of learning and memory (Patterson et al., 1992, 2001), 
selectively increase BDNF mRNA levels in the hippocampus. Transgenic animals with 
diminished BDNF expression lose their ability to induce LTP (Patterson et al., 1996) and are 
impaired in learning a spatial memory task (Linnarsson et al., 1997). Quenching endogenous 
BDNF with function-blocking anti-BDNF antibodies has been shown to impair learning and 
memory in rats in both the water maze and in an inhibitory avoidance task (Ma et al., 1998; 
Mu et al., 1999). Similarly, blocking endogenous BDNF was able to significantly reduce LTP 
(Ma et al., 1998). Moreover, replenishing the depleted hippocampus with exogenous BDNF 
seems to ameliorate these deficits. Exogenous BDNF application (Patterson et al., 1996) or 
transfection of hippocampal slices with a BDNF expressing adenovirus (Korte et al., 1995) 
has been shown to restore the ability to induce LTP. BDNF, but not NGF or NT-3, seems to 
play a role in consolidating short-term memories into long-term memories (Johnston and 
Rose, 2001). Clinical studies support the importance of BDNF in learning and memory in 
humans (Egan et al., 2003; Hariri et al., 2003). A study conducted by Egan et al. (2003) has 
found that individuals expressing a specific polymorphism in the BDNF gene exhibit learning 
impairments. 
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  1.4.2 BDNF and its intracellular signaling pathways in memory  
 
The binding of BDNF to its receptor tyrosine kinase, TrkB, leads to the dimerization and 
autophosphorylation of tyrosine residues in the intracellular domain of the receptor and 
subsequent activation of cytoplasmic signaling pathways including the Akt and 
phosphatidylinositol-3 kinase (PI3K), the mitogen-activated protein kinase (MAPK), and the 
phospholipase-γ (PLC- γ) pathways (Figure 1.10) (Kaplan and Miller 2000). Akt, a serine-
threonine protein kinase which is a downstream target of PI3K has been demonstrated to 
phosphorylate the mammalian target of rapamycin (mTOR). The PI3K/Akt/mTOR signaling 
pathway plays an important role in the regulation of mRNA translation. BDNF increases 
protein synthesis by enhancing translation initiation via multiple signaling pathways including 
PI3K and Akt (Takei et al., 2001). Regarding the cellular mechanisms of BDNF-induced 
synaptic plasticity in vitro, activation of MAPK and PI3K is required to mediate the BDNF-
induced modulation of high-frequency synaptic transmission. It was demonstrated that BDNF 
triggers LTP in the hippocampus in vivo through MAPK and selective induction of the 
dendritic mRNA species Arc (Ying et al., 2002). In addition, it was shown that the radial arm 
maze training for spatial reference and working memory activates the BDNF/TrkB/PI3K/Akt 
signal pathway in the hippocampus of well-trained rats (Mizuno et al., 2000). Activation of 
the BDNF/TrkB/PI3K/Akt signal pathway in the hippocampus of well-trained animals is 
associated with an increase in phosphorylated 4E-BP1 and a decrease in phosphorylated eEF-
2, indicating an increase in activity to translate mRNA into protein. These findings suggest 
that activation of TrkB /PI3K and protein synthesis signaling pathway by BDNF in the 
hippocampus is important for spatial memory (Mizuno et al., 2003).  
 
In contrast to the activation of TrkB/PI3K signaling for spatial memory in the positively 
motivated radial arm maze test, the distinct signaling molecule MAPK appears to be activated 
by BDNF in the hippocampus for acquisition of fear memory in the negatively motivated 
passive avoidance test (Tyler et al., 2002, Alonso et al., 2002). MAPK/Erk also regulates 
protein synthesis dependent plasticity by increasing phosphorylation of eukaryotic initiation 
factor 4E (eIF4E). The 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 (Kelleher et 
al., 2004; Klann and Dever, 2004). Thus, MAPK/Erk plays a critical role in protein synthesis 
dependent plasticity as well. 
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Another signaling pathway activated by BDNF is the PLC-gamma pathway. The 
phosphorylation of Tyr785 recruits and activates PLC-gamma which in turn hydrolyzes 
phosphatidylinositol 4,5-bisphosphate, to produce diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3) (Huang and Reichardt, 2003; Reichardt, 2006). DAG activates protein 
kinase C (PKC), and IP3 releases Ca2+ from intracellular stores. In developing hippocampal 
neurons, focal application of BDNF results in fast calcium transients at postsynaptic sites 
(Lang et al., 2007). Some studies link the PLC-γ pathways underlying BDNF induced Ca2+ 
transients directly to synaptic plasticity. The Ca2+ elevation triggered by PLCc increases Ca2+-
sensitive adenyl cyclase (AC) activity that is necessary for the formation of synaptic PSD-95-
TrkB complexes (Ji et al., 2005) and that is involved in cyclic AMP responsive element 
binding (CREB)-dependent transcription (Nguyen et al., 1994; Shaywitz and Greenberg, 
1999). 
 
Although the reasons why distinct signaling pathways are activated are unclear, it is likely 
that these three signaling pathways are involved in BDNF-dependent memory formation. 
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Figure 1.10. BDNF–TrkB signalling pathways. BDNF binds TrkB with high affinity to induce its dimerization and 
autophosphorylation of tyrosine residues in the cytoplasmic kinase domain that serve as docking sites for effector molecules 
and trigger the activation of three main signalling pathways: PLCγ, PI3K and ERK cascades, which ultimately lead to the 
phosphorylation and activation of the transcription factor CREB that mediates transcription of genes essential for the survival 
and differentiation of neurons. The recruitment of PLCγ increases intracellular Ca2+ levels and leads to the activation of 
CaMKII to phosphorylate CREB. PI3K can be activated via the Shc/Grb2/SOS complex through Gab1 and by IRS1/2. Lipid 
products generated by the activated PI3K, the phosphatidylinositides, bind and activate protein kinase Akt, upstream of 
CREB. The ERK cascade can be activated both by the Shc/Grb2/SOS complex and by PI3K. ERK phosphorylation leads 
directly to CREB phosphorylation. Both Akt and ERK activate mTOR, responsible for enhanced translation initiation. PLCγ, 
phospholipase Cγ; PI3K, phosphatidylinositol 3-kinase; ERK, extracellular signal-regulated kinase; CaMKII, calcium-
calmodulin dependent kinase; Shc, src homology domain containing; Grb2, growth factor receptor-bound protein 2; SOS, son 
of sevenless; Gab1, Grb-associated binder 1; IRS1/2, insulin receptor substrates 1/2; CREB, cAMP-calcium response element 
binding protein; Ras, GTP binding protein; Raf, Ras associated factor; MEK, MAP/Erk kinase; mTOR, mammalian target of 
rapamycin; (Picture taken from Cunha et al., 2010) 
 
 
1.4.3 Energy metabolism and BDNF 
 
BDNF is intimately connected with energy metabolism. Mice that either lack one copy of the 
BDNF gene or have a conditioned deletion of BDNF in the postnatal brain are hyperphagic 
and develop obesity (Rios et al., 2001). Moreover, mice with reduced BDNF levels are both 
obese and hyperglycemic (Lyons et al., 1999; Kernie et al., 2000). Peripheral or central 
infusion of BDNF has been found to reduce body weight, normalize glucose levels (Tonra et 
al., 1999), ameliorate lipid metabolism in diabetic rodents (Tsuchida et al., 2002), and 
increase insulin sensitivity (Pelleymounter et al., 1995; Nakagawa et al., 2000). 
Hypoglycemia and intermittent fasting both increase BDNF levels whereas hyperphagia and 
high oxidative stress (OS) levels, the harmful by-products of energy metabolism, decrease 
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BDNF levels (Lindvall et al., 1992; Lee et al., 2002; Wu et al., 2004a). It is also notable that, 
in the mature CNS, the BDNF protein is most abundant in brain areas foremost associated 
with cognitive and neuroendocrine regulation, the hippocampus and hypothalamus, 
respectively (Nawa et al., 1995). Evidence showed that during exercise, cellular energy 
metabolism can modulate BDNF-mediated synaptic plasticity in the hippocampus. Indeed, by 
infusing 1,25-dihydroxyvitamin D3 (D3), a modulator of energy metabolism that acts on 
mitochondria, directly into the hippocampus during 3 days of voluntary wheel running, 
Vaymann and colleagues found that BDNF, synapsin I, and CREB where significantly 
reduced (Vaynman et al., 2006b). Moreover, disrupting energy metabolism in the 
hippocampus reduced the expression p-CAMKII, the signal transduction cascade downstream 
to BDNF action. Other findings from the study showed that exercise increases the expression 
of the uncoupling protein 2 (UCP2), a mitochondrial protein, which uncouples substrate 
oxidation from ATP synthesis (Bouillaud et al., 1985; Boss et al., 1997; Vidal-Puig et al., 
1997; Sanchis et al., 1998; Mao et al., 1999). In human, a study by Yeo et al. (2004) 
documented a case that may provide clues to evaluate the role of BDNF in metabolism and 
cognition in human subjects. A human patient with a de novo mutation affecting TrKB, the 
consort receptor of BDNF, exhibited both hyperphagia and obesity and also suffered 
developmental delays and other defects in higher order neurologic functions. Thus, 
metabolism and cognitive function seem to have common signaling pathways (Gomez-Pinilla 
et al., 2008).  
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1.4.4 Metabolic plasticity: between synaptic plasticity and energy metabolism 
 
Metabolic plasticity is defined by processes that underlie synaptic plasticity at the energy 
metabolism level, resulting in correlated metabolic adaptations. The notion of metabolic 
plasticity has indeed found experimental validation (Magistretti 2006). Evidence has been 
obtained in a restricted number of experimental paradigms for activity dependent long-term 
metabolic adaptations (Barrett et al., 2003; Gonzalez-Lima and Garrosa, 1991; Hyden et al., 
2000; Maviel et al., 2004; Welker et al., 1992; Zhang and Wong-Riley, 1999). Such 
adaptations in metabolic pathways are mediated by transcriptional mechanisms that modulate 
the expression of genes involved in energy metabolism (Allaman et al., 2000; 2003; 2004; 
Debernardi et al., 2003; Pierre et al., 2003; Sorg and Magistretti, 1992). As mentioned earlier, 
MCT2 might be one of those target proteins. A restricted set of neuroactive substances 
regulates neuronal MCT2 expression. It is the case of noradrenaline, insulin and IGF-1, all 
known to be involved in synaptic plasticity (Pierre et al., 2003; Chenal and Pellerin, 2007; 
Chenal et al., 2008). Furthermore, based on the peculiar MCT2 distribution (localization at the 
postsynaptic density, colocalization with PSD95 and GluR2 subunit AMPA receptor,…), 
evidences suggest that lactate metabolism and synaptic plasticity could be linked processes. 
 
However, most of the data on metabolic plasticity collected so far relate to in vitro analyses at 
the molecular level. The mechanisms of metabolic plasticity in a well-established paradigm of 
learning and memory are starting to be explored. Recently, Suzuki and colleagues 
demonstrated for the first time that lactate transfer through monocarboxylate transporters, 
notably MCT2 is essential for the establishment of long-term memory (Suzuki et al., 2011). In 
this context, such evidences suggest that metabolic plasticity could be a new essential 
component for synaptic plasticity processes and memory formation.  
 
 
1.4.5 Metabolic plasticity in a learning and memory paradigm 
 
It is now widely recognized that learning and memory processes are correlated with functional 
and structural modifications at the synaptic level, resulting in cellular and molecular changes, 
named neuronal plasticity. A variety of behavioural paradigms are available to explore the 
mechanisms of learning and memory in laboratory animals. Spatial learning is one of the best 
established of such behavioural paradigms; in addition the role of a particular brain area, the 
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hippocampus in such spatial learning has been extensively characterized. Indeed, the 
hippocampus is involved in coding, consolidation as well as retrieval of spatial memory in 
rodents (O’Keefe and Nadel, 1979; Riedel et al., 1999). However, it is still unclear how the 
hippocampus is working. Electrophysiological studies, partial hippocampal lesion studies and, 
more recently human brain imaging, have suggested the existence of functional specialization 
within the hippocampus (Jung et al., 1994; Lepage et al., 1998; Moser and Moser, 1998; 
Poucet and Buhot, 1994). In addition, studies in rodents have shown that markers of activity 
(in particular metabolic markers such as 2-deoxyglucose 2-DG), evolve spatially and 
temporally over the different phases of the learning paradigm, including during recall 
(Bontempi et al., 1999). Glucose utilization was mapped in a spatial learning paradigm, in the 
eight-arm radial maze (Ros et al., 2006). Results obtained indicate that the metabolic demand 
during the various learning phases evolved spatially and temporally in the areas engaged by 
the task, in particular in the hippocampus. In keeping with the initial hypothesis, distinct 
patterns of metabolic activity were observed during the learning and recall phases. Analysis of 
metabolic activity in the hippocampus revealed different patterns over the rostro-caudal axis 
in its three major subregions, the CA1, CA3 and dentate gyrus (DG). Thus, as learning 
proceeded, more portions of the CA1 and CA3 became engaged metabolically, moving from 
the posterior and intermediate parts toward the anterior level. In addition, during recall, 
increased metabolic activity could be observed only in the anterior parts of the dentate gyrus 
(Ros et al., 2006). This set of data is in keeping with the notion that metabolic adaptations 
(plasticity) are occurring as a correlate of learning and recall. 
 
 
1.5  Questions and aim of the present study 
 
Few data are available concerning MCT regulation in the brain. Previously, it was 
demonstrated that the predominant neuronal monocarboxylate transporter MCT2 was 
enhanced by three different factors: noradrenaline, a neurotransmitter (Pierre et al., 2003; 
Chenal and Pellerin, 2007), insulin, a hormone (Chenal et al., 2008) and insulin-like growth 
factor (IGF-1), a neurotrophic factor (Chenal et al., 2008). Common points among these 
neuroactive substances were that the MCT2 regulation occurred by a translational mechanism 
and they were known to induce long-term changes in synaptic transmission (Kobayashi and 
Yasoshima, 2001; Trejo et al, 2007; van der Heide et al, 2006). 
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Synaptic plasticity and behaviour are likely dependent on the capacity of neurons to meet the 
energy demands imposed by neuronal activity. As described in the introduction, lactate seems 
to be the preferred energetic substrate for neurons during glutamatergic activity (Pellerin and 
Magistretti, 1994). The concept that energy metabolism might be coupled to synaptic 
plasticity has first been proposed together with the implication of BDNF in such interactions 
(Vaynman et al., 2006 ; Gomez-Pinilla et al., 2008). Considering the critical role of MCT2 in 
lactate uptake and its utilization by neurons, we studied first the intriguing possibility of a 
coupling between neuronal MCT2 regulation to adapt the supply of lactate in synaptic 
plasticity context, and then if these mechanisms of regulation are essential to learning and 
memory processes. 
 
In the present study we addressed three main questions: 
 
1- Does MCT2 expression regulated by BDNF in vitro? If yes, by which pathways and by 
which mechanism? 
2- Does intrahippocampal BDNF injection affect the expression of MCTs?  
3- Does an in vivo downregulation of hippocampal MCT2 affect mice cognition? 
 
In the first part of this thesis, it became of interest to investigate whether brain derived 
neurotrophic factor (BDNF), a key molecule involved in synaptic plasticity, could regulate 
MCT2 expression in cultured neurons and to characterize signal transduction pathways 
involved in this effect. We were also interested to investigate if MCT2 could be regulated by a 
miRNA, known to be constitutively expressed in cells and to exert a repressor effect on 
protein translation. Some of them are known to regulate proteins involved in synaptic 
plasticity and neuronal growth (Fiore et al., 2008). Then, we investigated in vivo the effect of 
BDNF in the hippocampus on MCT expression in parallel with several pre- and postsynaptic 
proteins and with two immediate early genes (Arc and Zif268), both transiently and rapidly 
activated during LTP as well as along the process of learning and memory formation (Davis et 
al., 2003; Plath et al., 2006; Lonergan et al., 2010). As hippocampal activation is known to be 
required for spatial learning tasks, we investigated in the last part, the impact of reducing 
hippocampal MCT2 expression on spatial performance in mice. Overall, our findings suggest 
the intriguing possibility that energy supply, via monocarboxylate transporters, could be an 
important determinant of learning and memory processes.  
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Chapter 2 
 
Brain-derived neurotrophic factor enhances the expression of the 
monocarboxylate transporter 2 through translational activation in 
mouse cultured cortical neurons 
(Robinet C and Pellerin L, 2010). 
 
 
 
2.1 Abstract 
 
MCT2 is the predominant neuronal monocarboxylate transporter allowing lactate use as an 
alternative energy substrate. It is suggested that MCT2 is upregulated to meet enhanced 
energy demands after modifications in synaptic transmission. Brain-derived neurotrophic 
factor (BDNF), a promoter of synaptic plasticity, significantly increased MCT2 protein 
expression in cultured cortical neurons (as shown by immunocytochemistry and western blot) 
through a translational regulation at the synaptic level. Brain-derived neurotrophic factor can 
cause translational activation through different signaling pathways. Western blot analyses 
showed that p44/p42 mitogen-activated protein kinase (MAPK), Akt, and S6 were strongly 
phosphorylated on BDNF treatment. To determine by which signal transduction pathway(s) 
BDNF mediates its upregulation of MCT2 protein expression, the effect of specific inhibitors 
for p38 MAPK, phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), 
mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase 
(MEK), p44/p42 MAPK (ERK), and Janus kinase 2 (JAK2) was evaluated. It could be 
observed that the BDNF-induced increase in MCT2 protein expression was almost completely 
blocked by all inhibitors, except for JAK2. These data indicate that BDNF induces an increase 
in neuronal MCT2 protein expression by a mechanism involving a concomitant stimulation of 
PI3K/Akt/mTOR/S6, p38 MAPK, and p44/p42 MAPK. Moreover, our observations suggest 
that changes in MCT2 expression could participate in the process of synaptic plasticity 
induced by BDNF. 
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2.2 Introduction 
 
Brain-derived neurotrophic factor (BDNF) is a widely expressed neurotrophin in the central 
nervous system (Skup, 1994). Acting through specific tyrosine kinase receptors, BDNF 
affects neuronal survival, differentiation, and synaptic plasticity after 
the activation of multiple intracellular signal transduction mechanisms, such as 
phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) 
signaling pathways (Bramham and Messaoudi, 2005). Presynaptically, BDNF potentiates 
depolarization-evoked Ca2+-dependent glutamate release while causing direct glutamate 
release through Ca2+ mobilization from Ins(1,4,5)P3-sensitive stores, whereas the 
postsynaptic actions of BDNF include changes in glutamate receptor phosphorylation, 
subcellular localization and synthesis, and local alterations in protein synthesis, as well as 
long-term changes in gene expression (Carvalho et al, 2008). These effects of BDNF 
contribute not only to synaptic plasticity but also to modifications in spine density and 
morphology (Carvalho et al, 2008). However, one aspect that has not been explored in the 
context of synaptic plasticity concerns putative changes in neuroenergetics. Indeed, it is likely 
that as a consequence of alterations in synaptic efficacy, the supply of energy substrates must 
be adapted to meet the energy needs imposed by new levels of synaptic response. In recent 
years, the role of monocarboxylates such as lactate as additional energy substrates for neurons 
has attracted increasing attention (Pellerin, 2003), raising interest for the identification of 
specific transporters in the central nervous system. MCT2 was shown to be the predominant 
monocarboxylate transporter expressed by neurons (Pierre et al, 2002). It belongs to a family 
of proton-linked carriers involved in the transport of lactate, pyruvate, and ketone bodies 
(Garcia et al, 1994, 1995). MCT2 immunoreactivity was found to be abundant in the neuronal 
processes of various brain regions, including the cortex, hippocampus, and cerebellum 
(Bergersen et al, 2002; Pierre et al, 2002). At the subcellular level, MCT2 is expressed on 
axons and dendrites (Pierre et al, 2002, 2009). Moreover, MCT2 is present at glutamatergic 
synapses and exclusively on postsynaptic elements (Bergersen et al, 2002, 2005; Pierre et al, 
2009). It is particularly enriched in the postsynaptic density as well as in an intracellular pool 
within the spines (Bergersen et al, 2005). Recent observations have shown that MCT2 
expression can be regulated in cultured neurons. Thus, it was found that noradrenaline, 
insulin, and insulin-like growth factor-1 (IGF-1) increase MCT2 protein expression in 
neurons through a translational mechanism (Chenal and Pellerin, 2007; Chenal et al, 2008). 
Interestingly, each of these neuroactive substances is known to induce long-term changes in 
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synaptic transmission (Kobayashi and Yasoshima, 2001; Trejo et al, 2007; van der Heide et 
al, 2006). Therefore, it became of interest to investigate whether BDNF could regulate MCT2 
expression in cultured neurons and to characterize the signal transduction pathways involved 
in this effect. In addition, the nature of the mechanism (transcriptional or translational) by 
which MCT2 expression is regulated by BDNF has been investigated. 
 
2.3 Material and methods 
 
Neuronal Cultures and Pharmacological Treatments 
Primary cultures of mouse cortical neurons were prepared from embryonic day 17 OF1 mice 
(Charles River, Lyon, France). As described previously (Debernardi et al, 2003), after 
decapitation and brain dissection, cortices were mechanically dissociated in phosphate-
buffered saline (PBS) supplemented with glucose (NaCl, 150 mmol/L; KCl, 3 mmol/L; 
KH2PO4, 1.5 mmol/L; Na2HPO4, 7.9 mmol/L; glucose, 33 mmol/L; penicillin, 0.006 g/L; 
streptomycin, 0.1 g/L; pH 7.4). Cells were plated on poly L-ornithine (15 mg/L)-precoated 
dishes and cultured in neurobasal-B27 medium (Brewer et al, 1993) supplemented with 
0.5 mmol/L L-glutamine. All experiments were carried out on day 7 in vitro. At this stage, 
cultures contained <5% of glial cells (Debernardi et al, 2003). Neuronal treatments with 
pharmacological agents were carried out without changing the medium before or during the 
incubation time. Brain-derived neurotrophic factor (CYT-207; Brunschwig, Basel, 
Switzerland) was added directly into the culture medium at various concentrations and cells 
were incubated for the indicated times. Rapamycin, 20 ng/mL (mammalian target of 
rapamycin (mTOR) inhibitor), SB202190 HCl, 10 μmol/L and SB203580 HCl, 10 μmol/L 
(p38 MAPK inhibitors), LY294002, 10 μmol/L (PI3K inhibitor), PD98059, 50 μmol/L 
(MAPK/ERK kinase (MEK inhibitor), UO126, 10 μmol/L (p44/p42 MAPK (ERK, 
extracellular signal-regulated kinase) inhibitor), and AG490 25 μmol/L (JAK2 (Janus kinase 
2) inhibitor) were added directly to the medium 30 mins before BDNF. All these inhibitors 
were purchased from Alexis Biochemicals (Lausen, Switzerland), except LY294002 (L9908; 
Sigma, Buchs, Switzerland) and SB203580 (S8307; Sigma). Transcription and translation 
inhibitors (5 μmol/L actinomycin D (ActD) and 10 μmol/L cycloheximide, respectively) were 
added 30 mins before pharmacological agents. All other chemicals were purchased from 
Sigma. Data represent mean±s.e.m. of ‘n’ determinations, which are independent 
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measurements (from different culture plates) obtained from at least three separate neuronal 
cultures. 
 
Immunocytochemistry and Related Quantification 
After removal of the culture medium, cells were carefully rinsed in PBS at 37°C and directly 
postfixed in an ice-cold paraformaldehyde fixative (4% in PBS for 30 mins at 20°C). Fixed 
cells were treated with casein (0.5% in PBS) for 1 h at room temperature to block nonspecific 
sites. For immunostaining, cultures were incubated overnight at 4°C in 50 μL of freshly 
prepared MCT2 antibody solution (anti-MCT2 diluted 1:500 in PBS containing 0.25% bovine 
serum albumin) (Pierre et al, 2000). After carefully rinsing in PBS, cultures were incubated in 
a solution containing Cy3-conjugated anti-rabbit Igs (diluted 1:500 for 2 h at room 
temperature; Jackson Immunoresearch, Baltimore, MD, USA). After rinsing in PBS twice and 
a final rinsing in water, coverslips were mounted with Vectashield (Reactolab SA, 
Burlingame, CA, USA). Coverslips were examined and photographed with an Axioplan2 
microscope (Zeiss, Hallbergmoos, Germany) using epifluorescence with an appropriate filter. 
To quantitatively assess the influence of different treatments on MCT2 protein expression, a 
quantitative analysis of images obtained by epifluorescence with a × 20 objective and 
acquired using a cooled CCD camera (Axiocam, Zeiss), together with the 4.6 Axiovision 
software (Zeiss) was carried out. Three fields were chosen randomly on each coverslip; they 
contained at least 20 MCT2-labeled neurons per field. All pictures were acquired and 
presented as different levels of gray with identical acquisition time for all. Pictures were then 
analyzed using NIH software (National Institutes of Health Image program, version 1.62, 
Rockville Pike, MD, USA). The fluorescence intensity of eight isolated cells taken randomly 
in each of the three captured areas was assessed. The average fluorescence intensity 
representing neuronal MCT2 expression was obtained by calculating the average of 24 
measurements per coverslip. Measurements were obtained in a blinded manner with the 
investigator unaware of the culture treatments. Mean and s.e.m. for a particular condition 
were calculated from average fluorescence intensity values of distinct coverslips representing 
independent determinations (numbers indicated on each bar of the graph). Data were 
statistically analyzed with an ANOVA (analysis of variance), followed by Dunnett's or 
Bonferroni's test. 
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Western Blot and Related Quantification 
Neurons in each culture dish were homogenized in 50 μL of buffer containing the following: 
Tris-HCl, pH 6.8, 20 mmol/L; sucrose, 0.27 mol/L; EGTA (ethylene glycol tetraacetic acid), 
1 mmol/L; EDTA (ethylene diamine tetraacetic acid), 1 mmol/L; NaF, 50 mmol/L; Triton X-
100, 1%; β-glycerophosphate, 10 mmol/L; DTT (dithiothreitol), 10 mmol/L; 4-
nitrophenylphosphate, 10 mmol/L; and a mixture of protease inhibitors (Complete, Roche 
Molecular Biochemicals, Mannheim, Germany). Each stimulated condition was examined in 
duplicate and the contents of the two Petri dishes were pooled. Protein samples were 
sonicated and heated at 95°C for 5 mins in half the final volume of SDS-PAGE sample buffer 
(Tris-HCl, 62.5 mmol/L; DTT, 50 mmol/L; SDS, 2%; glycerol, 10%; and bromophenol blue, 
0.1%). Samples were loaded onto polyacrylamide gels composed of a 10% or 6% acrylamide-
bisacrylamide running gel and a 4.5% acrylamide-bisacrylamide stacking gel. After 
electrophoresis, proteins were transferred onto nitrocellulose membranes (Trans-Blot Transfer 
Medium 162-0115; Bio-Rad, Reinach, Switzerland) using a Transblot semi-dry transfer cell 
(Bio-Rad). For protein detection, membranes were incubated in a blocking solution of Tris-
buffered saline supplemented with Tween-20 (TBST; Tris-HCl, pH 7.5, 50 mmol/L; NaCl, 
150 mmol/L; and Tween-20, 0.1%) containing 5% nonfat milk for 1 h at room temperature. 
Membranes were incubated overnight at 4°C with the antiphospho-serine/threonine protein 
kinase from AKT virus (Akt)-Ser473 (1:700), antiphospho-p44/p42 MAPK-Thr202/Tyr204 
(both 1:1,000), antiphospho-mTOR-Ser1448 (1:1,000), anti-mTOR (1:1,000), antiphospho-
S6-Ser235/236 ribosomal protein (1:1,000), and anti-β-actin (A5441; Sigma). All primary 
antibodies were purchased from Cell Signalling (BioConcept, Allschwil, Switzerland), except 
anti-β-actin (A5441; Sigma). After three washes in TBST, membranes were incubated with 
the secondary antibodies Alexa Fluor 680 goat anti-IgG (Juro, Lucerne, Switzerland) and 
IRDye 800 goat anti-mouse IgG (BioConcept), diluted at 1:5,000 in TBST containing 1% 
nonfat milk, for 2 h at room temperature, and protected from light. After three washes in 
TBST, membranes were scanned using the Odyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, NE, USA), which permits detection and quantification of proteins of 
interest. β-Actin, revealed in green, was used for normalization and the proteins of interest 
were revealed in red. As phospho-mTOR has a very high molecular weight (289 kDa), actin 
was not visible on the same gel. To normalize western blots for phospho-mTOR, samples 
were loaded in duplicate onto a 6% running gel and proteins were transferred onto a 
nitrocellulose membrane using a 10% methanol transfer buffer. The membrane was then cut 
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into two identical pieces and probed either with the phospho-mTOR antibody (1:1,000) or 
with the mTOR antibody (1:1,000). Thus, quantifications were performed on samples 
resolved on the same gel and transferred onto the same membrane, and normalization was 
conducted against mTOR (instead of β-actin). The remaining of the procedure was 
unchanged. 
 
Quantitative Real-Time Reverse Transcriptase-PCR 
Quantitative determination of MCT2 mRNA expression levels was performed by quantitative 
reverse transcriptase-PCR according to Heid et al (1996) using an ABI Prism 7000 sequence 
detection system from Applied Biosystems (Rotkreuz, Switzerland). The following sets of 
oligonucleotides were used: 5′ → 3′; ActinFo, GCTTCTTTGCAGCTCCTTCGT; ActinRe, 
ATATCGTCATCCATGGCGAAC (Embl: X03672); MCT2Fo, 
CAGCAACAGCGTGATAGAGCTT; MCT2Re, TGGTTGCAGGTTGAATGCTAAT 
(Embl: NM_011391); NPYFo, ACCAGACAGAGATATGGCAAGAGA; NPYRe, 
GGCGTTTTCTGTGC (produced by Microsynth, Balgach, Switzerland). 
 
Preparation and Stimulation of Synaptoneurosomes 
Synaptoneurosomes were prepared from the forebrains of 8- to 14-day-old mice pups (10 to 
15 pups per preparation) according to a previously published protocol (Rao and Steward 
(1991), as modified by Schratt et al (2004)). Briefly, the total forebrains were dissected in 
20 mL of homogenization buffer (0.32 mol/L sucrose, 0.1 mmol/L EDTA, 0.25 mmol/L DTT, 
and 3 mmol/L HEPES, pH 7.4) and disrupted using a Teflon-coated Dounce-Potter 
homogenizer (B. Braun, Crissier, Switzerland) by eight up-and-down strokes. Nuclei and cell 
debris were pelleted by 2 mins of centrifugation at 2,000 g. The supernatant was collected and 
centrifuged for an additional 10 mins at 14,000 g to pellet a crude synaptoneurosome-
containing fraction (P2). The pellet was then brought up to 8 mL total volume (with a solution 
of 0.32 mol/L sucrose and 1 mmol/L NaHCO3). This suspension (4 × 2 mL) was layered onto 
three different discontinuous sucrose gradients (0.85, 1, 1.2 mmol/L) that had been 
equilibrated at 4°C for 1 h. The gradient was centrifuged at 45,000 g for 45 mins in a Centrikon 
T-1075 ultracentrifuge using a SW 41.14Ti swinging bucket rotor. Synaptoneurosomes were 
collected from the 1/1.2 mol/L interface (500 μL for 2 mL of P2), washed twice in 1 × PBS (in 
a 2-mL tube), with a centrifugation at 7,000 g for 2 mins. Synaptoneurosomes were 
resuspended in 500 μL of synaptoneurosome incubation buffer (10 mmol/L Tris, pH 7.5, 
 68 
2.2 mmol/L CaCl2, 0.5 mmol/L Na2HPO4, 0.4 mmol/L KH2PO4, 4 mmol/L NaHCO3, and 
80 mmol/L NaCl). Synaptoneurosomes were centrifuged at 7,000 g for 2 mins, the supernatant 
was discarded, and synaptoneurosomes in the lower fraction were either used immediately or 
stored at −80°C. No significant differences were observed between results from freshly 
prepared or frozen synaptosomes such that results were pooled. Enrichment of the 
synaptosomal fraction was controlled by performing western blotting for the postsynaptic 
protein PSD-95 (data not shown). The synaptoneurosome pellet was thawed on ice for 
30 mins and diluted in a prewarmed (37°C) synaptoneurosome incubation buffer containing a 
mixture of antiproteases (Complete 11257000; Roche Molecular Biochemicals) to yield a 
protein concentration between 2 and 9 mg/mL. Synaptoneurosome samples (100 μL) were 
exposed to either ActD (5 μmol/L) or cycloheximide (10 μmol/L) for 30 mins before 
application of 100 ng/mL BDNF for 6 h. The reaction was stopped by adding 20 μL of SDS 
buffer (5 ×), and samples were boiled for 5 mins and served as starting material for western 
blotting. 
 
 
 
2.3 Results 
 
2.3.1 Effect of BDNF on MCT2 protein expression in cultured neurons 
 
To assess the effect of BDNF on neuronal MCT2 protein expression, cultured cortical neurons 
were treated with BDNF for 6 h at various concentrations up to 100 ng/mL. Experiments 
conducted with BDNF concentrations of 10, 50, and 100 ng/mL followed by 
immunocytochemistry led to a striking enhancement of fluorescence intensity corresponding 
to higher levels of MCT2 immunoreactivity (IR) at 100 ng/mL (Figure 1A). Western blot 
analysis showed that the maximal increase of MCT2 expression was found with 100 ng/mL. 
At lower concentrations, MCT2 expression had a tendency to be increased, but the effect was 
not significant statistically (Figure 1B). 
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Fig.1. Concentration-dependent effect of BDNF on MCT2 expression in primary cultures of mouse cortical neurons. 
A) Immunocytochemical stainings for MCT2 in untreated cultures (Ctrl) and cultures treated with BDNF for 6h at different 
concentrations. B) Western blot analysis of MCT2 expression in primary cultures of mouse cortical neurons treated with 
BDNF for 6h at various concentrations up to 100ng/ml. Western-blot were quantified using Odyssey software (LI-COR). 
Results are expressed as percent of control after the values had been normalized using -actin signal as reference. Statistical 
analysis was performed using ANOVA followed by Dunnett’s test. ** indicates MCT2 protein levels significantly different 
from control with p<0.01. Numbers in the graph bars represent the number of independent experiments for each condition. 
 
 
Changes in the levels of MCT2 IR induced by BDNF were also studied as a function of time 
(1, 6, 12, and 24 h). It was observed that 100 ng/mL BDNF caused a 40% increase in MCT2 
IR 6 h after the beginning of the treatment that remained elevated at 12 and 24 h (Figure 2A). 
Western blot analysis showed that the increase of MCT2 expression was already found 
significant as early as after 1 h of BDNF stimulation (100 ng/mL) and that this significant 
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increase was still present up to 24 h (Figure 2B). The effect of BDNF was found to be as 
robust as the previously described effect of noradrenaline (100 mmol/L) on MCT2 expression 
after 6 h of treatment (Figure 2C). 
 
Fig.2. Time course of the effect of BDNF on MCT2 protein expression in primary cultures of mouse cortical neurons. 
A) MCT2 IR and related quantification of primary cultures of mouse cortical neurons treated with BDNF at a final 
concentration of 100ng/ml for various periods of time up to 24h. Left panels represent immunocytochemical stainings for 
MCT2 in untreated cultures (Ctrl) or cultures treated with BDNF for 6h. The bar graph represents the quantitative 
determination of fluorescence intensity corresponding to MCT2 IR in cultured neurons treated with BDNF for various 
periods of time up to 24h. Results are expressed as percentage of control fluorescence intensity and represent the mean±SEM 
of independent determinations (numbers indicated on bars) from four distinct experiments. The value of fluorescence 
intensity for each determination represents the average level from 24 cells on the same coverslip. B) and C) Western blot 
analysis of MCT2 protein expression in cultures of mouse cortical neurons treated with BDNF 100ng/ml or Noradrenaline 
(NA 6h) for the indicated times as compared with untreated cells (Ctrl). Western blots were quantified using Odyssey 
sofware (LI-COR). Results are expressed as percentage of control (mean±SEM) after the values had been normalized using 
-actin signal as reference. Statistical analysis was performed using ANOVA followed by Dunnett’s test. * p<0.05, ** 
p<0.01, *** p<0.001 vs. control (Ctrl) for MCT2 protein levels. Numbers in the graph bars represent the number of 
independent experiments for each condition. 
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2.3.2 Putative involvement of distinct signal transduction pathways in BDNF-induced MCT2 
expression  
 
Involvement of specific signal transduction mechanisms involved in the effect of BDNF on 
MCT2 expression was investigated with a series of inhibitors. Cultured cortical neurons were 
pretreated with five different inhibitors (LY294002, a specific PI3K inhibitor; rapamycin, a 
specific mTOR inhibitor; PD98058, a specific MEK inhibitor; SB202190, a specific p38 
MAPK inhibitor; and AG490, a specific JAK2 inhibitor) 30 mins before the addition of 
BDNF (100 ng/mL) for 6 h. The six panels on the left of Figure 3A show that a 30-min 
pretreatment of cultured mouse cortical neurons with LY294002 (10 mmol/L), rapamycin (20 
ng/mL), PD98058 (50 mmol/L), or SB202190 (10 mmol/L) blocked the BDNF-induced 
increase in MCT2 IR after 6 h of treatment. In contrast, AG490 (25 mmol/L) had no effect 
(not shown). The quantification of MCT2 IR shows that all inhibitors (with the exception of 
AG490) prevented the induction of MCT2 protein expression by BDNF, reducing the overall 
expression by ~40% (Figure 3A). Similar results were obtained by western blot, confirming 
the MCT2 IR data (Figure 3B). The effect of all five inhibitors alone (without posttreatment 
with BDNF) was tested previously on cultured cortical neurons and no change in MCT2 IR 
was observed compared with the control condition (data not shown). To further validate our 
observations, two more inhibitors were tested for their effect on BDNF-induced MCT2 
expression (UO126, a specific p44/p42 MAPK inhibitor, and SB203580, another specific p38 
MAPK inhibitor). Cultured cortical neurons were pretreated with UO126 (10 mmol/L) and 
SB203580 (10 mmol/L) 30 mins before the addition of BDNF (100 ng/mL) for 6 h. Western 
blot analysis shows that UO126 and SB203580 significantly reduced MCT2 protein 
expression induced by BDNF (Figure 3C). 
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Fig.3. Effect of different signaling pathway inhibitors on BDNF-stimulated MCT2 expression in primary cultures of 
mouse cortical neurons. Primary cultures of mouse cortical neurons were pretreated for 30 mins with specific signaling 
pathway inhibitors (PD98095, 50 μmol/L (PD); SB202190, 10 μmol/L (SBa); LY294002, 10 μmol/L (LY); rapamycin, 20
ng/mL (Rap); AG490 25 μmol/L (AG); UO126, 10 μmol/L (UO); SB203580, 10 μmol/L (SBb)) before stimulation with 
BDNF 100 ng/mL for 6 h (BDNF 6 h). (A) Left panels represent immunocytochemical stainings for MCT2 in untreated cells 
(Ctrl), cultures treated with BDNF alone for 6 h (BDNF), or pretreated for 30 mins with each inhibitor (LY, Rap, PD, SBa) 
before the addition of BDNF. The bar graph represents the quantitative determination of fluorescence intensity corresponding 
to MCT2 IR in cultured neurons treated with the specific signaling pathway inhibitors followed by exposure to BDNF for 6
h. Results are expressed as percentage of control fluorescence intensity and represent the mean±s.e.m. of independent 
determinations (numbers indicated on bars) from four distinct experiments. The value of fluorescence intensity for each 
determination represents the average level from 24 cells on the same coverslip. (B and C) Western blot analysis of MCT2 
expression in cultures of mouse cortical neurons treated with specific signaling pathway inhibitors (+LY, Rap, PD, SBa, AG, 
UO, SBb) before stimulation with BDNF 100 ng/mL for 6 h (BDNF 6 h). Western blots were quantified using Odyssey 
software (LI-COR Biosciences, Lincoln, NE, USA). Results are expressed as percentage of control (mean±s.e.m.) after the 
values had been normalized using β-actin signal as the reference. Statistical analysis was performed using ANOVA followed 
by Bonferroni's test. *P<0.05, **P<0.01 versus control (Ctrl). #P<0.05 versus 6 h BDNF treatment. Numbers in the graph bars 
represent the number of independent experiments for each condition. 
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2.3.3 Activation by BDNF of the different signal transduction pathways implicated in MCT2 
upregulation 
 
It became necessary to assess the effect of BDNF on each signal transduction pathway 
putatively implicated in MCT2 upregulation and to verify the efficacy of each inhibitor used. 
Cultured cortical neurons were treated with BDNF (100 ng/mL) for three time periods (5 
mins, 30 mins, and 1 h). First, to evaluate the activation of the PI3K/Akt/mTOR/S6 pathway, 
the phosphorylation levels of Akt on Ser473, mTOR on Ser2448, and S6 ribosomal protein on 
Ser235/236 were determined by western blot. Brain-derived neurotrophic factor induced the 
phosphorylation of Akt after 5 mins of treatment (Figure 4A). The level of phosphorylation 
was increased by ~300% above control (set at 100%) after 5 mins of treatment. Maximal 
activation was reached after 30 mins. Phosphorylation of Akt was sustained for 1 h of BDNF 
treatment. To obtain the confirmation that Akt signaling can be inhibited in a manner similar 
to MCT2 upregulation, cultured cortical neurons were pretreated with 10 mmol/L LY294002 
for 30 mins before the addition of BDNF (100 ng/mL) for 5 mins, 30 mins, and 1 h. Indeed, 
LY294002 pretreatment prevented the phosphorylation of Akt induced by BDNF in cultured 
cortical neurons (Figure 4A). Activation of mTOR by BDNF treatment was investigated by 
monitoring its level of phosphorylation. Brain-derived neurotrophic factor induced the 
phosphorylation of mTOR within 5 mins after the beginning of the treatment (Figure 4B). 
Phosphorylation of mTOR was further increased by more than 50% above the control level 
after 1 h of BDNF treatment. To determine whether mTOR activation can be prevented in the 
same manner as MCT2 upregulation, cultured cortical neurons were pretreated with 20 ng/mL 
rapamycin for 30 mins before adding BDNF (100 ng/mL) for 5 mins, 30 mins, and 1 h. 
Rapamycin pretreatment completely prevented the phosphorylation of mTOR induced by 
BDNF in cultured cortical neurons at 30 mins (Figure 4B). S6 phosphorylation represents one 
of the late steps in the activation of the PI3K/Akt/mTOR/S6 pathway. Phosphorylation levels 
of S6 were assessed after BDNF treatment. Brain-derived neurotrophic factor induced the 
phosphorylation of S6 within 5 mins after the beginning of the treatment (80% above control; 
Figure 4C). Maximal activation was reached after 1 h with an increase of 350% above control. 
As the S6 protein is known to be a downstream effector of the Akt/mTOR signaling pathway, 
cultured cortical neurons were pretreated with 20 ng/mL rapamycin (inhibitor of mTOR) for 
30 mins before the addition of BDNF for 5 mins, 30 mins, and 1 h. It was observed that 
rapamycin pretreatment completely prevented the phosphorylation of S6 ribosomal protein 
induced by BDNF in cultured cortical neurons (Figure 4C).
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Fig.4. Effect of BDNF on the phosphorylation levels of Akt, mTOR and S6 in cultured mouse cortical neurons. 
Western blot analysis of phospho-Akt (A), phospho-mTOR (B), phospho-S6 (C) levels in cultures of mouse cortical neurons 
treated with BDNF 100ng/ml for the indicated times as compared with untreated cells (ctrl). A) LY294002, a specific PI3K 
inhibitor, was added to the culture medium at the concentration of 10µM, 30min before to incubation with BDNF 100ng/ml 
during 5min, 30min and 1h. Western blots were quantified using Odyssey software (LI-COR). Results are expressed as 
percent of control after the values had been normalized using -actin signal as reference. B) and C) Rapamycin, a specific 
mTOR inhibitor, was added to the culture medium at the concentration of 20ng/ml, 30min prior to incubation with BDNF 
100ng/ml. Results are expressed as percent of control after the values had been normalized using either -actin signal (A,C) 
or mTOR signal (B) as reference. Statistical analysis was performed using ANOVA followed by Bonferroni’s test. **, *** 
indicates phospho-Akt, phospho-mTOR or phospho-S6 protein levels significantly different from control with p< 0.01, 
p<0.001 respectively. #, ##, ### indicates phospho-Akt, phospho-mTOR or phospho-S6 protein levels significantly different 
from BDNF-treated condition with p<0.05, p<0.01, p<0.001 respectively. Numbers in the graph bars represent the number of 
independent experiments for each condition. 
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Mitogen-activated protein kinase activation is purported to be involved in the effect of BDNF 
on MCT2 expression. Phosphorylation levels of p44 and p42 MAPK (phospho-ERK) on 
Thr202/Tyr204 were determined by western blot after treatment of cultured cortical neurons 
with BDNF (100 ng/mL) for three different time periods (5 mins, 30 mins, and 1 h). Brain-
derived neurotrophic factor induced the phosphorylation of p44 and p42 MAPK after 5 mins 
of treatment (Figure 5A). The level of phosphorylation was increased by more than 500% (for 
both p44 and p42) above control (set at 100%) at that time. Phosphorylation of p44 and p42 
MAPK was sustained for 1 h of BDNF treatment. To ascertain whether MAPK activation can 
be prevented similar to MCT2 upregulation, cultured cortical neurons were pretreated with 50 
mmol/L PD98059 for 30 mins before the addition of BDNF (100 ng/mL) for 5 mins, 30 mins, 
and 1 h. As expected, PD98059 pretreatment attenuated the phosphorylation of p44 and p42 
MAPK induced by BDNF in cultured cortical neurons (Figure 5A). 
 
Activation of p38 MAPK is another possible signaling mechanism involved in BDNF-
induced MCT2 upregulation. Phosphorylation levels of p38 MAPK on Thr180/Tyr182 were 
determined by western blot. Brain-derived neurotrophic factor induced the phosphorylation of 
p38 MAPK that reached a maximum after 1 h with an increase of B150% above control (set at 
100%; Figure 5B). To investigate whether p38 MAPK activation can be prevented using the 
inhibitor previously used, cultured cortical neurons were pretreated with 10 mmol/L 
SB202190 for 30 mins before the addition of BDNF (100 ng/mL) for 5 mins, 30 mins, and 1 
h. SB202190 pretreatment was found to prevent phosphorylation of p38 MAPK induced by 
BDNF in cultured cortical neurons (Figure 5B). 
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Fig.5. Effect of BDNF on the 
phosphorylation levels of ERK and 
p38 MAPK in cultured mouse 
cortical neurons. Western blot 
analysis of phospho-ERK (A) and 
phospho-p38 MAPK (B) levels in 
cultures of mouse cortical neurons 
treated with BDNF 100ng/ml for the 
indicated times as compared with 
untreated cells (ctrl). A) PD98058, a 
specific MEK inhibitor, was added to 
the culture medium at the 
concentration of 50µM, 30min before 
to incubation with BDNF 100ng/ml 
during 5min, 30min and 1h. B) 
SB202190, a specific p38 MAPK 
inhibitor, was added to the culture 
medium at the concentration of 10µM, 
30min prior to incubation with BDNF 
100ng/ml. Western blots were 
quantified using Odyssey software 
(LI-COR). Results are expressed as 
percent of control after the values had 
been normalized using -actin signal 
as reference. Statistical analysis was 
performed using ANOVA followed by 
Bonferroni’s test. *** indicates 
phospho-ERK or phospho-p38 MAPK 
levels significantly different from 
control with p<0.001. ##, ### 
indicates phospho-ERK or phospho-
p38 MAPK levels significantly 
different from BDNF-treated condition 
with p<0.01, p<0.001 respectively. 
Numbers in the graph bars represent 
the number of independent 
experiments for each condition.  
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2.3.4 BDNF enhances MCT2 expression by a translational mechanism 
 
The effect of BDNF on MCT2 mRNA expression was investigated by quantitative reverse 
transcriptase-PCR on total RNA from mouse cortical neurons. Neurons were treated with 
BDNF (100 ng/mL) for various time points up to 24 h. Figure 6A shows that BDNF exerted 
no enhancing effect on MCT2 mRNA levels at any time point, whereas NPY mRNA levels (a 
peptide known to be transcriptionally regulated) showed a significant increase after 12 and 24 
h. A small but significant decrease in MCT2 mRNA levels was observed at 3 h. To ascertain 
whether the effect of BDNF on MCT2 expression requires the activation of translation but not 
of transcription, cultured neurons were treated with inhibitors for these two processes. 
Application of cycloheximide (10 mmol/L), a protein synthesis inhibitor, 30 mins before 
BDNF stimulation (100 ng/mL), prevented the enhancement of MCT2 protein expression 
(Figure 6B). Quite unexpectedly, the mRNA synthesis inhibitor ActD (5 mmol/L) also 
blocked the effect of BDNF on MCT2 protein expression. To determine whether the 
enhancement in MCT2 protein synthesis occurs at the synaptic level and requires 
transcriptional activation, an experiment was conducted on synaptoneurosomes (Figure 6C). 
Brain-derived neurotrophic factor (100 ng/mL) induced an increase in MCT2 protein 
expression after 6h in this preparation. The effect of BDNF was prevented by cycloheximide 
(10 mmol/L) but not by ActD (5mmol/L). 
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Fig.6. Effect of transcription and translation inhibitors on BDNF-induced enhancement of MCT2 protein expression 
in primary cultures of mouse cortical neurons. Western blot analysis of MCT2 expression in primary cultures of mouse 
cortical neurons exposed to either actinomycin D (ActD) or cycloheximide (CHX) for 30min prior to application of 100ng/ml 
BDNF for 6h. Western blots were quantified using Odyssey software (LI-COR). Results are expressed as percent of control 
after the values had been normalized using -actin signal as reference. Statistical analysis was performed using ANOVA 
followed by Bonferroni’s test. * indicates MCT2 protein levels significantly different from control with p<0.05. #, ## 
indicates MCT2 protein levels significantly different from BDNF-treated condition with p<0.05, p<0.01 respectively. 
Numbers in the graph bars represent the number of independent experiments for each condition 
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2.4 Discussion 
 
In recent years, BDNF has emerged as a major regulator of synaptic transmission and 
plasticity at adult synapses in many regions of the central nervous system (Bramham and 
Messaoudi, 2005). Among the mechanisms subserving synaptic plasticity, enhancement of 
localized protein synthesis constitutes a critical process for long-term adaptation of synaptic 
efficacy. Brain-derived neurotrophic factor is one of the major activity-dependent modulators 
of dendritic protein synthesis and it is known to activate specific components of the 
translational machinery in neurons (Bramham and Messaoudi, 2005; Steward and Schuman, 
2003). Previously, it has been shown that the rapid induction of protein synthesis by BDNF is 
mediated both through the PI3K pathway, as it involves the activation of PI3K and mTOR 
(Bramham and Messaoudi, 2005; Schratt et al, 2004; Yoshii and Constantine-Paton, 2007), as 
well as through the MAPK signaling pathway (Kelleher et al, 2004). Interestingly, BDNF was 
shown in this study to enhance MCT2 protein expression in cultured cortical neurons through 
a stimulation of translation. This is supported by the observations that no changes in MCT2 
mRNA levels were detected, whereas MCT2 protein expression was enhanced by BDNF in 
synaptoneurosomes, a preparation that can sustain translation but not transcriptional 
activation. The observation that the mRNA synthesis inhibitor ActD can prevent 
BDNFinduced enhancement of MCT2 protein expression in intact cells but not in 
synaptoneurosomes is intriguing. It cannot be excluded that as a general transcription 
inhibitor, ActD indirectly interferes with the translation process in intact cells by reducing the 
expression of some essential components. The effect of BDNF on MCT2 protein expression 
was shown to involve the activation of three distinct signaling pathways, all classically 
implicated in the regulation of translation initiation (Hay and Sonenberg, 2004). Thus, a 
concomitant activation of PI3K/Akt/mTOR, p38 MAPK as well as MEK/ ERK kinases was 
found to be necessary for the enhancement of MCT2 protein expression by BDNF (Figure 7). 
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Fig.7. Putative signalling pathways leading to translational activation and enhanced MCT2 protein synthesis following 
BDNF treatment in cultured cortical neurons. BDNF, acting via TrkB receptors, can activate distinct signal transduction 
pathways involving specific kinases leading to translation initiation. Two pathways investigated in this study are illustrated 
here (PI3K/Akt/mTOR/S6 and MAPK signalling pathways). Proteins highlighted were directly investigated for their level of 
phosphorylation. First, phosphorylation of PI3K can cause the phosphorylation and activation of Akt. Akt then directly 
phosphorylates mTOR which in turn phosphorylates p70S6K. The target of p70S6K, the ribosomal S6 protein, once 
phosphorylated, participates in the tranlational machinery as part of the 40S complex. Second, the MAPK cascade is also 
activated by BDNF requiring activation of MEK. MEK phosphorylates the p44- and p42- MAPK which can activate, among 
others, MNK1. Once activated, MNK1 phosphorylates eIF4E on Ser209 and it correlates with enhanced rates of translation of 
capped mRNA. Specific inhibitors for some kinases have been used to distinguish the implication of each pathway in the 
effect of BDNF: LY294002, PI3K inhibitor; Rapamycin, mTOR inhibitor; PD98058, MEK inhibitor; SB202190 and 
SB203580, p38 MAPK inhibitors; AG490, JAK2 inhibitor. 
 
 
Such an observation suggests a putative cross talk between the different signaling pathways 
activated by BDNF to regulate translational activation, a possibility previously proposed by 
others (Almeida et al, 2005; Bramham and Messaoudi, 2005). It is noted that noradrenaline (a 
neurotransmitter), insulin (a hormone), and IGF-1 (a neurotrophic factor) were also previously 
shown to regulate MCT2 protein expression at the translational level, notably by activating 
the PI3K/Akt/mTOR/S6 kinase pathway in cultured cortical neurons (Chenal and Pellerin, 
2007; Chenal et al, 2008). As each of these neuroactive substances, similar to BDNF, has 
been implicated in different forms of synaptic plasticity, it suggests that MCT2 represents a 
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common target for such signals, pointing to a putatively important role of MCT2 in relation to 
synaptic modifications.  
 
In view of the current results, it appears that MCT2 belongs to a group of neuronal proteins 
specifically regulated at the translational level. Until now, more than 100 different mRNAs 
coding for proteins involved in neurotransmission and in the modulation of synaptic activity 
have been identified in dendrites. Local protein synthesis from these mRNAs is postulated to 
provide the basic mechanism of long-term changes in the strength of neuronal connections 
(Skup, 2008). Postsynaptic proteins that undergo enhancement of their synthesis locally 
include calmodulin kinase II (Ouyang et al, 1999; Wu and Cline, 1998), MAP2 (Blichenberg 
et al, 1999), Arc/Arg 3.1 (Steward and Schuman, 2001), and GluR1, as well as GluR2 AMPA 
receptor subunits (Ju et al, 2004). Although the presence of MCT2 mRNA has not been 
described yet in dendrites, it seems likely that the translational regulation of MCT2 expression 
would occur locally. Our results obtained with synaptoneurosomes support this conclusion. 
The MCT2 protein is not only present in dendrites but it is also specifically associated with 
spines, where it was found to be expressed in the postsynaptic density as well as on vesicle-
like structures forming an intracellular pool (Bergersen et al, 2005). MCT2 was recently 
found to interact with a specific subset of postsynaptic proteins (Pierre et al, 2009). This is 
particularly the case with GluR2, a subunit of the glutamatergic AMPA receptor subtype. It 
was shown that MCT2 seems not only to determine the subcellular localization of GluR2 in 
neural cells but also to regulate its expression levels (Maekawa et al, 2009). In addition, it was 
observed that MCT2 together with GluR2 undergoes a trafficking process between the plasma 
membrane and an intracellular pool under conditions inducing synaptic plasticity (Pierre et al, 
2009). Translocation of GluR2 to and from the plasma membrane has been implicated in 
synaptic plasticity mechanisms, such as long-term potentiation and long-term depression 
(Kessels and Malinow, 2009; Malenka, 2003; Sheng and Kim, 2002). Thus, MCT2 
localization and interaction with specific synaptic proteins involved in plasticity mechanisms 
strengthen the view that its expression may be regulated in a manner similar to its partners. In 
this regard, increased MCT2 protein expression by BDNF may be part of a coordinated 
mechanism of local synthesis for various postsynaptic proteins involved in the long-term 
regulation of glutamatergic transmission. Although a major effort has been devoted to 
decipher the molecular events involved in synaptic plasticity, including those induced by 
BDNF, few studies have explored the concomitant changes in neuroenergetics that could take 
place with alterations in synaptic transmission. Recently, the concept that energy metabolism 
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might be coupled to synaptic plasticity has been proposed together with the implication of 
BDNF in such interactions (Vaynman et al, 2006). Indeed, BDNF was shown to enhance 
mitochondrial activity (El Idrissi and Trenkner, 1999). Regarding the energy substrates that 
might be concerned, lactate has attracted much attention recently. Lactate has been shown to 
be a preferential oxidative substrate for neurons both in vitro (McKenna et al, 1993, 1994) and 
in vivo (Hyder et al, 2006; Serres et al, 2005). Lactate is not only able to sustain synaptic 
vesicle turnover and synaptic transmission (Morgenthaler et al, 2006; Rouach et al, 2008; 
Schurr et al, 1988) but it is also shown to allow, at least in part, the establishment of long-
term potentiation (Izumi et al, 1997; Yang et al, 2003). In addition, glutamatergic activity 
increases the production and release of lactate by astrocytes (Pellerin and Magistretti, 1994), 
and it has been purported that such an effect participates in a mechanism to provide lactate as 
an additional energy substrate to neurons to sustain their activity (Pellerin et al, 2007). As the 
primary role of MCT2 is to supply neurons with nonglucose energy substrates, e.g., lactate, 
changes in MCT2 expression might facilitate the utilization of alternative substrates. Indeed, 
overexpression of MCT2 in neurons was shown to enhance lactate consumption by neurons 
stimulated with kainite (Bliss et al, 2004). Our observation that MCT2 can be upregulated by 
BDNF is consistent with the possibility of a coupling between lactate utilization and synaptic 
plasticity. It is hypothesized that to meet higher energy demands caused by enhanced synaptic 
transmission after synaptic plasticity, MCT2 expression is increased to facilitate lactate 
supply at potentiated synapses. 
 
In conclusion, we have shown that BDNF enhances the expression of the monocarboxylate 
transporter MCT2 in cultured cortical neurons through a translational regulation. A possible 
role for such an effect could be to enlarge the local lactate transporter pool to allow 
potentiated synapses to meet higher energy demands on activation. 
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Chapter 3 
 
Possible regulation of MCT2 protein synthesis via miRNA 
 
 
 
 
 
3.1 Introduction 
 
3.1.1 Protein synthesis, from mRNA to protein: an overview 
 
Following transcription, processing and nucleocytoplasmic export, mRNAs are competent for 
translation. The complex process of translating mRNA into protein can be divided into four 
stages: initiation, elongation, termination and recycling (Figure 3.1). During initiation, the 
ribosome is assembled at the initiation codon in the mRNA with a methionyl initiator tRNA 
bound in its peptidyl (P) site. During elongation, aminoacyl tRNAs enter the acceptor (A) site 
where decoding takes place. If the correct tRNA is present, the ribosome catalyzes the 
formation of a peptide bond. After, tRNAs and the mRNA are translocated such that the next 
codon is moved into the A site, and the process is repeated. Termination takes place when a 
stop codon is encountered and the finished peptide is released from the ribosome. In the final 
stage, recycling, the ribosomal subunits are dissociated, releasing the mRNA and deacylated 
tRNA and setting the stage for another round of initiation (Kapp and Lorsch 2004). 
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Figure 3.1 Schematic representation of the events of eukaryotic translation. The initiation steps bring together the 40S 
and 60S ribosomal subunits, mRNA, and the initiator tRNA, which is complexed to the amino acid methionine (Met). During 
elongation, amino acids are brought to the polysome, and peptide bonds are formed between the amino acids. The sequence 
of amino acids in the growing protein is directed by the sequence of nucleic acid codons in the mRNA. After the last peptide 
bond of the protein has been made, one of the codons UAG, UGA, or UAA signals the termination of translation. The 
ribosomal subunits and message can be reutilized (Picture taken from Scott F. Gilbert, 7th edition, “A companion to 
developmental biology”). 
 
 
One mechanism used by eukaryotes to regulate gene expression is the control of translation 
rate. Translational regulation plays critical roles in cell growth, proliferation, and 
development. Advantages of translational control include rapid response and a mean to affect 
the level of gene product in the absence of transcription (Mathews 1996). Translation rates 
can be controlled at each of the three steps of translation: initiation, elongation and 
termination. However, regulation occurs predominantly during the initiation step. The rate-
limiting step in translation initiation under most circumstances is binding of the 43S 
preinitiation complex to mRNA. This step is the primary target for translational control 
(Gingras et al., 1999). Two general modes of control exist. There is a global control in which 
the translation of most mRNAs in the cell is regulated and mRNA-specific control whereby 
the translation of a defined group of mRNAs is modulated without affecting general protein 
biosynthesis (Gebauer and Hentze 2004). Global regulation mainly occurs via the 
modification of eIFs (translation initiation factors), whereas mRNA-specific regulation is 
driven by regulatory protein complexes that recognize specific elements usually present in 5’ 
and /or 3’-UTRs of target elements (Dever 2002; Wilkie et al., 2003; Gebauer and Hentze 
2004) 
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3.1.2 Dendrites as separate translational compartments - local protein synthesis  
 
Although direct behavioral evidence for the contribution of local translation in memory 
storage is limited, there is clear evidence that local translation plays a key role in synaptic 
plasticity (Sutton and Schuman, 2006). Given that transcriptional activation at the cell soma is 
required for late-phase LTP in normal hippocampal slices (Nguyen et al., 1994), initial ideas 
regarding the sites of translational control naturally focused on the cell soma, and early 
studies provided some support for this idea (Frey et al., 1989). More recent studies have 
suggested, however, that in some circumstances, translation in the dendrites themselves is 
critical, and even that somatic translation may be dispensable. For example, the neurotrophin 
BDNF induces potentiation of CA3-CA1 synaptic transmission in hippocampal slices from 
which CA1 dendrites have been surgically isolated from their cell bodies, and this effect 
requires new protein synthesis (Kang and Schuman, 1996). In a similar slice preparation, 
activation of group 1 metabotropic glutamate receptors (mGluRs) or paired-pulse low-
frequency stimulation can induce a form of LTD that requires dendritic, but not somatic, 
protein synthesis (Huber et al., 2000). Moreover, several recent studies have also 
demonstrated that isolated hippocampal dendrites of pyramidal cells can support protein-
synthesis-dependent forms of LTP (Cracco et al., 2005; Vickers et al., 2005; Huang and 
Kandel, 2005), and that focal dendritic application of protein-synthesis inhibitors in intact 
slices inhibits late LTP (Bradshaw et al., 2003). 
 
A study has demonstrated a rapid form of synaptic plasticity, elicited by dopamine agonists, 
that requires local protein synthesis (Smith et al., 2005). Restricted application of a dopamine 
D1/D5 receptor agonist to a dendritic segment led to an increase in endogenous protein 
synthesis in cultured hippocampal neurons. In addition, D1/D5 receptor activation led to a 
rapid, protein-synthesis inhibitor-sensitive increase in the frequency of spontaneous miniature 
excitatory postsynaptic currents (mEPSCs or “minis”), likely mediated by an increase in the 
number and size of synaptic GluR1 particles. These data suggest that local protein synthesis 
may be important for the conversion of synapses from a silent to an active state. Taken 
together, these studies indicate that the site where plasticity is initiated can determine the 
cellular location where protein synthesis is required. 
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3.1.3 MicroRNA: role in regulation of protein synthesis  
 
The discovery of microRNAs (miRNAs) has introduced an important new layer of regulatory 
control of gene expression. miRNAs are short non-coding RNAs, about 21 nucleotides long, 
that modulate gene expression at the post-transcriptional level by guiding cellular machinery 
to the 3′-untranslated region (3′-UTR) of specific messenger RNAs (mRNAs) to control their 
expression. Most miRNAs are transcribed by polymerase II, although a few human miRNAs 
have been shown to be transcribed by polymerase III (Borchert et al., 2006). The primary 
transcript (pri-miRNA) can be up to several thousands nucleotides long and contains internal 
hairpin structures. Within the nucleus, the pri-miRNA is processed by the RNase III enzyme 
Drosha, resulting in a 70 nt long hairpin precursor miRNA (pre-miRNA) containing a 2-nt 
3′overhang. This overhang is recognized by Exportin-5, which transports the pre-miRNA into 
the cytoplasm (Figure 3.2). In the cytoplasm, the pre-miRNA is further cleaved by the RNase 
III enzyme Dicer. This results in the formation of an intermediary miRNA: miRNA* duplex 
consisting of the 21 nt mature miRNA and its star sequence, miRNA*. Following 
unwinding of the miRNA duplex by a helicase, the mature miRNA is incorporated into the 
RNA-induced silencing complex (RISC), whereas the miRNA* is usually degraded. Binding 
of a miRNA to its target mRNA requires both RISC and the presence of Argonaute (Ago) 
proteins. Depending on the degree of complementarity between the miRNA and its target, the 
target mRNA can either be cleaved and degraded or translationally repressed (Figure 3.2). 
Perfect complementarity induces degradation of the mRNA, whereas non-perfect 
complementarity results in translational inhibition. In animals, miRNA silencing of gene 
expression is predominantly mediated by translational blockade. The miRNA induced 
translational inhibition appears to be reversible in a few instances (Bhattacharyya et al., 2006; 
Schratt et al., 2006), rendering the miRNA mediated regulation dynamic and responsive to 
specific cellular needs.  
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Figure 3.2. RNA biogenesis and mode of action (Picture taken from Schratt 2009). 
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3.1.4 Synaptic protein synthesis associated with synaptic plasticity 
 
New protein synthesis is required for certain forms of long-term memory establishment and in 
some cases newly synthesized proteins derive from the local translation of mRNAs within 
neuronal processes. A subset of these mRNAs is located in the dendritic shaft and in spines 
(Sutton and Schuman, 2006; Siegel et al., 2011), small actin-rich protrusions from dendrites 
and the primary sites of excitatory synaptic contact. Several recent findings suggest that 
miRNA function in the translational control of dendritically localized mRNAs. Both miRNAs 
and pre-miRNAs have been detected in synaptoneurosomes (Lugli et al., 2008; Siegel et al., 
2009). The involvement of miRNAs in the regulatory control of local protein synthesis at the 
mammalian synapse was provided by a study of brain-specific miRNA, miR-134, in cultured 
hippocampal neurons (Figure 3.3). miR-134 is located in the synaptodendritic compartment 
where it co-localizes and inhibits translation of Lim-domain containing protein kinase 1 
(Limk1), a regulator of actin filament dynamics involved in dendritic spine morphology. The 
downregulation of Limk1 protein synthesis restricts the growth of dendritic spines, thereby 
limiting excitatory synapse development. Interestingly, the interaction between Limk1 mRNA 
and miR-134 is relieved by exposure of neurons to brain-derived neurotrophic factor (BDNF), 
a neurotrophin secreted in response to synaptic stimulation (Figure 3.3) (Schratt et al., 2006; 
Fiore et al., 2008). The overexpression of miR-134 produced a dendritic spine volume 
phenotype similar to Limk1 loss of function. Schratt and colleagues have found that 
membrane depolarization elevated the expression of the miR-134 precursor. The induction of 
miR-134 expression could form part of a negative feedback loop that restores RISC silencing 
after an initial burst of synaptic protein synthesis. But the mechanism underlying the switch 
between translational inhibition and activation of Limk1 or other proteins by miR-134 is 
currently unkown. 
 
In an interestingly related study, Vo et al. found the expression of a microRNA (miR-132) to 
be a direct target of BDNF regulation, which was mediated through the transcription factor 
CREB (Vo et al., 2005). A computational search predicted that P250GAP (a possible 
regulator of Rho or Rac) would be a target of miRNA132. Both miRNA-132 overexpression 
and Knockdown of P250GAP expression induced neurite outgrowth in transfected rat primary 
cortical neurons. These observations indicate that CREB acts through the miR-132-mediated 
silencing of P250GAP to promote neurite growth (Vo et al., 2005). 
 
 94 
miR-138, another brain-specific miRNA, is located in dendrites and regulates negatively spine 
size. miR-138 inhibits the expression of Acyl protein thioesterase1 (APT1), a 
depalmitoylating enzyme controlling the palmitoylation status of proteins at the synapse and 
hence their membrane association. Several signalling molecules are substrates for APT1, 
notably G protein alpha subunits (Gα). All together, evidences show that synaptic protein 
synthesis under miRNA control is associated with synaptic plasticity.  
 
 
 
 
 
Figure 3.3. MicroRNA function in dendritic spine morphogenesis and synaptic plasticity. Dendritic microRNAs, such as 
miR-134, are synthesized and processed in the neuronal cell soma, where they are presumably assembled together with their 
target mRNAs (e.g. Limk1) into transport granules that mediate localization to the synaptodendritic compartment. Inset: 
within dendrites, the miR-134/Limk1 complex is stored close to dendritic spines in a translationally inactive state due to the 
inhibitory function of miR-134. Upon synaptic stimulation, the release of BDNF inactivates miR-134 by an unknown 
mechanism, giving rise to Limk1 mRNA translation and spine remodeling. Note that the mechanism of dendritic transport of 
miR-134 and other miRNAs has not yet been experimentally addressed and could involve transport of miRNA precursors 
into dendrites and local processing. (Taken from Fiore et al., 2008) 
 
 
Mammalian hippocampal neurons are enriched in miRNA-134 that inhibits translation of 
Limk1 (a protein involved in spine development), thus blocking excitatory synaptic 
transmission and size of dendritic spines. But, the molecular mechanism by which miRNAs 
silence the expression of their target mRNAs remains unclear. As previously described, 
neuronal activity via BDNF release derepressed the miR-134–mediated translation inhibition 
of Limk1 mRNA (Schratt et al., 2006). In chapter 2, we observed that MCT2 seems to be 
regulated by a translational mechanism following BDNF stimulation both in primary neuronal 
cultures and in synaptoneurosome preparations (Robinet and Pellerin 2010). Because 
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miRNAs regulate the expression of target genes affecting protein translation and since a 
single miRNA is able to target up to a few hundreds of different mRNAs (Lewis et al., 2005), 
we decided to investigate the putative regulation of MCT2 translation by miRNA, and more 
specifically as a new target of miR-134 following BDNF stimulation. 
 
 
3.2 Experimental procedure 
 
Neuronal Cultures and Pharmacological Treatments 
Primary cultures of mouse cortical neurons were prepared from embryonic day 17 OF1 mice 
(Charles River, Lyon, France). As described previously, after decapitation and brain 
dissection, cortices were mechanically dissociated in phosphate-buffered saline (PBS) 
supplemented with glucose (NaCl, 150 mmol/L; KCl, 3 mmol/L; KH2PO4, 1.5 mmol/L; 
Na2HPO4, 7.9 mmol/L; glucose, 33 mmol/L; penicillin, 0.006 g/L; streptomycin, 0.1 g/L; pH 
7.4). Cells were plated on poly L-ornithine (15 mg/L)-precoated dishes and cultured in 
neurobasal-B27 medium supplemented with 0.5 mmol/L L-glutamine. All experiments were 
carried out on day 7 in vitro. At this stage, cultures contained <5% of glial cells. Neuronal 
treatments with pharmacological agents were carried out without changing the medium before 
or during the incubation time. Brain-derived neurotrophic factor (CYT-207; Brunschwig, 
Basel, Switzerland) was added directly into the culture medium at various concentrations and 
cells were incubated for the indicated times. All other chemicals were purchased from Sigma.  
 
Neuronal transfection 
After 6 days, primary neuronal cultures were transfected either with the siRNA Alexafluor 
488 or with the anti-miRNA (anti-miR134 or anti-miR132) using a lipid-based transfection 
reagent (HiPerFect, Qiagen). The appropriate amount of siRNA or anti-miRNA (5µl from 
initial concentration of 20µM, for a final concentration of 50nM) was diluted in Neurobasal 
medium, and then, 5 μL of transfecting agent (lyophilized samples were diluted in H2O at a 
concentration of 1 mg/mL, storage at 4 °C) were added and diluted in Neurobasal medium to 
a final volume of 1ml. The medium was mixed and incubated at room temperature for 10 min 
to allow transfection complex formation. The transfection complexes were added dropwise 
onto the cells. The cells were incubated at 37°C until silencing analysis. The transfection was 
visualized by immunocytochemistry. 
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Immunocytochemistry and Related Quantification 
After removal of the culture medium, cells were carefully rinsed in PBS at 37°C and directly 
postfixed in an ice-cold paraformaldehyde fixative (4% in PBS for 30 mins at 20°C). Fixed 
cells were treated with casein (0.5% in PBS) for 1 h at room temperature to block nonspecific 
sites. For immunostaining, cultures were incubated overnight at 4°C in 50 μL of freshly 
prepared MAP2 antibody solution (anti-MAP2 diluted 1:200 in PBS containing 0.25% bovine 
serum albumin). After carefully rinsing in PBS, cultures were incubated in a solution 
containing Cy3-conjugated anti-rabbit Igs (diluted 1:500 for 2 h at room temperature; Jackson 
Immunoresearch, Baltimore, MD, USA). After rinsing in PBS twice and a final rinsing in 
water, coverslips were mounted with Vectashield (Reactolab SA, Burlingame, CA, USA). 
Coverslips were examined and photographed with an Axioplan2 microscope (Zeiss, 
Hallbergmoos, Germany) using epifluorescence with an appropriate filter. 
 
Western Blot and Related Quantification 
Neurons in each culture dish were homogenized in 50 μL of buffer containing the following: 
Tris-HCl, pH 6.8, 20 mmol/L; sucrose, 0.27 mol/L; EGTA (ethylene glycol tetraacetic acid), 
1 mmol/L; EDTA (ethylene diamine tetraacetic acid), 1 mmol/L; NaF, 50 mmol/L; Triton X-
100, 1%; β-glycerophosphate, 10 mmol/L; DTT (dithiothreitol), 10 mmol/L; 4-
nitrophenylphosphate, 10 mmol/L; and a mixture of protease inhibitors (Complete, Roche 
Molecular Biochemicals, Mannheim, Germany). Each stimulated condition was examined in 
duplicate and the contents of the two Petri dishes were pooled. Protein samples were 
sonicated and heated at 95°C for 5 mins in half the final volume of SDS-PAGE sample buffer 
(Tris-HCl, 62.5 mmol/L; DTT, 50 mmol/L; SDS, 2%; glycerol, 10%; and bromophenol blue, 
0.1%). Samples were loaded onto polyacrylamide gels composed of a 10% or 6% acrylamide-
bisacrylamide running gel and a 4.5% acrylamide-bisacrylamide stacking gel. After 
electrophoresis, proteins were transferred onto nitrocellulose membranes (Trans-Blot Transfer 
Medium 162-0115; Bio-Rad, Reinach, Switzerland) using a Transblot semi-dry transfer cell 
(Bio-Rad). For protein detection, membranes were incubated in a blocking solution of Tris-
buffered saline supplemented with Tween-20 (TBST; Tris-HCl, pH 7.5, 50 mmol/L; NaCl, 
150 mmol/L; and Tween-20, 0.1%) containing 5% nonfat milk for 1 h at room temperature. 
Membranes were incubated overnight at 4°C with anti-MCT2 (Pierre et al., 2000), anti-Limk1 
(Cell signaling) and anti-β-actin (Sigma). After three washes in TBST, membranes were 
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incubated with the secondary antibodies Alexa Fluor 680 goat anti-IgG (Juro, Lucerne, 
Switzerland) and IRDye 800 goat anti-mouse IgG (BioConcept), diluted at 1:5,000 in TBST 
containing 1% nonfat milk, for 2 h at room temperature, and protected from light. After three 
washes in TBST, membranes were scanned using the Odyssey Infrared Imaging System (LI-
COR Biosciences, Lincoln, NE, USA), which permits detection and quantification of proteins 
of interest. β-Actin, revealed in green, was used for normalization and MCT2 was revealed in 
red.  
 98 
3.3 Preliminary results  
 
 
In order to study the putative control of miR-134 on MCT2 expression following BDNF 
stimulation, the transfection of an inhibitor of miR-134 (Anti-miR134) was performed on 
primary cultures of cortical neurons. If miR-134 regulates MCT2 expression, we would 
expect to obtain an upregulation of MCT2 after transfection of the Anti-miR-134. First, we 
controlled the transfection quality and transfection rate of a fluorescent siRNA (siRNA 
Alexafluor 488) using the Hiperfect transfection reagent on primary neuronal cultures (Figure 
3.4, a,b,c). We performed a MAP2 immunostaining (in red) of neuronal cultures to localize 
siRNA Alexafluor 488 (in green) in neurons. Results showed that siRNA Alexafluor 488 
seems to be associated with neuronal processes, suggesting that some siRNA Alexafluor 488 
has entered into the cell (Figure 3.4, a). However, we also observed that these siRNAs were 
bound together, often forming fluorescent clusters outside cells, that probably partially 
prevented their internalization into cells (Figure 3.4, b,c).  
 
 
 
 
 
Figure 3.4. Transfection of primary cultures of mouse cortical neurons treated with siRNA Alexafluor 488 (in green) using 
HiPerFect transfection Reagent (Qiagen) at a final concentration 2.75μl/ml. Panels represent immunocytochemical stainings 
for MAP2 (in red). The nuclei are labelled with DAPI (in blue). Magnification, 63X ; calibration bar, 15μm. As pointed out 
by white arrows, fluorescent siRNAs were associated with neuronal processes (a) but often formed clusters outside cells 
(b,c).  
  
 
 
a) b) c)
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Figure 3.5. Effect of miRNA inhibitors (anti-miR134 and anti-miR132) on MCT2 expression following BDNF stimulation in 
primary neuronal cultures. Primary cultures of mouse cortical neurons are pretreared for 10 mins with anti-miR (2.75μl/ml). 
Neurons treated with BDNF 100ng/ml for 6h were used as positive control. The bar graph represents the quantitative 
determination of fluorescent intensity corresponding to MCT2 IR in cultured neurons treated or not with anti-miR followed 
by exposure to BDNF for 6h. Results are expressed as percentage of control fluorescence intensity and reprensent the mean 
+/- s.e.m. from ten distinct experiments. One-way ANOVA followed by Dunnet’s post hoc test were used for data analysis. 
P-values < 0.05 were considered as statistically significant. 
 
 
 
To assess the effect of Anti-miR134 on neuronal MCT2 protein and Limk1 protein expression 
(used as positive control), cultured cortical neurons were treated with the Anti-miR134 for 
24h prior to add BDNF (100 ng/mL) for 6 h. We used the miR-132 repressor as negative 
control. Indeed, it is known that miR-132 is a direct target of BDNF regulation, which seems 
to act through the transcription factor CREB. Western blot analysis showed that BDNF 
significantly increased MCT2 expression (p<0.05). However, BDNF did not significantly 
increase Limk1 expression due to the high variability obtained (Figure 3.5a). The transfection 
of the Anti-miR134 had a tendency to increase the level of MCT2 and Limk1 but these effects 
were not significant statistically (p=0.061, n=10) (Figure 3.5a). Concerning the effect of anti-
miR132, we did not observe any effect on MCT2 expression (Figure 3.5b). 
Despite the fact that transfection levels were very low, we could still observed a tendency 
toward an increase in the level of MCT2 protein by inhibiting the miR-134. These results 
suggest to us that if we could improve the transfection rate, we would obtain a significant 
effect of the Anti-miR134 on MCT2 expression. Here, the use of viral vectors might be a 
useful alternative approach that was used successfully by Christensen and co-workers for this 
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purpose (Christensen et al., 2010). Indeed, they obtained very good transfection rate and low 
cell death. 
 
3.4 Discussion and perspectives 
 
Brain-specific miRNAs play a role in synaptic function, and in CNS neurons, BDNF is also a 
key player in synaptic plasticity. The interaction between BDNF and brain-specific miRNAs 
is an area of recent focus. Remarkably, the loss of brain-specific miRNAs enhances learning 
and memory in mice (Konopka et al., 2010). The authors show that in Dicer mutant mice, the 
efficacy at hippocampal synapses and translation of BDNF was higher than in control 
(Konopka et al., 2010). As mentioned above, Schratt et al. reported involvement of miR134 in 
BDNF-regulated dendritic spine size in hippocampal neurons (Schratt et al., 2006). The miR-
134 is localized in dendrites, and negatively regulates spine size by repressing the translation 
of Limk1 mRNA, which is known to regulate dendritic structures (Meng, 2004). They 
demonstrated that BDNF relieves suppression of Limk1 translation caused by miR-134 
(Schratt et al., 2006).  In the same manner, our results tend to show that BDNF seems to 
inhibit the suppression of MCT2 translation caused by miR-134 in primary neuronal culture. 
A recent study shows that miR-134 regulates memory and neuronal plasticity (Gao et al., 
2010). The mammalian Sir2 homolog SIRT1 seems to promote synaptic plasticity by an 
upregulation of CREB expression via a repression of miR-134, as mutant mice lacking SIRT1 
catalytic activity showed reduction in both CREB and BDNF proteins and upregulation of 
miR134. A knockdown of miR134 rescues the hippocampal long-term potentiation and 
memory impairments caused by SIRT1 deficiency in mutant mice lacking SIRT1 catalytic 
activity in a brain-specific manner (Gao et al., 2010). However, until now no study was 
performed on a putative regulation of miR134 on some synaptic proteins involved in synaptic 
plasticity, such as AMPA receptor and NMDA receptors. Thus, if miR-134 is involved in 
synaptic plasticity, and that BDNF increases the level of MCT2 by inhibiting the repressor 
effect of miR-134, it would further suggest that MCT2 is also implicated in synaptic plasticity 
processes (as previously suggested in the discussion of chapter 2). However, to confirm these 
findings, it would be interesting to demonstrate a similar localization of miR-134 and MCT2 
mRNA in dendrites by using a technique such as fluorescent in situ hybridization (Fish) (as 
already performed for MCT2 by Chenal J., thesis report, 2007). Indeed, miR134 was found in 
the dendritic compartment of hippocampal neurons (Schratt et al., 2006). 
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Therefore it is tempting to speculate that miRNAs (for exemple miR-134) might also control 
local protein synthesis, synaptic plasticity (reviewed by Konopka et al., 2011) and energy 
metabolism in neurons (lactate uptake through MCT2, figure 3.6). But further studies are 
necessary to test this hypothesis. It would be first important to test the complementarity 
between the 5’ end of the miRNA, called the seed region, and the 3’ UTR of the target 
mRNA, as it appears to be critical for binding. More variability is tolerated in the base pairing 
at the 3’end of the miRNA (reviewed by Bushati N and Cohen SM, 2007). Then, it would be 
interesting to study the putative regulation of MCT2 and other postsynaptic proteins such as 
the AMPA receptor GluR2 subunit via miR-134 in the context of synaptic plasticity. Indeed, 
we recently demonstrated in our lab that MCT2 and GluR2 are colocalized, follow the same 
trafficking process and influence their respective levels of expression (Bergersen et al., 2001; 
Pierre et al., 2009, Maekawa et al., 2009). 
 
 
 
Figure 3.6. MicroRNA function in dendritic synaptic plasticity and energy metabolism. Dendritic microRNAs, such as miR-
134, are synthesized and processed in the neuronal cell soma, where they are presumably assembled together with their target 
mRNAs (e.g. MCT2) into transport granules that mediate localization to the synaptodendritic compartment. Inset: within 
dendrites, the miR-134/MCT2 complex is stored close to dendritic spines in a translationally inactive state due to the 
inhibitory function of miR-134. Upon synaptic stimulation, the release of BDNF inactivates miR-134 by an unknown 
mechanism, giving rise to MCT2 mRNA translation and lactate uptake. (Modified from Fiore et al., 2008) 
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In contrast to miR-134, miR-132 contributes to the action of BDNF. miR-132 has been 
identified as a direct target of CREB (cAMP response element binding protein). miR-132 
exerts its positive effect by inhibiting the GTPase activating protein p250GAP, a negative 
regulator of neurite outgrowth. In cultured cortical neurons, BDNF induces upregulation of 
miR-132 (Vo et al., 2005). Interestingly, overexpression of miR-132 increases the outgrowth 
of primary neurites, and transfection of an antisense RNA for miR-132 results in a substantial 
decrease in neurite outgrowth (Vo et al., 2005). Our results showed that miR-132 inhibitor 
(Anti-miR-132) had no effect on MCT2 expression (Figure 3.5b). An explanation could be 
that MCT2 expression is independent of the transcription factor CREB. However, we 
previously observed that the transcription inhibitor Actinomycin D (ActD) prevented BDNF 
effect on MCT2 expression, suggesting that BDNF needs to activate a transcription factor to 
have a positive effect on MCT2 translation following BDNF stimulation (Robinet and 
Pellerin, 2010). In this case, miR-132 was not an appropriate miRNA control for this 
experiment. Recently it was also reported that BDNF induced a marked increase in miR-132 
levels in cultured cortical neurons (Kawashima et al., 2010). While BDNF increased the 
expression of synaptic proteins including NR2A, NR2B, and GluR1, it was demonstrated that 
transfection of double strand-miR-132 also up-regulates these glutamate receptors 
(Kawashima et al., 2010). Similar experiments could be performed in primary neuronal 
cultures by overexpression of miR-132 to quantify the level of MCT2 expression. 
 
Finally, another miRNA that might regulate MCT2 could be miR-29 (miR-29 a,b,c). miR-29 
is abundantly expressed in many tissues including brain, pancreas, liver, heart, in both murine 
and human models (Smirnova et al., 2005 ; Pullen et al., 2011 ; Roderburg C et al., 2011; Soci 
UP et al., 2011). It has been studied particularly in pancreatic beta cells. Its overexpression in 
beta cells is notably associated with type 2 diabetes, leading to insulin resistance (He A et al., 
2007). Recently, it has been shown that miR-29 isoforms (miR-29a and miR-29b) contribute 
to the beta-cell-specific silencing of the MCT1 transporter. Indeed, inhibition of miR-29 
isoforms in primary mouse islets increases MCT1 mRNA levels (Pullen et al., 2011). In brain, 
miR-29 expression is minimal throughout the embryonic and perinatal periods. Expression of 
miR-29 is enhanced at P14 (Smirnova L et al., 2005). Since MCT1 shares features with 
MCT2, we would suspect that miR-29 could also bind MCT2 and could regulate its 
expression. However, miR-29 is more strongly expressed in astrocytes than in neurons 
(Smirnova L et al., 2005) and there are differences in the 3’-UTR sequences between MCT1 
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and MCT2 (Halestrap P and Price 1999). Nevertheless, as it constitutes the first example of a 
MCT regulated by a miRNA, it might indicate that expression of other MCTs in other tissues 
might be also under control of different miRNAs. 
 
We believed it is likely that MCT2 synthesis can be also regulated by a miRNAs (e.g. miR-
134 or miR-132). Until now, very few data are available on the negative control of synaptic 
protein synthesis during synaptic plasticity. Furthermore, the fascinating possibility of a 
miRNA-dependent synthesis regulation in neuronal metabolism has never been studied.    
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Chapter 4 
 
 
Brain-Derived Neurotrophic Factor enhances the hippocampal 
expression of key postsynaptic proteins in vivo including the 
monocarboxylate transporter MCT2 
(Robinet and Pellerin, 2011). 
 
 
 
 
 
4.1 Abstract 
 
Brain-derived neurotrophic factor (BDNF) promotes synaptic plasticity via an enhancement in 
expression of specific synaptic proteins. Recent results suggest that the neuronal 
monocarboxylate transporter MCT2 is a postsynaptic protein critically involved in synaptic 
plasticity and long-term memory. To investigate in vivo whether BDNF can modulate the 
expression of MCT2 as well as other proteins involved in synaptic plasticity, acute injection 
of BDNF was performed in mouse dorsal hippocampal CA1 area. Using 
immunohistochemistry, it was found that MCT2 expression was enhanced in part of the CA1 
area and in the dentate gyrus 6 hours after a single intrahippocampal injection of BDNF. 
Similarly, expression of the immediate early genes Arc and Zif268 was enhanced in the same 
hippocampal areas, in accordance with their role in synaptic plasticity. Immunoblot analysis 
confirmed the significant enhancement in MCT2 protein expression. In contrast, no changes 
were observed for the glial monocarboxylate transporters MCT1 and MCT4. When other 
synaptic proteins were investigated, it was found that PSD95 and GluR2 protein levels were 
significantly enhanced while no effect could be detected for synaptophysin, SNAP25, 
αCaMKII and GluR1. These results demonstrate that MCT2 expression can be upregulated 
together with other key postsynaptic proteins in vivo under conditions related to synaptic 
plasticity, further suggesting the importance of energetics for memory formation. 
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4.2 Introduction 
 
The neurotrophin BDNF plays an important role in activity-dependent synaptic plasticity 
mechanisms such as long-term potentiation (LTP) (Bramham and Messaoudi, 2005). 
Moreover, it has been proposed to participate in processes leading to memory formation 
(Yamada and Nabeshima, 2003). Indeed, several studies have shown an increase in BDNF 
mRNA expression and TrkB activation during memory acquisition and consolidation 
(reviewed in Yamada and Nabeshima, 2003). Application of BDNF to hippocampal slices 
facilitates the induction of synaptic potentiation and enhances basal synaptic transmission in 
CA1 pyramidal neurons (Ji et al., 2010). Similarly, acute intrahippocampal infusion of BDNF 
leads to a long-lasting enhancement of synaptic transmission in the rat dentate gyrus 
(Messaoudi et al., 1998) and induces LTP in intact adult hippocampus (Ying et al., 2002). The 
BDNF-induced long-lasting potentiation requires ERK pathway activation and the 
upregulation of Arc and Zif268 synthesis (Rosenblum et al., 2002; Ying et al.,2002). Arc and 
Zif268 are two immediate early genes (IEGs) transiently and rapidly activated during LTP as 
well as along the process of learning and memory formation (Davis et al., 2003; Plath et al., 
2006; Lonergan et al., 2010). Ultimately, it is purported that BDNF exerts its effect on 
synaptic function by regulating local translation of a specific subset of synaptic proteins 
(Santos, 2010). While a few of these proteins have been described, more remain to be 
identified. Moreover, BDNF-induced enhancement in expression of several key synaptic 
proteins still awaits confirmation in vivo. 
 
Apart from classical proteins involved in synaptic transmission, BDNF possibly regulates the 
expression of proteins involved in other cellular functions. In this regard, putative changes in 
energetics occurring upon synaptic plasticity and possible regulation of associated proteins 
have not been explored. Recently, the role of monocarboxylates, and particularly lactate, as 
additional energy substrates for neurons has attracted attention (Pellerin, 2003). Release and 
uptake of these substrates are dependent on the presence of specific carriers known as 
monocarboxylate transporters (MCTs) that are expressed by both neurons and glial cells 
(Pierre and Pellerin, 2005). Possible BDNF-mediated alterations in expression of these 
transporters in vivo has never been investigated. In the present study, the level of expression 
of six synaptic proteins, two IEGs, as well as three monocarboxylate transporters were 
determined in mouse hippocampus 6 hours after a single intrahippocampal infusion of BDNF. 
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Results clearly indicate that the neuronal monocarboxylate transporter MCT2 is one of the 
key postsynaptic proteins upregulated as part of the synaptic changes induced by BDNF. 
  
4.3 Experimental procedures 
 
Animals 
Seven-week-old C57Bl/6Rj male mice (~20g) were obtained from the Janvier Breeding 
Center (Le Genest Saint-Isle, France) and received 1 week prior to the experiments to 
acclimatize them to the animal facility. They were housed in a temperature-controlled 
environment with 12:12h light-dark cycle and given free access to food and water. Animal 
experiments were performed in accordance with the Animal Care and Use Committee 
guidelines (Service vétérinaire du Canton de Vaud, Switzerland). 
 
Surgery and intrahippocampal injection of BDNF 
Mice were weighed and anesthetized by intraperitoneal injection with a mixture of Ketamine 
(24µl) and Xylazine (10µl) diluted in 100µl NaCl 0.9%, and positioned in a stereotaxic 
apparatus (Stoelting, WI, USA). Rectal temperature was maintained at 36°C with a 
thermostatically controlled electric heating pad. Stereotaxic coordinates relative to Bregma 
were: anteroposterior (AP) : -1.85 ; mediolateral (ML) : -1.25 ;  dorsoventral (DV): -1.4. A 
single intrahippocampal injection was performed using a 5 µL Hamilton syringe with a 33-
gauge needle. The needle was inserted into the dorsal hippocampal CA1 area and 2 µl of 
phosphate buffered saline (PBS) or 2 µg of Brain-derived neurotrophic factor (BDNF) in 2 µl 
PBS were injected slowly during 20 min (Brain-Derived neurotrophic factor human, 
recombinant expressed in E.coli, Sigma-Aldrich). Mice completely recovered 1 h after the 
surgery. Mice were sacrificed 6 h after the end of surgery. 
 
Western blotting and related quantification 
Once mice had been sacrificed, the brain was rapidly removed and put into a cold solution of 
phosphate buffered saline (PBS 1X). Hippocampi were rapidly dissected on ice, directly 
freezed in liquid nitrogen and stored at -80°C. 
For western blotting, hippocampal tissue was homogenized and sonicated in a 0.32 M sucrose 
solution containing HEPES 1 mM, MgCl2 1 mM, NaHCO3 1 mM, phenyl-methyl-sulphonyl 
fluoride 0.1 mM, pH 7.4, in presence of a complete set of protease inhibitors (Complete, 
Roche, Switzerland). Protein concentrations were determined by the BCA method. Ten 
 127
micrograms of protein were heated at 95°C in SDS-PAGE sample buffer (62.5 mM Tris-HCl, 
50 mM DTT, 2% SDS, 10% glycerol and 0.1% bromophenol blue) and loaded onto 10% 
polyacrylamide gels. After electrophoresis, samples were transferred on nitrocellulose 
membranes (Biorad Laboratories). For protein detection, membranes were incubated in a 
blocking solution of Tris-buffered saline supplemented with Tween-20 (TBST; Tris-HCl 50 
mM pH 7.5, NaCl 150 mM, and Tween-20, 0.1%) containing 5% nonfat milk for 1 h at room 
temperature. Membranes were incubated overnight at 4°C with a mixture containing the 
primary antibodies: anti-MCT4 (Santa Cruz, CA, USA), anti-GluR1 and anti-GluR2/3 
(Chemicon, CA, USA) diluted 1/500 ; anti-MCT1, anti-MCT2 antibodies, anti-synaptophysin 
(Sigma, Buchs, Switzerland), anti-SNAP25 (Alomone labs, Jerusalem, Israel), anti-PSD95 
and anti-CamKIIα (Cell Signaling, MA, USA) diluted 1/1000 ; anti-βactin (Sigma, Buchs, 
Switzerland), diluted 1/10000; anti-βtubulin (Sigma, Switzerland), diluted 1/1000. These 
antibodies were diluted in TBS, 0.1% Tween, 5% bovine serum albumin (BSA). After three 
washes in TBST, membranes were incubated with the secondary antibodies Alexa Fluor 680 
goat anti IgG (Juro, Lucerne, Switzerland) and IRDye_800 antimouse IgG (BioConcept, 
Allschwil, Switzerland), diluted at 1:5000 in TBST containing 1% nonfat milk, for 2 h at 
room temperature, and protected from light. For anti-MCT1, peroxydase-conjugated donkey 
anti-rabbit IgG was used as secondary antibodies (Amersham, Piscataway, NJ, USA) diluted 
1:10000. After three washes in TBST, membranes were scanned and quantified with the 
Odyssey®Infrared Imaging System (LI-COR® Biosciences, Lincoln, NE, USA). For MCT1 
detection, Enhanced Chemiluminescence (ECL) was required for detection and ImageJ 
software (http://rsbweb.nih.gov/ij/) was used for the quantification. -Actin or β-Tubulin was 
used for normalization of proteins of interest. 
 
Immunohistochemistry  
Under urethane anaesthesia (1.5g/kg i.p.), animals were perfused intracardially with a 
heparinised solution of saline (25 IU/ml in 0.9% NaCl, during 2 min) followed by a freshly 
prepared solution of 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.4, for 15 min). 
Brains were removed and fixed in 4% paraformaldehyde for 2h, then cut on a vibratome 
(Leica VT1000M) to obtain coronal sections (40 µm thick), which were collected in 
phosphate buffer saline (PBS). Sections were rinsed several times in PBS and incubated with 
casein (0.5% in PBS) for 1 h to block non-specific sites. They were incubated overnight at 
4°C in freshly prepared primary antibody solution diluted in PBS containing 0.25% BSA: 
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anti-MCT2 (1:500), anti-MAP2 (1:200; sigma), anti-Arc (1:200; Santa Cruz Biotechnology, 
Heidelberg, Germany), anti-EGR1 (1:500; Cell Signaling, Allschwil, Switzerland).  
After careful rinsing in PBS, sections were incubated in a solution containing Cy3-conjugated 
anti-rabbit Igs (diluted 1/500, 2 h, room temperature; Jackson Immunoresearch, MD, USA) 
and/or anti-mouse FITC-conjugated Igs (diluted 1:200, 2h, room temperature; Jackson 
Immnoresearch). After rinsing in PBS twice and a final rinsing in water, slices were mounted 
with Vectashield-DAPI (Reactolab SA, CA, USA). 
 
Microscopy 
Brain slices were examined and photographed with an Eclipse 80i microscope (Nikon, 
Kingston, England) using epifluorescence with an appropriate filter together with the NIS-
Elements Microscope Imaging 5.1 software (Nikon). They were also examined under a Zeiss 
LSM 710 Quasar confocal microscope using the DPSS 561-10, 561nm laser illumination. 
Stacks were made of images taken with 0.5 to 0.8µm step size. Pictures were treated with 
Imaris software, version 7.0.0. 
 
Statistical analysis 
All values are presented as mean ± SEM. Mann Whitney’s test, or one-way ANOVA 
followed by Dunnett’s post-hoc test were used for data analysis with GraphPad Prism® 
software, version 5.0 (La Jolla,CA). P values < 0.05 were considered as statistically 
significant.  
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4.4 Results 
 
Intrahippocampal injections of BDNF (or PBS) were made in the right (or left) hippocampus 
of 7 week-old C57/Bl6 mice. Six hours later, hippocampal expression of MCT2 was 
examined by immunohistochemistry on coronal sections taken at different levels along the 
anteroposterior axis. Results showed that MCT2 immunofluorescence was stronger in a 
portion of the pyramidal cell layer of the CA1 area as well as in the granule cell layer of the 
dentate gyrus for the BDNF-injected hippocampus compared to the contralateral, PBS-
injected structure, as indicated by arrows (Fig.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effect of acute intrahippocampal injection of BDNF in vivo on MCT2 protein expression. MCT2 
immunolabelling in coronal brain sections at three different hippocampal levels 6 hours after injection of either PBS (left 
column) or 2 µg BDNF (right column). As pointed out by arrows, stronger immunolabelling is visible in portions of the 
hippocampus injected with BDNF compared to PBS, particularly in the CA1 area and in the dentate gyrus. Magnification, 
10x; Calibration bar, 100µm. Numbers at the bottom right on right column images refer to position from bregma. 
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No sign of lesion was detected in the surroundings of the needle tract. Confocal microscopy 
showed at high magnification a visible increase of MCT2 staining in neurons after BDNF 
treatment compared to PBS control (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of acute intrahippocampal injection of BDNF in vivo on neuronal MCT2 expression in the 
hippocampal CA1 area. Double immunofluorescent labellings for the neuronal marker MAP2 (green) and MCT2 (red) in 
coronal hippocampal sections (-2.06 mm from bregma) obtained after 6 hours from animals injected with either PBS (top 
row) or 2 µg BDNF (bottom row). A stronger MCT2 immunolabelling is clearly visible in CA1 pyramidal neurons after 
BDNF injection compared to control (PBS). Pictures were obtained with a confocal microscope and images correspond to a 
projection of 18 sections of 0.5µm. Magnification, 63x ; Calibration bar, 15µm. 
 
 
 Under the same conditions, the expression of two immediate early genes, Arc and Zif268, 
known to be implicated in synaptic plasticity, was evaluated by immunohistochemistry. 
Double immunostainings for Arc or Zif268 proteins with the neuronal marker MAP2 revealed 
an enhancement in neuronal expression of these two immediate early gene products after 
BDNF injection compared to PBS control in the same hippocampal area as for MCT2 (Fig. 
3).  
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Figure 3. Effect of acute intrahippocampal injection of BDNF in vivo on neuronal Arc and Zif268 expression in the 
hippocampal CA1 area. Double immunofluorescent labellings for the neuronal marker MAP2 (green) and either Arc or 
Zif268 (red) in coronal hippocampal sections (-2.06 mm from bregma) obtained after 6 hours from animals injected with 
either PBS (top rows) or 2 µg BDNF (bottom rows). A strong immunolabelling for both Arc and Zif268 is observed in CA1 
hippocampal neurons after BDNF injection compared to control (PBS). Pictures were obtained with a confocal microscope 
and images correspond to a projection of 18 sections of 0.5µm. Magnification, 40x; Calibration bar, 20µm. 
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In order to further characterize the extent and nature of the changes induced by BDNF, 
expression levels of several synaptic and extra-synaptic proteins, including MCT2, were 
determined by immunoblot on hippocampal extracts. Western blot analysis of hippocampal 
extracts from BDNF-injected tissue showed a significant increase (125 ± 12% vs. control) of 
MCT2 expression compared to control (no injection, contralateral side) or PBS-injected 
animals (Fig. 4A). Basal hippocampal MCT2 expression levels were not different between 
anesthetized (Keta/Xyla+) and unanesthetized (Keta/Xyla-) mice, excluding a confounding 
effect of anesthesia (Fig. 4B). Expression levels of MCT1 and MCT4, two other 
monocarboxylate transporters present in the brain but predominantly on glial cells, were not 
altered (Fig. 4C and D, respectively).  
 
 
 
 
 
Figure 4. Effect of intrahippocampal 
injection of BDNF in vivo on MCT1, 
MCT2 and MCT4 protein expression 
levels. Western blot analysis of MCT2 (A 
and B), MCT1 (C) and MCT4 (D) 
expression in hippocampal protein 
extracts. Right hippocampi were injected 
with 2µg BDNF and collected after 6h. 
Left hippocampi were used as control. 
Effect of anesthesia (Ketamine/xylazine) 
on hippocampal MCT2 protein 
expression was also performed as control 
(B). Western blots were quantified using 
Odyssey software (LI-COR Biosciences, 
Lincoln, NE, USA) or ImageJ software 
(http://rsbweb.nih.gov/ij/). Results are 
expressed as percentage of control (mean 
± s.e.m.) after the values were normalized 
using -actin or β-tubulin signal as 
reference. Statistical analysis was 
performed using one-way ANOVA 
followed by Dunnett’s test (A) or 
performed using a Mann Whitney’s test 
(B,C,D). Asterisk indicates MCT2 protein 
levels significantly different from control 
(Ctrl) with p < 0.05. n = 6 mice for each 
condition.  
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In parallel to monocarboxylate transporters, the effect of BNDF on the hippocampal 
expression of several pre- and postsynaptic proteins was determined by Western blot (Fig. 
5A). Quantitative analysis of immunoblots for synaptophysin and SNAP25, two presynaptic 
proteins, showed no expression change 6 hours after BDNF injection (Fig. 5B and C, 
respectively). A similar analysis on some postsynaptic proteins gave differential results. No 
expression change was observed for the protein kinase aCamKII and the glutamate receptor 
subunit GluR1 (Fig. 5D and F). In contrast, a significant increase of the postsynaptic density 
scaffold protein PSD95 (118 ± 9%) and of the glutamate receptor subunit GluR2/3 (124 ± 
7%) compared to control (no injection) was observed 6 hours after BDNF injection (Fig. 5E 
and G). 
 
 
 
 
 
Figure 5. Effect of Intra-
hippocampal injection of BDNF in 
vivo on expression levels of several 
presynaptic and postsynaptic 
proteins. Western blot analysis of 
synaptophysin, SNAP25, aCamKII, 
PSD95, GluR1 and GluR2/3 
expression on hippocampal protein 
extracts (A). Right hippocampi were 
injected with 2µg BDNF and 
collected after 6h. Left hippocampi 
were used as control. Western blot 
quantification for synaptophysin (B), 
SNAP25 (C), CamKII (D), PSD95 
(E), GluR1 (F) and GluR2/3 (G), 
performed with Odyssey sofware (LI-
COR Biosciences, Lincoln, NE, 
USA). Results are expressed as 
percentage of control (mean ± s.e.m.) 
after the values were normalized 
using -actin signal as reference. 
Statistical analysis was performed 
using a Mann Whitney’s test. 
Asterisk indicates PSD95 and 
GluR2/3 protein levels different from 
control (Ctrl) with p < 0.05. n = 6 
mice for each condition. 
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4.5 Discussion 
 
As it is proposed to provide the underlying mechanism subserving learning and memory 
processes, synaptic plasticity is the subject of intense attention. Brain-derived neurotrophic 
factor represents an essential signal released under learning-associated conditions that 
contributes to the modifications of synaptic transmission taking place in this context 
(Gottmann et al., 2009; Yoshii and Constantine-Paton, 2010). Then, activation of TrkB 
receptors by BDNF leads to a cascade of events including transcriptional and translational 
steps that will result in the synthesis of a specific subset of synaptic proteins (Santos et al., 
2010).  However, relatively few information exist in vivo about the specific proteins that are 
subject to regulation by BDNF. Moreover, evidence for a possible modulation of proteins 
essential in energy metabolism are scarce and limited to in vitro (Burkhalter et al. 2007; 
Robinet and Pellerin 2010). This question was addressed here by investigating the putative 
changes in expression of several key synaptic proteins including monocarboxylate 
transporters, a group of proteins involved in energy substrate transfer and supply to neurons, 
following an intrahippocampal BDNF injection. 
 
MCT2 is the predominant monocarboxylate transporter expressed by neurons whereas MCT1 
and MCT4 are expressed by glial cells (Pellerin et al., 2005). At the subcellular level, MCT2 
is expressed on axons and dendrites (Pierre et al., 2002; 2009). Moreover, MCT2 is present at 
glutamatergic synapses and exclusively on postsynaptic elements (Bergersen et al., 2002 ; 
Pierre et al., 2009). It is particularly enriched in the postsynaptic density of asymmetric 
synapses as well as in an intracellular pool within spines (Bergersen et al., 2005). Recently, it 
was demonstrated in cultured neocortical neurons that BDNF induces the expression of 
MCT2 via a regulation of local translation (Robinet and Pellerin, 2010). Data obtained in the 
present study showing increased MCT2 protein levels after BDNF injection further extend 
this observation to the hippocampus in vivo.   
 
Interestingly, this increased neuronal expression of MCT2 in the hippocampus following 
BDNF injection is matched in terms of distribution by a similar enhancement in neuronal 
expression of both Arc and Zif268 proteins. Induction of the immediate early genes (IEGs) 
Arc (also known as Arg3.1) and Zif268 (also known as EGR1) is required for late long-term 
potentiation (l-LTP) and long-term memory formation (Guzowski et al., 2000; Jones et al., 
2001). In parallel, BDNF-induced long-lasting potentiation leads to an upregulation of Arc 
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and Zif268 synthesis (Rosenblum et al., 2002; Ying et al., 2002). Arc mRNA is rapidly 
transported to dendrites and translated locally where it plays a critical role in local translation 
as well as in trafficking of AMPA receptors (Bramham et al., 2008). In parallel, Zif268 
regulates the transcription of some late response genes and is involved in the degradation of 
synaptic proteins as well as in receptor trafficking (McDade et al., 2009).  Considering their 
spatially- and timely-related appearance, it is not excluded that Arc and Zif268 could be 
involved in the regulation of MCT2 expression and subcellular distribution induced by 
BDNF. Indeed, it was previously shown that BDNF-induced upregulation of MCT2 protein 
expression in cultured neurons requires a transcriptional step although MCT2 mRNA levels 
were not affected (Robinet and Pellerin, 2010). Thus, transcriptional activation of Arc and 
Zif268 might be critical to allow a translationally-regulated enhancement of MCT2 protein 
levels. Such a possibility will require to be further investigated both in vitro and in vivo. 
 
BDNF was shown previously in vitro to enhance the expression of a few synaptic proteins. 
PSD95 is a scaffold protein of the postsynaptic density that plays an important role in 
synaptic plasticity (Gardoni et al., 2009). BDNF can induce the transport of PSD95 to 
dendrites and it was suggested that activation of the PI3K-Akt pathway by BDNF could lead 
to enhanced PSD95 synthesis (Yoshii and Constantine-Paton, 2007). Indeed, it was reported 
that activation of the PI3K-Akt pathway causes an increase of PSD95 expression in 
hippocampal slices (Lee et al., 2005). In cultured cortical neurons, BDNF was shown to 
enhance PSD95 protein expression (Matsumoto et al., 2006). Our data provide a confirmation 
that BDNF can enhance PSD95 protein levels in vivo, supporting the idea that more PSD95 
proteins are necessary to sustain BDNF-induced synaptic modifications. PSD95 colocalizes 
with MCT2 both in vitro and in vivo (Pierre et al. 2009). As PSD95 is a necessary component 
of the postsynaptic density, it might be required to ensure proper insertion of newly formed 
MCT2 in the postsynaptic membrane. 
 
AMPA-type glutamate receptors are composed of distinct subunits known as GluR1 to 
GluR4. The synaptic distribution and levels of GluR1 and GluR2 subunits have been shown 
to be modulated as part of the mechanism of synaptic plasticity (Sprengel 2006; Keifer and 
Zheng, 2010). It was demonstrated in both neocortical and hippocampal neurons in culture 
that BDNF treatment causes an enhancement of GluR1 and GluR2 protein expression levels 
(Narisawa-Saito et al., 1999; Matsumoto et al., 2006). Our observations in vivo that BDNF 
raises GluR2/3 protein levels partly confirm these data. It also emphasizes the important role 
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that the GluR2 subunit appears to play in synaptic plasticity (Isaac et al., 2007; Bassani et al., 
2009). MCT2 was shown previously to not only colocalize but also directly interact with 
GluR2 (Pierre et al. 2009). Moreover, changes in the expression levels of MCT2 have been 
shown to modify both the expression levels and the subcellular distribution of GluR2 subunits 
(Maekawa et al. 2009). Thus, it appears that MCT2 and GluR2 must be concomitantly 
regulated in order to fulfill their respective roles in the adaptation to changes in synaptic 
transmission. 
 
In contrast to PSD95 and GluR2, no change could be detected in the expression of several 
other proteins. This is the case for the other monocarboxylate transporters MCT1 and MCT4. 
Since these transporters are rather expressed by glial cells, regulation of their expression 
might be under the control of other signals that remain to be identified. The protein kinase 
αCamKII is a postsynaptic protein that has been involved in the process of synaptic plasticity 
(Miyamoto, 2006). BDNF has been reported to enhance αCamKII protein levels, notably in 
synaptosomes (Schratt et al., 2004). Surprisingly, no change in αCamKII protein levels could 
be evidenced in vivo under our experimental conditions. Similarly, the expression of the 
GluR1 subunit was not modified despite being enhanced by BDNF in vitro (Matsumoto et al., 
2006). A possible explanation for these differences could be related to our experimental 
protocol. Since a single dose of BDNF was used and observation was made at only one time-
point, possible changes in GluR1 and αCamKII protein expression might have been 
overlooked. Moreover, since hippocampal extracts were prepared from the entire 
hippocampus while the effect of injected BDNF was restricted to only portions of the tissue, 
putative differences might have been diluted in Western blot analyses. Further experiments 
investigating changes in expression at different times after BNDF injection (and at different 
doses), as well as using more restricted portions of the hippocampus, will be needed to clarify 
this point. 
 
The presynaptic proteins synaptophysin and SNAP25 are involved in the mechanism of 
vesicle-dependent neurotransmitter release (Valtorta et al., 2004). BDNF was reported to 
enhance the expression of synaptophysin but not SNAP25 in neocortical neuronal cultures 
(Matsumoto et al., 2006). In our study, protein levels of synaptophysin and SNAP25 were not 
altered by intrahippocampal infusion of BDNF. The difference between in vitro and in vivo 
results might come from the developmental stage of each preparation. Since BDNF is known 
to promote synaptic maturation (Gottmann et al., 2009), involving synthesis of pre- and 
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postsynaptic proteins, such an effect might be more prominent in cultured cells prepared from 
embryonic animals than in adult mice. 
 
Our data emphasize the fact that neuronal expression of MCT2, in parallel with other proteins 
known or highly suspected to participate in the mechanism of synaptic plasticity such as the 
immediate early genes Arc and Zif268, the postsynaptic scaffold protein PSD95 as well as the 
AMPA receptor GluR2 subunit, is upregulated by BDNF in the hippocampus in vivo. 
Considering the critical role of MCT2 in lactate uptake and utilization by neurons, our results 
point to the intriguing possibility of a coupling between neuronal lactate utilization and 
synaptic plasticity. Indeed, the concept that energy metabolism might be coupled to synaptic 
plasticity has been proposed together with the implication of BDNF in such interactions 
(Vaynman et al., 2006 ; Gomez-Pinilla et al., 2008). In addition, a recent study has shown that 
lactate import into neurons through MCT2 is necessary for long-term memory formation 
(Suzuki et al., 2011). In this context, it is tempting to hypothesize that to meet higher energy 
demands caused by enhanced synaptic transmission after synaptic plasticity, increased MCT2 
expression induced by BDNF would facilitate lactate supply at potentiated synapses.  
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Chapter 5 
 
The neuronal lactate transporter MCT2 is required for hippocampal-
dependent short-term memory 
(Robinet C et al., in progress). 
 
 
 
 
 
5.1 Abstract 
 
Lactate has been proposed as an essential energy substrate to sustain neuronal functions. 
Neuronal lactate supply and utilization is critically dependent on expression of the neuronal 
monocarboxylate transporter MCT2. Here, we present evidence that reducing hippocampal 
MCT2 expression interferes with the acquisition of some forms of memory in mice. MCT2 
knockdown primarily affecting the hippocampal dentate gyrus area produced working 
memory deficits in two spatial tasks while reference memory appeared unimpaired. In 
parallel, it reduced performance for short but not long latencies in a passive avoidance task. 
These results suggest that neuronal lactate supply via MCT2 is critical for the establishment 
of short-term memory and support the notion that a clear dissociation can be made between 
short-term and long-term memory on the basis of selective, region-specific protein 
downregulation. 
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5.2 Introduction 
 
Monocarboxylate transporters (MCTs) are a small group of proton-linked membrane carriers 
that allow the release, passage and uptake of energy substrates such as lactate, pyruvate and 
ketone bodies (Pierre and Pellerin, 2005). Three MCT isoforms are expressed in the central 
nervous system and MCT2 represents the predominant neuronal monocarboxylate transporter. 
MCT2 is expressed not only on axons and dendrites, but it is particularly enriched in dendritic 
spines, being associated with the postsynaptic density of glutamatergic synapses (PSD) 
(Bergersen et al., 2005). It was also shown to interact with the AMPA receptor subunit 
GluR2/3 and to undergo a similar trafficking between the plasma membrane and an 
intracellular pool under conditions related to synaptic plasticity (Pierre et al., 2009). Such 
findings suggest the intriguing possibility that energy supply, via monocarboxylate 
transporters, could be an important determinant of learning and memory processes. Indeed, it 
has been recently demonstrated that interfering with the hippocampal expression of 
monocarboxylate transporters, including MCT2, and lactate supply to neurons prevented the 
formation of long-term memory in the context of an inhibitory avoidance learning paradigm 
(Suzuki et al. 2011). As hippocampal activation is known to be required for spatial learning 
tasks, we investigated the impact of reducing hippocampal MCT2 expression on spatial 
performance in mice. 
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5.3 Material and Methods 
 
Animals 
Twenty-four male C57BL/6 Rj mice were purchased at seven weeks of age (~20g), from 
Janvier Breeding Center (Le-Genest-Saint-Isle, France) and group housed in a temperature-
controlled environment with 12:12h light-dark cycle with free access to food and water. 
Surgery took place at 8 weeks, and behavioural testing started 2 weeks thereafter. 
 
Construction of shRNA plasmids  
Oligonucleotides containing 17 nucleotides from the H1 promoter, the sense-strand, a loop, 
the anti-sense strand for Rat and mouse siMCT2 and a universal control were synthesized. 
siMCT2 : 
CTAGTTTCCAAAAATAGGATTAATAGCCAACACTATGACAGGAAGTAGTGTTGGC
TATTAATCCTAGGGGATCTGTGGTCTCATACAGAAC,  
siUNIV: 
CTAGTTTCCAAAAAGTATCGATCACGAGACTAGTGACAGGAAGCTAGTCTCGTGA
TCGATACGGGGATCTGTGGTCTCATACAGAAC.  
These oligonucleotides and the primer H1-3F: CACCGAACGCTGACGTCATCAACCCG 
were used to perform a PCR reaction on the pBC-H1 plasmid (Drouet et al. 2009). The PCR 
product was cloned in the pENTR/D-TOPO plasmid (Invitrogen, Cergy Pontoise, France). 
The H1-shRNA cassette was then transferred with the LR clonase recombination system 
(Invitrogen, Villebon sur Yvette, France) in the SIN-cPPT-PGK-GFP-WPRE-LTR-TRE-
gateway vector (SIN-CWP-GFP-TRE-gateway) (Drouet et al. 2009).  
 
Lentiviral vector production 
Lentiviral vectors encoding the various siRNA were produced in 293T cells with a four-
plasmid system as previously described (Hottinger et al. 2000). The lentiviral particles were 
produced and purified with the vivapure LentiSELECT 500 kit (Sartorius stedim, Aubagne, 
France). The Sartobind® ion exchange membrane adsorber technology used in LentiSELECT 
efficiently and rapidly capture and recover large virus particles (3000 nm pores). Briefly, 
500ml of supernatant are harvested and filtrated on the provided filter. The surpernatant is 
pumped through the filter at 10-20ml/min. After the assembly of the lentiselect column and 
connection with the peristaltic pump, 150ml of loading buffer is pumped through the column 
at 10ml/min. The flow through is treated as biohazard waste. Once bound, virus particles are 
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purified by washing away nonspecifically bound protein with 120ml of washing buffer at 
15ml/min. The viral particles are then eluted using a buffered 30 ml solution containing a high 
concentration of sodium chloride. The elution is performed with a 20ml syringe at a 1ml/min 
debit. Finally, the eluate is collected in PBS buffer and ultracentrifuged at 19000rpm/min, 4°C 
for 90min to concentrate it. The virus pellet is resuspended in PBS buffer and stored at -80° 
until use. The particle content of each batch of virus is determined by p24 antigen ELISA 
(RETROtek, Gentaur, Paris, France). 
 
Surgery and intrahippocampal injection of lentivirus 
Mice were weighed and anesthetized with isoflurane setup and positioned in a stereotaxic 
apparatus (Stoelting, WI, USA). Rectal temperature was maintained at 36°C with a 
thermostatically controlled electric heating pad. Stereotaxic coordinates relative to Bregma 
were based on the brain atlas of Paxinos and Watson (1986): anteroposterior (AP):  -1.85 ; 
mediolateral (ML) : -1.25 and +1.25 ;  dorsoventral (DV): -1.4. A single intrahippocampal 
injection was performed using a 5 µL Hamilton syringe with a 30 ½-gauge needle. The needle 
was inserted into the hippocampal CA1 area and 2μl of 545'000 ng P24/ ml were injected 
slowly during 15 min. Mice were injected with a lentiviral vector containing a siMCT2-GFP 
sequence (Lenti-siMCT2) into the right dorsal hippocampus (CA1 area) while the left, 
LentiUniv-injected hippocampus was used as control. Mice completely recovered 15 min 
after the surgery.  Behavioral testing started 14 days after surgery. 
 
Morris watermaze task 
A circular tank (150 cm ∅) was filled with water at 25±1 °C, made opaque by addition of 
milk. Mice learn to localize and step on an invisible, circular platform (14 cm ∅) located at 
the centre of the NW quadrant of the tank. Training schedule consisted of six daily trials 
during four consecutive days. Release points were chosen pseudorandomly, with the 
exception of the first release point of each day, which was always opposite to the escape 
platform (SW), in order to better assess the episodic component of the task.  At day 5, the 
platform was removed for the first, 60 s trial (probe trial) to assess spatial reference learning 
proficiency. At the end of the 60 s trial, the platform was placed in the SW quadrant and mice 
further trained during 5 trials to find the platform on this novel location (reversal learning). 
Swim paths were videorecorded and analyzed by a videotracking system (EthoVision, 
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Noldus, The Netherlands). Variables assessed were escape latencies and, for the probe trial, 
times in quadrants and annulus.  
 
Radial maze task (spatial working memory) 
The apparatus was an eight-arm radial maze (RAM), consisting of an open central platform of 
16.5 cm diameter, from which radiate eight transparent tunnels made of Plexiglas (6 x 6 x 50 
cm). Access to the tunnels was regulated by remotely operated plexiglas sliding doors. In 
addition, two wooden barriers (1.5 x 1 x 6 cm), placed on each arm floor at 0 and 25 cm from 
the entry, helped in discouraging haphazard visits of already visited arms, and in preventing 
sight of the bait (10 μl of condensed milk) placed at the end of the lanes. An arm visit was 
counted when the mouse had jumped beyond the second barrier, placed halfway in the lane.  
 
We designed a two-trial protocol, requiring mice to discriminate recently visited vs non-
visited arms within a trial (working memory), while suppressing interference of spatial 
information between trials (non-matching-to-place, episodic memory). Each trial was made of 
two steps : it started with three open, baited arms, disposed at 0, 90 and 215 degrees, to 
prevent chained responses. Once the baits retrieved, three more baited arms, at 45, 180 and 
260 degrees were made accessible (step 2). Entries in already visited arms were counted as 
errors. A trial was terminated when all 6 baits had been retrieved, or after 5 minutes. Upon 
completion of the first trial, mice were confined in the central arena during 2 minutes under an 
opaque lid, baits replaced, and the second daily trial started, for which the baiting pattern had 
been rotated of 90 degrees (i.e. : 0, 135 and 270 degrees for the step 1, and 90, 180 and 315 
degrees for step 2) (Fig. 1). This training was preceded by a two-days habituation phase 
during which mice where food restrained to reach 90 to 85% of their initial body weight, and 
familiarized to the bait taste and the arena.  
 
Passive Avoidance Test 
Memory formation and retention was also assessed in a passive avoidance paradigm. The 
apparatus (Med Associates, St. Alban, VT, USA) was a skinner box with a lit and a dark 
compartment, separated by a guillotine door, and placed in a sound-proof cubiculum. Training 
consisted in placing the mouse in the lit side of the box, with the guillotine door open. Upon 
reaching the dark side of the box, the door was closed, mice received a mild footshock (0.3 
mA during 2 s), and immediately transferred to a clean cage. A second training session was 
administered after 5 minutes after the end of the first session. Memory for the aversive events 
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was tested 10 minutes after the end of the second training session, and 24 hours later. 
Absolute and relative latencies to enter the dark side were taken as a measure of memory 
proficiency.        
 
Behavioral assessment 
Working memory will be reflected by the retention of trial specific or trial unique information 
for short periods of time (thus rather associated with short-term memory) while reference 
memory will be reflected by retention of intertrial information (and involves long-term 
memory) (Hodges, 1996). 
 
Immunohistochemistry  
Under urethane anathesia (1.5g/kg i.p.), animals were perfused intracardially with a 
heparinized solution of saline (25 IU/ml in 0.9% NaCl, during 2 min) followed by a freshly 
prepared solution of 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.4, for 15 min). 
Brains were removed and fixed in 4% paraformaldehyde for 2h, then cut on a vibratome 
(Leica VT1000M) to obtain coronal sections (40 µm thick), which were collected in 
phosphate buffer saline (PBS). Sections were rinsed several times in PBS and incubated with 
casein (0.5% in PBS) for 1 h to block non-specific sites. They were incubated overnight at 
4°C in freshly prepared MCT2 antibody solution (anti-MCT2 diluted 1:500 in PBS containing 
0.25% BSA). After careful rinsing in PBS, sections were incubated in a solution containing 
Cy3-conjugated anti-rabbit Igs (diluted 1/500, 2 h, room temperature; Jackson 
Immunoresearch, MD, USA). After rinsing in PBS twice and a final rinsing in water, 
coverslips were mounted with Vectashield (Reactolab SA, CA, USA). Coverslips were 
examined and photographed with an Axioplan2 microscope (Zeiss, Hallbergmoos, Germany) 
using epifluorescence with an appropriate filter. 
 
Western blotting and related quantification 
For western blotting, hippocampal tissue was homogenized and sonicated in a buffer of 0.32 
M sucrose containing HEPES 1 mM, MgCl2 1 mM, NaHCO3 1 mM, phenyl-methyl-
sulphonyl fluoride 0.1 mM, pH 7.4, in presence of a complete set of protease inhibitors 
(Complete, Roche, Switzerland). Protein concentrations were determined by the BCA 
method. Ten micrograms of protein were heated at 95°C in SDS-PAGE sample buffer (62.5 
mM Tris-HCl, 50 mM DTT, 2% SDS, 10% glycerol and 0.1% bromophenol blue) and loaded 
onto 10% polyacrylamide gels. After electrophoresis, samples were transferred to 
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nitrocellulose membranes (Biorad Laboratories). For protein detection, membranes were 
incubated in a blocking solution of Tris-buffered saline supplemented with Tween-20 (TBST; 
Tris-HCl, pH 7.5, 50 mM; NaCl, 150 mM; and Tween-20, 0.1%) containing 5% nonfat milk 
for 1 h at room temperature. Membranes were incubated overnight at 4°C with a mixture 
containing the primary antibodies: anti-MCT4 (Santa Cruz, CA, USA), anti-GluR1 and anti-
GluR2/3 (Chemicon, CA, USA) diluted 1/500 ; anti-MCT1, anti-MCT2 antibodies (Pierre et 
al., 2000), anti-synaptophysin (Sigma, Buchs, Switzerland), anti-SNAP25 (Alomone labs, 
Jerusalem, Israel), anti-PSD95 and anti-CamKIIα (Cell Signaling, MA, USA) diluted 1/1000 ; 
anti-βactin (Sigma, Buchs, Switzerland), diluted 1/10000. These antibodies were diluted in 
TBS, 0.1% Tween, 5% bovine serum albumin (BSA). After three washes in TBST, 
membranes were incubated with the secondary antibodies Alexa Fluor 680 goat anti IgG 
(Juro, Lucerne, Switzerland) and IRDye_800 antimouse IgG (BioConcept, Allschwil, 
Switzerland), diluted at 1/5000 in TBST containing 1% nonfat milk, for 2 h at room 
temperature, and protected from light. After three washes in TBST, membranes were scanned 
using the Odyssey®Infrared Imaging System (LI-COR® Biosciences, Lincoln, NE, USA) 
which permits detection and quantification of proteins of interest. -Actin, revealed in green, 
was used for normalization and proteins of interest were revealed in red. 
 
Quantitative Real-time Reverse transcriptase-PCR 
Quantitative determination of MCT2 mRNA expression levels was performed from mouse 
hippocampal extracts by quantitative reverse transcriptase-PCR according to Heid et al (1996) 
using ABI Prism 7000 sequance detection system from Applied Biosystems (Rotkreuz, 
Switzerland). The following sets of oligonucleotides were used : 5’→3’; ActinFo, 
GCTTCTTTGCAGCTCCTTCGT; ActinRe, ATATCGTCATCCATGGCGAAC (Embl: 
X03672); MCT2Fo, CAGCAACAGCGTGATAGAGCTT; MCT2Re, 
TGGTTGCAGGTTGAATGCTAAT (Embl: NM_011391); 
NPYFo,ACCAGACAGAGATATGGCAAGAGA; NPYRe, GGCGTTTTCTGTGC 
(produced by Microsynth, Balgach, Switzerland). 
 
Microscopy 
Brain slices were examined and photographed with an Eclipse 80i microscope (Nikon, 
Kingston, England) using epifluorescence with an appropriate filter together with the NIS-
Elements Microscope Imaging 5.1 software (Nikon). They were also examined under a Zeiss 
LSM 710 Quasar confocal microscope using the DPSS 561-10, 561nm laser illumination. 
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Stacks were made of images taken with 0.5 to 0.8µm step size. Pictures were treated with 
Imaris software, version 7.0.0. 
 
Statistical analysis 
All values are presented as mean ± SEM. Mann Whitney’s test was used for data analysis 
with GraphPad Prism® software, version 5.0 (La Jolla,CA). P* values < 0.05; P**<0.01; 
P***<0.001 were considered as statistically significant.  
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5.4 Results  
 
5.4.1 MCT2 downregulation in hippocampus after injection of Lenti-siMCT2 
infecting primarily the dentate gyrus area 
 
Cellular localization of transgene encoding the MCT2 siRNA was histologically verified upon 
the end of behavioural testing, 15 weeks after the injection. Viral infection, as revealed by 
GFP expression, was at that time mostly localized in dentate gyrus granule cells, while 
comparatively less pyramidal neurons in CA1/CA2 showed GFP labelling (Fig.1A to 1E). 
Confirmation of MCT2 downregulation was provided by quantitative immunoblotting 
(Fig.1F). A significant reduction of MCT2 expression was detected in Lenti-siMCT2-injected 
hippocampal extracts compared to extracts from control hippocampi that were injected with a 
universal siRNA control lentivirus containing a siUniv-GFP sequence (Lenti-Univ) (- 25.3 ± 
11.8% vs. control). In parallel, a significant decrease in MCT2 mRNA expression was 
observed by quantitative RT-PCR in Lenti-siMCT2 vs control, LentiUniv-injected 
hippocampal extracts (- 12.5 ± 1.6% vs. control; Fig.1G). Observation at high magnification 
using confocal microscopy after MCT2 immunofluorescent labeling (in red) revealed a 
selective downregulation of MCT2 expression in infected, GFP-positive neurons (in green) 
compared to uninfected cells (Fig.1H and 1I). 
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Figure1. Downregulation of MCT2 by lentiviral injection into the hippocampus . A) Right hemisphere was injected with 
siMCT2-GFP+ lentivirus into the CA1. Left hemisphere was used as control. B) and C) Infection pattern of hippocampal 
injection at different level along the anteroposterior axis. Lentiviral infection into the dentate gyrus (D) and into the CA1-
CA2 (E). The expression of MCT2 (in red) was downregulated in infected siMCT2-GFP+ neurons (in green) (H) and (I). 
Images were taken at 4X or 10X magnification with fluorescence microscope for images A) to E), and at 63X magnification 
with confocal microscope for images H) and I), (Arrows point out an uninfected neuron). Quantification of MCT2 
downregulation in hippocampus by immunoblot (n=6) (F). Quantification of MCT2 mRNA downregulation by quantitative 
RT-PCR (n=8) (G). Mann Whitney test was applied to the data. * P<0.05, **P<0.01. 
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5.4.2 Spatial working memory impairment in MCT2 knockdown mice without 
obvious reference memory deficits. 
 
Hippocampal-dependent learning proficiency was first assessed with a classical reference 
memory task in the Morris Water Maze. The experiment was conducted twice 
(pseudoreplication) using each time 6 MCT2-KD and 6 control mice. Testing order was such 
to maintain constant intertrial times of about 15 minutes, in order to evaluate short-term 
memory over the six daily trials. The release point of each first daily trial was kept constant 
(SW), while the release points of the subsequent five trials changed pseudorandomly. 
Therefore, while the evolution of escape latencies of the first daily trial provided a good 
measure of day-by-day spatial reference learning, the average escape latencies of the 
following trials provided a measure of intrasession, short-term memory. Escape latencies of 
trials 2 to 6 were significantly longer for MCT2-KD mice (Fig.2B), indicating a deficit in 
short-term memory; in contrast, escape latencies for the first daily trial were virtually identical 
for MCT2-KD and control mice (Fig. 2A), suggesting unimpaired day-to-day reference 
learning. This evidence is also supported by the similar preference for the target quadrant 
shown in the probe trial (Fig.2C). However, when considering the time spent during the probe 
trial within the exact perimeter of the platform position, a reduced accuracy of the MCT2-KD 
mice was also detected (Fig. 2D). 
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Figure. 2. Spatial reference and working memory in acquisition or probe period in the Morris watermaze. A) Spatial 
reference memory analysed on the first trial latency of the day. B) Spatial working memory was analysed on trial 2 to trial 6 
for each day. The probe trial was evaluated the 5th day where the spent time into each sectors (Sect) (C) and each ring sectors 
(Ring) (D) were measured. Data are expressed as means ± SEM of 12 wildtype mice (WT) and 12 MCT2-knockdown mice 
(MCT2 KD). Mann Whitney test was applied to the data. *P<0.05, **P<0.01. 
 
 
 
 
To further assess working memory ability of MCT2-KD mice, we designed an experiment 
requiring discrimination of just visited vs. non-visited arms in an 8-arm radial maze. Mice 
were tested in two consecutive daily trials over four days (protocol details are described in the 
methods section). Entries into already visited arms within each trial were counted as working 
memory errors. Episodic and working memory components of the task were assessed by 
means of repeated-measures ANOVA on the sum of errors made in the two daily trials, over 
the four days. While all mice reduced the number of working memory errors over time (F (df 3, 
30) = 29.5, p < .0001), MCT2-KD mice committed more errors at any time (F (df 1, 22) = 19; p < 
0.005) confirming the spatial working memory deficit observed in the watermaze (Fig. 3). 
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Figure 3. Spatial working memory and reference memory errors for 4 days acquisition in the RAM. A) Schematic 
maze protocol of trial 1 and trial 2. Black arms were open in first hand and grey arms were open once black arms were been 
visited/eat by mice. B) Spatial reference memory analysed from the 3-open arms of trials. C) Spatial working memory was 
analysed once the 6 arms were open for the both trials.  Data are expressed as means ± SEM of 12 wildtype mice (WT) and 
12 MCT2-knockdown mice (MCT2 KD). Mann Whitney test was applied to the data. *P<0.05, **P<0.01, ***P<0.001 
 
 
 
Because these results also suggested a deficit in acquisition more than in retrieval of spatial 
information, we performed an inhibitory avoidance protocol that had been successfully used 
to dissociate these two steps of the learning process (Cole and Jones 1995; Decker et al. 
1990). Namely, mice underwent two discrete training sessions, at 5 minutes interval, where 
they received a 0.3 mA footshock 3 s after having entered the dark compartment of a shuttle-
box. Latency to re-enter the dark compartment, assessed 5 minutes after the first footshock 
event, provides a measure of learning proficiency; latencies assessed 10 minutes and 24 hours 
after the end of the second training session respectively provide a measure of short- and long-
term memory. All mice spontaneously re-entered the shock compartment five minutes after 
the first training trial, yet MCT2-KD with significantly reduced latency as compared to their 
initial dark escape time (Fig.4A). In contrast, almost all mice presented a maximal escape 
inhibition at both 10 minutes and 24 hours, showing similar retention abilities (Fig.4B). 
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Figure 4. Dynamics of episodic memory formation evaluated with the passive avoidance task. The latencies after five 
minutes (5min) (A) and 24 hours (24h) (B) were evualuated after training1 (foot shock). Data are expressed as means ± SEM 
of 12 wildtype mice (WT) and 12 MCT2-knockdown mice (MCT2 KD). Mann Whitney test was applied to the data. 
*P<0.05. 
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5.5 Discussion 
 
The hippocampus is a brain structure important for learning and memory processes in rodents. 
It is notably involved in episodic memory formation (Baddeley, 2001), especially in a spatial 
context (Wang and Morris, 2010). Spatial learning engages distinct processes such as working 
and reference memory that can be evaluated separately with appropriate tasks (Hodges, 1996). 
Our results show that a knockdown of MCT2 in the hippocampus (MCT2 KD) impairs spatial 
working memory (SWM) without effect on spatial reference memory (SRM). Since the same 
deficits were observed in glutamate receptor mutant mice such as GluRA -/- mice (Schmitt et 
al., 2003), NR2A-/- mice (Bannerman et al., 2008), as well as NR1deltaDG mice (Niewoehner et 
al., 2007), there is a possible link between MCT2 and glutamatergic transmission in working 
memory. Supporting this hypothesis, some studies have previously demonstrated that MCT2 
and AMPA receptor GluR2 subunits colocalize at the post-synaptic density of glutamatergic 
synapses and seem to be tightly bound to each other (Bergersen et al., 2005, Pierre et al., 
2009). Moreover, they not only translocate to the plasma membrane together after glutamate 
stimulation (Pierre et al., 2009) but the level of MCT2 expression directly influences GluR2 
intracellular trafficking, fate and expression levels (Maekawa et al., 2009). Thus, our results 
point at the possibility that energetic metabolism via MCT2 is essential for glutamate 
receptor-dependent working memory. 
 
Although the role of the hippocampus in memory is well recognized, the specific role of the 
different sub-regions in spatial working (SWM) vs reference memory (SRM) is less clear. 
Studies investigating this aspect have shown that neurotoxic lesions of the dentate gyrus or 
the CA3, but not the CA1 sub-region induced a deficit in spatial working memory (Lee and 
Kesner, 2003). Furthermore, both NR1deltaDG and NR1deltaCA3 mice revealed a spatial working 
memory impairment despite normal hippocampus-dependent spatial reference memory in the 
radial maze (Niewoehner et al., 2007; Nakazawa et al., 2002), whereas both NR1deltaCA1 mice 
and GluR2deltaCA1 showed a spatial reference memory deficit (Tsien et al., 1996; Wiltgen BJ et 
al., 2010). Therefore, evidences suggest that SWM and SRM require different specific sub-
regions of the hippocampus: dentate gyrus or CA3 for SWM and CA1 for SRM. In this 
context, it is interesting to note that the findings of Suzuki and colleagues, showing a 
reference memory impairment caused by downregulating MCTs including MCT2 in the 
hippocampus (Suzuki et al., 2011) contrast with our results. This discrepancy could be in fact 
due to a difference in the degree of protein downregulation within each hippocampal sub-
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region. Indeed, while in our case it seems to be the granule cells of the dentate gyrus that were 
primarily targeted by the lentiviral infection, it is likely that oligodeoxynucleotide injections 
as performed by Suzuki and collaborators might have affected more the CA1 area. Thus, it is 
most likely that MCT2 is important for both working and reference memory, the distinction 
between these two forms of memory being revealed depending of the hippocampal sub-region 
affected. 
 
Little is known about the exact mechanisms implicated in SWM and SRM, although it can be 
suspected that working memory relies more on short-term memory processes (STM) while 
reference memory relies rather on long-term memory processes (LTM). These two time-
dependent memory processes are based on separate molecular mechanisms and can be 
independently modulated (Izquierdo 1995; 1997,1999; Niewoehner et al., 2007; Bannerman et 
al., 2008; Sanderson et al., 2007; Wilgen et al., 2010). STM involves early-LTP (E-LTP), a 
synaptic plasticity process requiring NMDA receptor activation with subsequent Ca2+ influx 
(Malenka et al., 1992) as well as translocation of additional AMPA receptors into 
postsynaptic membrane (Kessels and Malinow 2009; Yang et al., 2008; Corera et al., 2009; 
Williams et al. 2007). In contrast, LTM requires late-LTP (L-LTP), which is protein 
synthesis-dependent (Frey and Morris 1997, Barco et al., 2002). Previously, it was 
demonstrated that MCT2 can be rapidly translocated to the membrane by various signals 
including brain-derived neurotrophic factor (BDNF) that has been implicated in long-term 
potentiation and synaptic plasticity (Pierre et al., 2009; Pierre K. poster; Société française des 
neuroscience, Bordeaux, 2010), similarly to AMPA receptor GluR subunits (Leonoudakis et 
al. 2004; Li and Keifer 2008; Lin et al., 2000; Lu et al., 2001; Passafaro et al., 2001). We also 
found that MCT2 downregulation induced STM deficits comparable to those observed in 
GluR1-/- (Sanderson et al., 2011). We can thus hypothesize that E-LTP-dependent STM 
involves the translocation of both AMPA receptors and MCT2. However, this hypothesis does 
not preclude the possibility that MCT2 is also involved in L-LTP-dependent LTM. Indeed, 
LTM deficits were also observed after blockade of MCT2 expression (Suzuki et al., 2011), 
suggesting that MCT2 synthesis could also play an important role in LTM formation. As 
BDNF, a key factor not only for E-LTP (via its effect on AMPA receptor subunit 
translocation) but also for L-LTP (via its effect on protein synthesis), was shown to enhance 
MCT2 protein synthesis in neurons both in vitro (Robinet and Pellerin, 2010) and in vivo 
(Robinet and Pellerin, 2011), this might explain the involvement of MCT2 in both 
mechanisms. 
 158
In conclusion, MCT2 seems to play a critical role during spatial working memory processes. 
As a corollary, it is possible that neuronal lactate utilization could be necessary to sustain the 
energy demand during high neuronal activity related to memory formation. Thus, our work 
highlights the putative importance of monocarboxylate transport in neurons for spatial 
memory formation, opening new interesting perspectives concerning the coupling between 
spatial memory and energy metabolism.    
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Chapter 6 
 
General discussion and perspectives 
 
 
 
 
Results obtained in this thesis highlight the important role of the neuronal monocarboxylate 
transporter MCT2 in conditions involving synaptic plasticity both in vitro and in vivo. 
Important implications for different areas that likely depend on neuroenergetics can be 
postulated and we present below a short discussion on some of these aspects. 
 
 
6.1 Putative role of MCT2 in adapting energy supply in synaptic plasticity 
 
 Long-term potentiation (LTP) is a persistent, use-dependent increase in the efficiency 
of synaptic transmission that can be induced by the delivery of high-frequency synaptic 
stimulation (HFS) (Reviewed by Robert D. Blitzer 2005). It has been proposed as one of the 
mechanisms implicated in synaptic plasticity, which form the cellular basis of memory.  LTP 
induction requires NMDA receptors activation with subsequent Ca2+ influx (Malenka et al., 
1992) as well as translocation of AMPA receptors at the synapse (Yang et al., 2008). LTP 
maintenance requires de novo protein synthesis (Frey and Morris 1997, Barco et al., 2002). 
This protein synthesis-dependent phase is stable and is taking place as early as 20 minutes 
after the induction. A possible link between MCT2 and LTP is supported by the findings of 
Pierre and coworkers (Pierre et al., 2009). Indeed, they observed that the GluR2 subunit of 
AMPA receptors and MCT2 were colocalized and concomitantly introduced into the 
membrane following glutamate stimulation (Pierre et al., 2009). Because during LTP 
induction AMPA receptors are translocated into the postsynaptic membrane, it is possible that 
MCT2 plays also a role in LTP induction. During the maintenance phase, LTP-related 
proteins that have to be synthesized are CamKII, AMPA receptors and delta PKC (Tsokas et 
al., 2005; Ju et al., 2004; Lisman et al., 2002). Since LTP maintenance requires AMPA 
receptors synthesis and MCT2 expression influence AMPA receptor GluR2 subunit 
expression levels (Maekawa et al., 2009), it might be possible that MCT2 plays also a role in 
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LTP maintenance. Recent studies started to elucidate the mechanisms responsible for LTP-
related protein synthesis. They showed that both MAPK and mTOR are necessary for LTP 
maintenance (Tsokas et al., 2005; Kelleher et al., 2004). Our results have shown that 
induction of MCT2 synthesis was regulated through PI3K/Akt/mTOR pathway as well as 
MAPK pathway following BDNF stimulation (Robinet and Pellerin 2010). Thus, the putative 
LTP-related MCT2 synthesis could occur via both PI3K/Akt/mTOR and MAPK pathways. 
 
Although evidences suggest that MCT2 could be involved in synaptic plasticity, its possible 
role in well-described processes such as LTP remains to be determined. In order to study the 
role of MCT2 in synaptic plasticity, we should perform some electrophysiological recordings 
on hippocampal slices. We could first downregulate the expression of MCT2 (using 
lentiviruses injected in vivo, Chap 5) in hippocampal slices or organotypic hippocampal slice 
culture. Then, study the effect of MCT2 downregulation on long-term potentiation (LTP) or 
long-term depression (LTD), two phenomena implicated in synaptic plasticity which form the 
cellular basis of memory. For example, it would be interesting to know whether MCT2 is 
crucial only for induction or for the maintenance of LTP, the two components for LTP 
establishment. 
 
 
6.2 Role of MCT2 in learning and memory: enhancing cognitive performance by 
overexpressing MCT2? 
 
 In the brain, it has been shown that during cognitive tasks, some metabolic changes 
occur. These include increased glucose consumption (Ros et al., 2006) and lactate production 
(Urrila et al., 2003, 2004). Another study showed that a physiological stimulation of neuronal 
activity produces an increase in both lactate and glucose in the rat brain (Fray et al., 1996). 
The increase in lactate level on stimulation coincides with the growing energy demand of 
increased neuronal activity (Magistretti and Pellerin, 1999). In parallel our results, and those 
of others, show that a downregulation of MCT2 in the hippocampus leads to memory deficits. 
Such deficits were proposed to be caused by disruption of lactate uptake and utilization by 
neurons (Suzuki et al., 2011). These findings suggest that energy supply, via monocarboxylate 
transporters, could be a necessary determinant of learning and memory processes, and in 
particular that neuronal lactate supply via MCT2 is important for the establishment of 
memory. 
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It would be interesting to investigate under which conditions memory could be enhanced by 
stimulating the expression of MCT2. In fact, it seems that cognitive performances can be 
influenced by different factors such as specific pharmacological treatments (e.g. cognitive 
enhancers), behavioral conditions, as well as lifestyle. Some of these might directly or 
indirectly target MCT2 expression (this aspect will be discussed in point 6.3). It is easy to 
imagine potential clinical applications. For example, in the context of neurogenerative 
diseases such as Alzheimer’s disease, it would be interesting to investigate whether an 
upregulation of MCT2 would lead to an increase in cognitive performance. In fact, patient 
suffering of Alzheimer’s disease progressively lose memory and develop a hypometabolism 
of glucose in specific brain regions, involving parieto-temporal and frontal areas (Mosconi et 
al., 2008). It might be worth investigating whether an upregulation of MCT2 would enhance 
memory in an Alzheimer’s disease mice model (this aspect will be discussed later in point 
6.4.2). 
 
6.3 The putative role of MCT2 in special diet and in exercise 
 
 Some evidences indicate that BDNF expression is affected by diet. Indeed, caloric 
restriction or certain diets affect levels of BDNF. Under high-fat diet, mice exhibited reduced 
levels of BDNF mRNA and protein in the hippocampus compared to mice under normal diet 
following a spatial memory task (Molteni et al., 2002). In addition, high-fat diet impairs 
neurogenesis, reducing the level of BDNF expression in the hippocampus (Park HR et al., 
2010). Since BDNF induced in vitro and in vivo an increase in the level of MCT2 expression 
in neurons (Robinet and Pellerin, 2010, 2011), and the high-fat diet reduces the level of 
BDNF, we could have expected to find a decrease of MCT2 expression on neurons. However 
it has been recently shown that high-fat diet induced expression of the three monocarboxylate 
transporter isoforms on neurons in different brain areas, suggesting that the exposure to a high 
fat diet sets a new metabolic environment for the brain that most likely leads to specific 
metabolic adaptations (Pierre et al., 2007). Another kind of high-fat diet with low 
carbohydrates, named ketogenic diet was shown to have an impact on neuronal metabolism as 
well as on astrocytic metabolism. Indeed, it was demonstrated that this diet decreased 
neuronal glucose metabolism and increased astrocytic metabolism (Melo et al., 2006). These 
changes may reflect adaptation of the brain to ketone bodies as a major source of energy. 
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These findings are consistent with the increase of MCTs under high-fat diet and further 
suggest that MCTs play a critical role under high-fat diet to fulfill neurons energy needs. 
 
In contrast to high-fat diet, dietary restriction in rats induces BDNF expression in the dentate 
gyrus in parallel with an increase in the number of newly generated cells suggesting that this 
diet affect the process of neurogenesis as well as neurotrophic factor production (Lee et al., 
2000). In addition, it was shown that a chronic caloric restriction was associated with an 
increase of BDNF in the prefrontal cortex, a reduction of tissue damages after traumatic brain 
injury and an improvement of spatial memory (Rich et al., 2010). Recent research has 
provided solid ground to the concept that limiting calorie intake slows down brain aging and 
protects from age-related neurodegenerative diseases (Reviewed by Contestabile A, 2009). 
For the moment, it is not known if caloric restriction modifies brain energetics or the 
expression levels of any energy substrate transporters including MCTs. 
 
BDNF expression can be also affected by exercise. It was shown that physical exercise 
increases BDNF levels in the hippocampus and the cortex (Cotman et al., 2002; Neeper et al., 
1996; Fuss et al., 2010), and this increase in BDNF may improve hippocampus-based 
learning, synaptic plasticity and neurogenesis (Cotman et al., 2002; Vaynman et al., 2004). 
Moreover, it was shown that forced exercise increased cerebral metabolism, including 
expression of GLUT1, GLUT3, phosphofructokinase (PFK), lactate dehydrogenase (LDH) 
and phosphorylated AMPA activity (Kinni H et al., 2011). Since exercise affects both BDNF 
expression level and increases cerebral metabolism, and because our results have shown that 
BDNF increased the level of MCT2 expression, it is likely that voluntary exercise will 
improve lactate utilization by neurons through MCT2. 
 
Taken together, exercise and caloric restriction increase the level of BDNF in the brain. It was 
also demonstrated that during exercise, the systemic lactate produced is known to be a brain 
energy source (van Hall G et al., 2009) and this lactate production increases BDNF blood 
concentration in humans (Schiffer T et al., 2011). It would be interesting to measure the level 
of lactate, BDNF and MCTs in the brain under exercise or caloric restriction. We could expect 
that during these physiological states, the level of MCT2 expression would be enhanced via 
BDNF stimulation, increasing lactate uptake in neurons and its neuronal utilization as 
additional energy substrate to sustain their activity. However, this would require additional 
experiments.
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6.4 Enhancing MCT2 expression as a neuroprotective mechanism 
 
6.4.1 Study of signaling pathways 
 
 Acute neurological insults like hypoxia-ischemia, seizures and hypoglycemia share 
common characteristics. They all induce neurotoxicity by disrupting neuronal energy profiles 
and produce hyperexcitation at glutamatergic synapses which leads to an increased glutamate 
release. Excess of glutamate is highly deleterious for the brain and must be cleared from the 
synaptic cleft by astrocytes. Thus, glutamate excess and hyperexcitation impair greatly the 
energy status of brain cells. 
 
 A solution proposed to counteract this effect was to increase energy supply by 
overexpressing the glucose transporter in neurons, thus providing more glucose to the cell. 
This was done in neurons infected with a defective herpes simplex virus (HSP) vector 
overexpressing the rat brain glucose transporter gene (Ho et al., 1995). This gene therapy 
permitted to protect cultured hippocampal, septal and spinal neurons from various necrotic 
insults (i.e hypoglycaemia, glutamate). In order to further improve neuronal energy supply, 
Bliss and coworkers used a dual cell, dual gene therapy approach (Bliss et al., 2004). They 
overexpressed both GLUT1 in astrocyte and MCT2 in neurons in mix cultures. This technique 
permitted to enhance glucose uptake by astrocytes and lactate uptake by neurons, thus, 
favoring the astrocyte-neuron lactate shuttle. This double therapy provided more 
neuroprotection than either therapy alone. Thus it seems of considerable importance to 
increase both glucose supply to astrocytes and lactate supply to neurons to overcome brain 
insults. These results are consistent with lactate being preferentially used by neurons in vitro 
and in vivo under certain conditions. Indeed, lactate was shown to be able to sustain synaptic 
activity (Schurr et al., 1988) and to play a major neuroprotective role in cerebral ischemia 
(Schurr et al., 2001a,b ; Berthet et al., 2009) 
 
 
Since MCT2 overexpression can provide neuroprotection after acute brain insults, the 
regulation of MCT2 is of particular importance. Our results demonstrated that MCT2 is in 
part controlled by the neurotrophic factor BDNF. The pathway induced by BDNF provides an 
interesting approach that could be further exploited to protect the brain against damages via 
increased MCT2 expression. In fact, apart from its effect on cellular differentiation and 
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synaptic plasticity, BDNF is one of the most important anti-apoptotic neurotrophin and its 
protective role has been demonstrated in several cell types (Hetman and Xia 2000). Our data 
have shown that BDNF activated PI3K/Akt and MAPK pathways. Each of these pathways 
was preferentially activated depending on the type of cellular injury (Hetman et al., 1999). In 
neural stem cells, BDNF acts as a neuroprotection agent against neurotoxin-exerted apoptotic 
death through PI3K/Akt and MAPK pathways (Nguyen et al., 2009). Indeed, mechanisms 
underlying the neuroprotective and functional effect of BDNF include the activation of 
neuronal pro-survival signaling pathways, including PI3K/Akt as well as MAPK (ERK) 
signaling pathway (Kaplan D.R. et al., 2000). Three other neuroactive substances (NA, 
Insulin and IGF-1) enhance MCT2 expression through activation of these pathways. All these 
substances were shown to have a role in neuroprotection. Indeed, in vitro experiments showed 
that insulin can reduce oxidative stress-induced apoptosis by activating the PI3K/Akt 
signaling pathway (Yu et al., 2006). Similarly IGF-1 was shown to protect cortical neurons 
from apoptosis via PI3K/Akt and ERK pathways (Willaime-Morawek et al., 2005) and 
noradrenaline (NA) has a neuroprotective effect on dopaminergic neurons by activation of 
MAPK signaling pathway (Troadec JD et al., 2002).  
 
These data suggest that the activation of PI3K/Akt and MAPK signaling pathway are 
involved in neuroprotection. Since MCT2 was shown to be upregulated via these signaling 
pathways and can participate to neuroprotection, it could be one of factors involved in the 
protective effect of these substances. It could be interesting to investigate this possible 
protective role for example in neurodegenerative diseases 
 
6.4.2  Neurodegenerative disorders 
 
 As described above, a link exists between dysregulation of BDNF signaling and some 
neurodegenerative pathologies. In fact, neurodegenerative disorders, such as Alzheimer’s 
disease (AD), Parkinson’s disease and Huntington’s disease, present an impairment in 
oxidative/energy metabolism, and thus altered glucose metabolism (Reviewed by Blass 2001). 
Two common points that they share is a decrease of cerebral glucose metabolism and a 
dysregulation of BDNF expression.   
 
Alzheimer’s disease is characterized by the progressive loss of synapses and, subsequently, of 
neurons themselves, which occurs within diverse cortical circuits, beginning in the entorhinal 
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cortex and the hippocampus, two structures essential for memory formation (Braak and 
Braak, 1991; Kordower et al., 2001; Masliah et al., 1994). BDNF is normally produced in the 
entorhinal cortex and the hippocampus in adulthood (Yan et al., 1997). Intriguingly, BDNF 
levels become deficient in the entorhinal cortex and the hippocampus in Alzheimer’s disease 
(Connor et al., 1997; Hock et al., 2000; Narisawa-Saito et al., 1996). Thus, the idea of a 
therapeutic application of BDNF in AD has emerged. Indeed, BDNF gene delivery improved 
learning and memory in hippocampus-dependent tasks in aged rats and non-human primate 
models (Nagahara et al., 2009). Concerning the metabolic state in AD patients, a severe 
reduction of the cerebral metabolic rate of glucose was detected (Zakzanis KK et al., 2003, 
Mosconi et al., 2008). Moreover, some studies suggest that two opposite metabolic processes 
may occur in AD brains: a reduction of neuronal glucose metabolism and an increase of 
astroglial metabolism (Allaman et al., 2010, Blass, 2001; Gibson, 2002). In this context, if 
BDNF plays a role in regulating lactate metabolism in the brain, as suggested by its role in 
MCT2 expression upregulation, it is likely that a deficit of BDNF will negatively affect 
lactate supply to neurons. Thus, it is possible that the re-establishment of BDNF 
release/expression in AD patients would enhance the level of MCT2, increasing lactate uptake 
in neurons. However, some experiments must be performed to confirm this hypothesis. For 
example, it would be interesting to study the expression of MCTs in brain of AD mouse 
models or of old mice. 
 
BDNF expression is also dysregulated in Parkinson’s disease, a neurodegenerative disorder 
that impairs motor function and cognitive ability, affecting dopaminergic neurons from 
substantia nigra projecting to the striatum. Indeed, the expression of BDNF protein and its 
mRNA are reduced in nigral neurons (Mogi et al., 1999; Parain et al., 1999). Moreover, a 
BDNF treatment in rodent models prevented the loss of dopaminergic neurons in the 
substantia nigra after chemical-induced lesion (Levivier et al., 1995; Frim et al.,1994). 
Furthermore, in non-human primates, BDNF protein infusion exhibited beneficial anatomical 
and behavioural effect by reducing cell loss and enhancing striatal reinnervation (Tsukahara et 
al., 1995). It could be interesting to investigate whether MCT2 expression is also dysregulated 
in this neuropathology.  
 
In the same manner, BDNF expression is dysregulated in Hungtinton’s disease (HD). 
Huntington’s disease is an autosomal dominant inherited neurodegenerative disease caused by 
the expansion of CAG triplicate repeats in the gene encoding the protein huntingtin (HTT). 
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The disease is characterized by involuntary choreiform movements, cognitive impairment and 
psychiatric dysfunction and has an onset in mid-adult life. Interestingly, BDNF levels decline 
in the striatum and the cerebral cortex in HD patients (Walker 2007). A BDNF infusion into 
the striatum of HTT-mutant mice increases the survival of striatal neurons and improves 
motor function (Canals et al., 2004). Recently, it was shown that astrocytes engineered to 
release BDNF can constitute a therapeutic approach for HD (Giralt A et al., 2010). But until 
now, BDNF therapy has not still been studied in non-human primate HD models. 
 
Thus, considering that BDNF regulates MCT2 expression, it could be a useful agent in the 
treatment of this neurodegenerative disease by promoting also lactate uptake into neurons 
coming from astrocytes. However, to confirm this hypothesis, many experiments remain to be 
performed. 
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Brain-derived neurotrophic factor enhances the
expression of the monocarboxylate transporter 2
through translational activation in mouse cultured
cortical neurons
Camille Robinet and Luc Pellerin
Department of Physiology, University of Lausanne, Lausanne, Switzerland
MCT2 is the predominant neuronal monocarboxylate transporter allowing lactate use as an
alternative energy substrate. It is suggested that MCT2 is upregulated to meet enhanced energy
demands after modifications in synaptic transmission. Brain-derived neurotrophic factor (BDNF), a
promoter of synaptic plasticity, significantly increased MCT2 protein expression in cultured cortical
neurons (as shown by immunocytochemistry and western blot) through a translational regulation at
the synaptic level. Brain-derived neurotrophic factor can cause translational activation through
different signaling pathways. Western blot analyses showed that p44/p42 mitogen-activated protein
kinase (MAPK), Akt, and S6 were strongly phosphorylated on BDNF treatment. To determine by
which signal transduction pathway(s) BDNF mediates its upregulation of MCT2 protein expression,
the effect of specific inhibitors for p38 MAPK, phosphoinositide 3-kinase (PI3K), mammalian target
of rapamycin (mTOR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated
kinase (ERK) kinase (MEK), p44/p42 MAPK (ERK), and Janus kinase 2 (JAK2) was evaluated. It
could be observed that the BDNF-induced increase in MCT2 protein expression was almost
completely blocked by all inhibitors, except for JAK2. These data indicate that BDNF induces an
increase in neuronal MCT2 protein expression by a mechanism involving a concomitant stimulation
of PI3K/Akt/mTOR/S6, p38 MAPK, and p44/p42 MAPK. Moreover, our observations suggest that
changes in MCT2 expression could participate in the process of synaptic plasticity induced by BDNF.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a widely
expressed neurotrophin in the central nervous
system (Skup, 1994). Acting through specific
tyrosine kinase receptors, BDNF affects neuronal
survival, differentiation, and synaptic plasticity after
the activation of multiple intracellular signal trans-
duction mechanisms, such as phosphoinositide
3-kinase (PI3K)/Akt and mitogen-activated protein
kinase (MAPK) signaling pathways (Bramham and
Messaoudi, 2005). Presynaptically, BDNF potentiates
depolarization-evoked Ca2+-dependent glutamate
release while causing direct glutamate release through
Ca2+ mobilization from Ins(1,4,5)P3-sensitive stores,
whereas the postsynaptic actions of BDNF include
changes in glutamate receptor phosphorylation,
subcellular localization and synthesis, and local
alterations in protein synthesis, as well as long-term
changes in gene expression (Carvalho et al, 2008).
These effects of BDNF contribute not only to
synaptic plasticity but also to modifications in spine
density and morphology (Carvalho et al, 2008).
However, one aspect that has not been explored in
the context of synaptic plasticity concerns putative
changes in neuroenergetics. Indeed, it is likely that
as a consequence of alterations in synaptic efficacy,
the supply of energy substrates must be adapted to
meet the energy needs imposed by new levels of
synaptic response.
In recent years, the role of monocarboxylates such
as lactate as additional energy substrates for neurons
has attracted increasing attention (Pellerin, 2003),
raising interest for the identification of specific
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transporters in the central nervous system. MCT2
was shown to be the predominant monocarboxylate
transporter expressed by neurons (Pierre et al, 2002).
It belongs to a family of proton-linked carriers
involved in the transport of lactate, pyruvate, and
ketone bodies (Garcia et al, 1994, 1995). MCT2
immunoreactivity was found to be abundant in the
neuronal processes of various brain regions, includ-
ing the cortex, hippocampus, and cerebellum (Ber-
gersen et al, 2002; Pierre et al, 2002). At the
subcellular level, MCT2 is expressed on axons and
dendrites (Pierre et al, 2002, 2009). Moreover, MCT2
is present at glutamatergic synapses and exclusively
on postsynaptic elements (Bergersen et al, 2002,
2005; Pierre et al, 2009). It is particularly enriched in
the postsynaptic density as well as in an intracellular
pool within the spines (Bergersen et al, 2005). Recent
observations have shown that MCT2 expression can
be regulated in cultured neurons. Thus, it was found
that noradrenaline, insulin, and insulin-like growth
factor-1 (IGF-1) increase MCT2 protein expression in
neurons through a translational mechanism (Chenal
and Pellerin, 2007; Chenal et al, 2008). Interestingly,
each of these neuroactive substances is known to
induce long-term changes in synaptic transmission
(Kobayashi and Yasoshima, 2001; Trejo et al, 2007;
van der Heide et al, 2006). Therefore, it became of
interest to investigate whether BDNF could regulate
MCT2 expression in cultured neurons and to
characterize the signal transduction pathways
involved in this effect. In addition, the nature of
the mechanism (transcriptional or translational) by
which MCT2 expression is regulated by BDNF has
been investigated.
Materials and methods
Neuronal Cultures and Pharmacological Treatments
Primary cultures of mouse cortical neurons were
prepared from embryonic day 17 OF1 mice (Charles
River, Lyon, France). As described previously
(Debernardi et al, 2003), after decapitation and brain
dissection, cortices were mechanically dissociated
in phosphate-buffered saline (PBS) supplemented
with glucose (NaCl, 150mmol/L; KCl, 3mmol/L;
KH2PO4, 1.5mmol/L; Na2HPO4, 7.9mmol/L; glucose,
33mmol/L; penicillin, 0.006 g/L; streptomycin,
0.1 g/L; pH 7.4). Cells were plated on poly
L-ornithine (15mg/L)-precoated dishes and cultured
in neurobasal-B27 medium (Brewer et al, 1993)
supplemented with 0.5mmol/L L-glutamine. All
experiments were carried out on day 7 in vitro. At
this stage, cultures contained <5% of glial cells
(Debernardi et al, 2003). Neuronal treatments with
pharmacological agents were carried out without
changing the medium before or during the incuba-
tion time. Brain-derived neurotrophic factor (CYT-
207; Brunschwig, Basel, Switzerland) was added
directly into the culture medium at various concen-
trations and cells were incubated for the indicated
times. Rapamycin, 20 ng/mL (mammalian target of
rapamycin (mTOR) inhibitor), SB202190 HCl,
10 mmol/L and SB203580 HCl, 10 mmol/L (p38 MAPK
inhibitors), LY294002, 10 mmol/L (PI3K inhibitor),
PD98059, 50 mmol/L (MAPK/ERK kinase (MEK
inhibitor), UO126, 10mmol/L (p44/p42 MAPK (ERK,
extracellular signal-regulated kinase) inhibitor), and
AG490 25 mmol/L (JAK2 (Janus kinase 2) inhibitor)
were added directly to the medium 30mins before
BDNF. All these inhibitors were purchased from
Alexis Biochemicals (Lausen, Switzerland), except
LY294002 (L9908; Sigma, Buchs, Switzerland) and
SB203580 (S8307; Sigma). Transcription and transla-
tion inhibitors (5 mmol/L actinomycin D (ActD) and
10 mmol/L cycloheximide, respectively) were added
30mins before pharmacological agents. All other
chemicals were purchased from Sigma. Data repre-
sent mean±s.e.m. of ‘n’ determinations, which are
independent measurements (from different culture
plates) obtained from at least three separate neuronal
cultures.
Immunocytochemistry and Related Quantification
After removal of the culture medium, cells were
carefully rinsed in PBS at 371C and directly postfixed
in an ice-cold paraformaldehyde fixative (4% in PBS
for 30mins at 201C). Fixed cells were treated with
casein (0.5% in PBS) for 1 h at room temperature to
block nonspecific sites. For immunostaining, cul-
tures were incubated overnight at 41C in 50 mL of
freshly prepared MCT2 antibody solution (anti-
MCT2 diluted 1:500 in PBS containing 0.25% bovine
serum albumin) (Pierre et al, 2000). After carefully
rinsing in PBS, cultures were incubated in a solution
containing Cy3-conjugated anti-rabbit Igs (diluted
1:500 for 2 h at room temperature; Jackson Immuno-
research, Baltimore, MD, USA). After rinsing in
PBS twice and a final rinsing in water, coverslips
were mounted with Vectashield (Reactolab SA,
Burlingame, CA, USA). Coverslips were examined
and photographed with an Axioplan2 microscope
(Zeiss, Hallbergmoos, Germany) using epifluores-
cence with an appropriate filter.
To quantitatively assess the influence of different
treatments on MCT2 protein expression, a quantita-
tive analysis of images obtained by epifluorescence
with a  20 objective and acquired using a cooled
CCD camera (Axiocam, Zeiss), together with the 4.6
Axiovision software (Zeiss) was carried out. Three
fields were chosen randomly on each coverslip; they
contained at least 20 MCT2-labeled neurons per
field. All pictures were acquired and presented as
different levels of gray with identical acquisition
time for all. Pictures were then analyzed using NIH
software (National Institutes of Health Image pro-
gram, version 1.62, Rockville Pike, MD, USA). The
fluorescence intensity of eight isolated cells taken
randomly in each of the three captured areas was
BDNF enhances neuronal MCT2 protein expression
C Robinet and L Pellerin
287
Journal of Cerebral Blood Flow & Metabolism (2010) 30, 286–298
assessed. The average fluorescence intensity repre-
senting neuronal MCT2 expression was obtained by
calculating the average of 24 measurements per
coverslip. Measurements were obtained in a blinded
manner with the investigator unaware of the culture
treatments. Mean and s.e.m. for a particular condi-
tion were calculated from average fluorescence
intensity values of distinct coverslips representing
independent determinations (numbers indicated on
each bar of the graph). Data were statistically analyzed
with an ANOVA (analysis of variance), followed by
Dunnett’s or Bonferroni’s test.
Western Blot and Related Quantification
Neurons in each culture dish were homogenized in
50 mL of buffer containing the following: Tris-HCl, pH
6.8, 20mmol/L; sucrose, 0.27mol/L; EGTA (ethylene
glycol tetraacetic acid), 1mmol/L; EDTA (ethylene
diamine tetraacetic acid), 1mmol/L; NaF, 50mmol/L;
Triton X-100, 1%; b-glycerophosphate, 10mmol/L;
DTT (dithiothreitol), 10mmol/L; 4-nitrophenylpho-
sphate, 10mmol/L; and a mixture of protease
inhibitors (Complete, Roche Molecular Biochem-
icals, Mannheim, Germany). Each stimulated condi-
tion was examined in duplicate and the contents of
the two Petri dishes were pooled. Protein samples
were sonicated and heated at 951C for 5mins in half
the final volume of SDS-PAGE sample buffer (Tris-
HCl, 62.5mmol/L; DTT, 50mmol/L; SDS, 2%; gly-
cerol, 10%; and bromophenol blue, 0.1%). Samples
were loaded onto polyacrylamide gels composed of
a 10% or 6% acrylamide-bisacrylamide running
gel and a 4.5% acrylamide-bisacrylamide stacking
gel. After electrophoresis, proteins were transferred
onto nitrocellulose membranes (Trans-Blot Transfer
Medium 162-0115; Bio-Rad, Reinach, Switzerland)
using a Transblot semi-dry transfer cell (Bio-Rad).
For protein detection, membranes were incubated in
a blocking solution of Tris-buffered saline supple-
mented with Tween-20 (TBST; Tris-HCl, pH 7.5,
50mmol/L; NaCl, 150mmol/L; and Tween-20, 0.1%)
containing 5% nonfat milk for 1 h at room tempera-
ture. Membranes were incubated overnight at 41C
with the antiphospho-serine/threonine protein ki-
nase from AKT virus (Akt)-Ser473 (1:700), antipho-
spho-p44/p42 MAPK-Thr202/Tyr204 (both 1:1,000),
antiphospho-mTOR-Ser1448 (1:1,000), anti-mTOR
(1:1,000), antiphospho-S6-Ser235/236 ribosomal pro-
tein (1:1,000), and anti-b-actin (A5441; Sigma). All
primary antibodies were purchased from Cell Signal-
ling (BioConcept, Allschwil, Switzerland), except
anti-b-actin (A5441; Sigma). After three washes in
TBST, membranes were incubated with the second-
ary antibodies Alexa Fluor 680 goat anti-IgG (Juro,
Lucerne, Switzerland) and IRDye 800 goat anti-
mouse IgG (BioConcept), diluted at 1:5,000 in TBST
containing 1% nonfat milk, for 2 h at room tempera-
ture, and protected from light. After three washes in
TBST, membranes were scanned using the Odyssey
Infrared Imaging System (LI-COR Biosciences,
Lincoln, NE, USA), which permits detection and
quantification of proteins of interest. b-Actin,
revealed in green, was used for normalization and
the proteins of interest were revealed in red. As
phospho-mTOR has a very high molecular weight
(289 kDa), actin was not visible on the same gel. To
normalize western blots for phospho-mTOR, samples
were loaded in duplicate onto a 6% running gel
and proteins were transferred onto a nitrocellulose
membrane using a 10% methanol transfer buffer. The
membrane was then cut into two identical pieces and
probed either with the phospho-mTOR antibody
(1:1,000) or with the mTOR antibody (1:1,000). Thus,
quantifications were performed on samples resolved
on the same gel and transferred onto the same
membrane, and normalization was conducted
against mTOR (instead of b-actin). The remaining of
the procedure was unchanged.
Quantitative Real-Time Reverse Transcriptase-PCR
Quantitative determination of MCT2 mRNA expres-
sion levels was performed by quantitative reverse
transcriptase-PCR according to Heid et al (1996)
using an ABI Prism 7000 sequence detection system
from Applied Biosystems (Rotkreuz, Switzerland). The
following sets of oligonucleotides were used: 50-30;
ActinFo, GCTTCTTTGCAGCTCCTTCGT; ActinRe, AT
ATCGTCATCCATGGCGAAC (Embl: X03672); MCT2Fo,
CAGCAACAGCGTGATAGAGCTT; MCT2Re, TGGTTG
CAGGTTGAATGCTAAT (Embl: NM_011391); NPYFo,
ACCAGACAGAGATATGGCAAGAGA; NPYRe, GGCGT
TTTCTGTGC (produced by Microsynth, Balgach,
Switzerland).
Preparation and Stimulation of Synaptoneurosomes
Synaptoneurosomes were prepared from the fore-
brains of 8- to 14-day-old mice pups (10 to 15 pups
per preparation) according to a previously published
protocol (Rao and Steward (1991), as modified by
Schratt et al (2004)). Briefly, the total forebrains were
dissected in 20mL of homogenization buffer
(0.32mol/L sucrose, 0.1mmol/L EDTA, 0.25mmol/L
DTT, and 3mmol/L HEPES, pH 7.4) and disrupted
using a Teflon-coated Dounce-Potter homogenizer
(B. Braun, Crissier, Switzerland) by eight up-
and-down strokes. Nuclei and cell debris were
pelleted by 2mins of centrifugation at 2,000 g. The
supernatant was collected and centrifuged for an
additional 10mins at 14,000 g to pellet a crude
synaptoneurosome-containing fraction (P2). The
pellet was then brought up to 8mL total volume
(with a solution of 0.32mol/L sucrose and 1mmol/L
NaHCO3). This suspension (4 2mL) was layered
onto three different discontinuous sucrose gradients
(0.85, 1, 1.2mmol/L) that had been equilibrated at 41C
for 1h. The gradient was centrifuged at 45,000g for
45mins in a Centrikon T-1075 ultracentrifuge using a
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SW 41.14Ti swinging bucket rotor. Synaptoneurosomes
were collected from the 1/1.2mol/L interface (500mL for
2mL of P2), washed twice in 1PBS (in a 2-mL tube),
with a centrifugation at 7,000g for 2mins. Synapto-
neurosomes were resuspended in 500mL of synapto-
neurosome incubation buffer (10mmol/L Tris, pH 7.5,
2.2mmol/L CaCl2, 0.5mmol/L Na2HPO4, 0.4mmol/L
KH2PO4, 4mmol/L NaHCO3, and 80mmol/L NaCl).
Synaptoneurosomes were centrifuged at 7,000g for
2mins, the supernatant was discarded, and synapto-
neurosomes in the lower fraction were either used
immediately or stored at 801C. No significant differ-
ences were observed between results from freshly
prepared or frozen synaptosomes such that results were
pooled. Enrichment of the synaptosomal fraction was
controlled by performing western blotting for the
postsynaptic protein PSD-95 (data not shown).
The synaptoneurosome pellet was thawed on ice
for 30mins and diluted in a prewarmed (371C)
synaptoneurosome incubation buffer containing
a mixture of antiproteases (Complete 11257000;
Roche Molecular Biochemicals) to yield a protein
concentration between 2 and 9mg/mL. Synapto-
neurosome samples (100 mL) were exposed to either
ActD (5 mmol/L) or cycloheximide (10 mmol/L)
for 30mins before application of 100ng/mL BDNF
for 6 h. The reaction was stopped by adding 20 mL
of SDS buffer (5 ), and samples were boiled for
5mins and served as starting material for western
blotting.
Results
Effect of Brain-Derived Neurotrophic Factor on MCT2
Protein Expression in Cultured Neurons
To assess the effect of BDNF on neuronal MCT2
protein expression, cultured cortical neurons were
treated with BDNF for 6h at various concentra-
tions up to 100ng/mL. Experiments conducted with
BDNF concentrations of 10, 50, and 100ng/mL
followed by immunocytochemistry led to a striking
enhancement of fluorescence intensity correspon-
ding to higher levels of MCT2 immunoreactivity (IR)
at 100ng/mL (Figure 1A). Western blot analysis
showed that the maximal increase of MCT2 expres-
sion was found with 100ng/mL. At lower concen-
trations, MCT2 expression had a tendency to
be increased, but the effect was not significant
statistically (Figure 1B).
Changes in the levels of MCT2 IR induced by
BDNF were also studied as a function of time (1, 6,
12, and 24h). It was observed that 100ng/mL BDNF
caused a 40% increase in MCT2 IR 6h after the
beginning of the treatment that remained elevated at
12 and 24h (Figure 2A). Western blot analysis
showed that the increase of MCT2 expression was
already found significant as early as after 1 h of
BDNF stimulation (100ng/mL) and that this signifi-
cant increase was still present up to 24h (Figure 2B).
The effect of BDNF was found to be as robust as the
previously described effect of noradrenaline
(100 mmol/L) on MCT2 expression after 6 h of treat-
ment (Figure 2C).
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Figure 1 Concentration-dependent effect of BDNF on MCT2
expression in primary cultures of mouse cortical neurons.
(A) Immunocytochemical stainings for MCT2 in untreated
cultures (Ctrl) and in cultures treated with BDNF for 6 h
at different concentrations. (B) Western blot analysis of MCT2
expression in primary cultures of mouse cortical neurons trea-
ted with BDNF for 6h at various concentrations up to 100ng/mL.
Western blots were quantified using Odyssey software
(LI-COR Biosciences, Lincoln, NE, USA). Results were ex-
pressed as percentage of control after the values were normal-
ized using b-actin signal as the reference. Statistical analy-
sis was performed using ANOVA followed by Dunnett’s test.
** indicates MCT2 protein levels significantly different from
control with P<0.01. Numbers in the graph bars represent the
number of independent experiments for each condition.
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Putative Involvement of Distinct Signal Transduction
Pathways in Brain-Derived Neurotrophic
Factor-Induced MCT2 Expression
Involvement of specific signal transduction mechan-
isms involved in the effect of BDNF on MCT2
expression was investigated with a series of inhibi-
tors. Cultured cortical neurons were pretreated with
five different inhibitors (LY294002, a specific PI3K
inhibitor; rapamycin, a specific mTOR inhibitor;
PD98058, a specific MEK inhibitor; SB202190, a
specific p38 MAPK inhibitor; and AG490, a specific
JAK2 inhibitor) 30mins before the addition of BDNF
(100ng/mL) for 6 h. The six panels on the left of
Figure 3A show that a 30-min pretreatment of
cultured mouse cortical neurons with LY294002
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Figure 2 Time course of the effect of BDNF on MCT2 protein expression in primary cultures of mouse cortical neurons. (A) MCT2 IR
and related quantification of primary cultures of mouse cortical neurons treated with BDNF at a final concentration of 100 ng/mL for
various periods of time up to 24h (1, 6, 12, and 24h). Left panels represent immunocytochemical stainings for MCT2 in untreated
cultures (Ctrl) or cultures treated with BDNF for 6 h. The bar graph represents the quantitative determination of fluorescence intensity
corresponding to MCT2 IR in cultured neurons treated with BDNF for various periods of time up to 24 h. Results are expressed as
percentage of control fluorescence intensity and are represented as the mean±s.e.m. of independent determinations (numbers
indicated on bars) from four distinct experiments. The value of fluorescence intensity for each determination represents the average
level from 24 cells on the same coverslip. (B and C) Western blot analysis of MCT2 protein expression in cultures of mouse cortical
neurons treated with BDNF 100ng/mL or noradrenaline 100 mmol/L (NA 6h) for the indicated times as compared with untreated
cells (Ctrl). Western blots were quantified using Odyssey software (LI-COR Biosciences, Lincoln, NE, USA). Results are expressed as
percentage of control (mean±s.e.m.) after the values had been normalized using b-actin signal as the reference. Statistical analysis
was performed using ANOVA followed by Dunnett’s test. *P<0.05, **P<0.01, ***P<0.001 versus control (Ctrl) for MCT2
protein levels. Numbers in the graph bars represent the number of independent experiments for each condition.
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(10 mmol/L), rapamycin (20ng/mL), PD98058
(50 mmol/L), or SB202190 (10 mmol/L) blocked the
BDNF-induced increase in MCT2 IR after 6 h of
treatment. In contrast, AG490 (25 mmol/L) had no
effect (not shown). The quantification of MCT2 IR
shows that all inhibitors (with the exception of
AG490) prevented the induction of MCT2 protein
expression by BDNF, reducing the overall expression
by B40% (Figure 3A). Similar results were ob-
tained by western blot, confirming the MCT2 IR data
(Figure 3B).
The effect of all five inhibitors alone (without
posttreatment with BDNF) was tested previously on
cultured cortical neurons and no change in MCT2 IR
was observed compared with the control condition
(data not shown). To further validate our observa-
tions, two more inhibitors were tested for their effect
on BDNF-induced MCT2 expression (UO126, a
specific p44/p42 MAPK inhibitor, and SB203580,
another specific p38 MAPK inhibitor). Cultured
cortical neurons were pretreated with UO126
(10 mmol/L) and SB203580 (10 mmol/L) 30mins
before the addition of BDNF (100ng/mL) for 6 h.
Western blot analysis shows that UO126 and
SB203580 significantly reduced MCT2 protein
expression induced by BDNF (Figure 3C).
Activation by Brain-Derived Neurotrophic Factor of
the Different Signal Transduction Pathways Implicated
in MCT2 Upregulation
It became necessary to assess the effect of BDNF on
each signal transduction pathway putatively impli-
cated in MCT2 upregulation and to verify the
efficacy of each inhibitor used. Cultured cortical
neurons were treated with BDNF (100ng/mL) for
three time periods (5mins, 30mins, and 1h). First, to
evaluate the activation of the PI3K/Akt/mTOR/S6
pathway, the phosphorylation levels of Akt on
Ser473, mTOR on Ser2448, and S6 ribosomal protein
on Ser235/236 were determined by western blot.
Brain-derived neurotrophic factor induced the
phosphorylation of Akt after 5mins of treatment
(Figure 4A). The level of phosphorylation was
increased by B300% above control (set at 100%)
after 5mins of treatment. Maximal activation was
reached after 30mins. Phosphorylation of Akt was
sustained for 1 h of BDNF treatment. To obtain the
confirmation that Akt signaling can be inhibited in a
manner similar to MCT2 upregulation, cultured
cortical neurons were pretreated with 10 mmol/L
LY294002 for 30mins before the addition of BDNF
(100ng/mL) for 5mins, 30mins, and 1h. Indeed,
LY294002 pretreatment prevented the phosphoryla-
tion of Akt induced by BDNF in cultured cortical
neurons (Figure 4A).
Activation of mTOR by BDNF treatment was
investigated by monitoring its level of phosphoryla-
tion. Brain-derived neurotrophic factor induced the
phosphorylation of mTOR within 5mins after the
beginning of the treatment (Figure 4B). Phosphoryla-
tion of mTOR was further increased by more than
50% above the control level after 1 h of BDNF
treatment. To determine whether mTOR activation
can be prevented in the same manner as MCT2
upregulation, cultured cortical neurons were
pretreated with 20ng/mL rapamycin for 30mins
before adding BDNF (100ng/mL) for 5mins, 30mins,
and 1h. Rapamycin pretreatment completely
prevented the phosphorylation of mTOR induced
by BDNF in cultured cortical neurons at 30mins
(Figure 4B).
S6 phosphorylation represents one of the late steps
in the activation of the PI3K/Akt/mTOR/S6 pathway.
Phosphorylation levels of S6 were assessed after
BDNF treatment. Brain-derived neurotrophic factor
induced the phosphorylation of S6 within 5mins
after the beginning of the treatment (80% above
control; Figure 4C). Maximal activation was reached
after 1 h with an increase of 350% above control. As
the S6 protein is known to be a downstream effector
of the Akt/mTOR signaling pathway, cultured cor-
tical neurons were pretreated with 20ng/mL rapa-
mycin (inhibitor of mTOR) for 30mins before the
addition of BDNF for 5mins, 30mins, and 1h. It was
observed that rapamycin pretreatment completely
prevented the phosphorylation of S6 ribosomal
protein induced by BDNF in cultured cortical
neurons (Figure 4C).
Mitogen-activated protein kinase activation is
purported to be involved in the effect of BDNF on
MCT2 expression. Phosphorylation levels of p44 and
p42 MAPK (phospho-ERK) on Thr202/Tyr204 were
determined by western blot after treatment of
cultured cortical neurons with BDNF (100ng/mL)
for three different time periods (5mins, 30mins, and
1h). Brain-derived neurotrophic factor induced the
phosphorylation of p44 and p42 MAPK after 5mins
of treatment (Figure 5A). The level of phosphoryla-
tion was increased by more than 500% (for both p44
and p42) above control (set at 100%) at that time.
Phosphorylation of p44 and p42 MAPK was sus-
tained for 1h of BDNF treatment. To ascertain
whether MAPK activation can be prevented similar
to MCT2 upregulation, cultured cortical neurons
were pretreated with 50 mmol/L PD98059 for 30mins
before the addition of BDNF (100ng/mL) for 5mins,
30mins, and 1h. As expected, PD98059 pretreatment
attenuated the phosphorylation of p44 and p42
MAPK induced by BDNF in cultured cortical
neurons (Figure 5A).
Activation of p38 MAPK is another possible
signaling mechanism involved in BDNF-induced
MCT2 upregulation. Phosphorylation levels of p38
MAPK on Thr180/Tyr182 were determined by wes-
tern blot. Brain-derived neurotrophic factor induced
the phosphorylation of p38 MAPK that reached a
maximum after 1 h with an increase ofB150% above
control (set at 100%; Figure 5B). To investigate
whether p38 MAPK activation can be prevented
using the inhibitor previously used, cultured cortical
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neurons were pretreated with 10 mmol/L SB202190
for 30mins before the addition of BDNF (100ng/mL)
for 5mins, 30mins, and 1h. SB202190 pretreatment
was found to prevent phosphorylation of p38 MAPK
induced by BDNF in cultured cortical neurons
(Figure 5B).
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25 mmol/L (AG); UO126, 10mmol/L (UO); SB203580, 10mmol/L (SBb)) before stimulation with BDNF 100ng/mL for 6 h (BDNF
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Western blot analysis of MCT2 expression in cultures of mouse cortical neurons treated with specific signaling pathway inhibitors (+
LY, Rap, PD, SBa, AG, UO, SBb) before stimulation with BDNF 100ng/mL for 6 h (BDNF 6h). Western blots were quantified using
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Brain-Derived Neurotrophic Factor Enhances MCT2
Expression by a Translational Mechanism
The effect of BDNF on MCT2 mRNA expression was
investigated by quantitative reverse transcriptase-
PCR on total RNA from mouse cortical neurons.
Neurons were treated with BDNF (100ng/mL) for
various time points up to 24h. Figure 6A shows that
BDNF exerted no enhancing effect on MCT2 mRNA
levels at any time point, whereas NPY mRNA levels
(a peptide known to be transcriptionally regulated)
showed a significant increase after 12 and 24h. A
small but significant decrease in MCT2 mRNA levels
was observed at 3 h. To ascertain whether the effect
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of BDNF on MCT2 expression requires the activation
of translation but not of transcription, cultured
neurons were treated with inhibitors for these two
processes. Application of cycloheximide (10mmol/L),
a protein synthesis inhibitor, 30mins before BDNF
stimulation (100ng/mL), prevented the enhance-
ment of MCT2 protein expression (Figure 6B). Quite
unexpectedly, the mRNA synthesis inhibitor ActD
(5mmol/L) also blocked the effect of BDNF on MCT2
protein expression. To determine whether the enhan-
cement in MCT2 protein synthesis occurs at the
synaptic level and requires transcriptional activation,
an experiment was conducted on synaptoneuroso-
mes (Figure 6C). Brain-derived neurotrophic factor
(100ng/mL) induced an increase in MCT2 protein
expression after 6h in this preparation. The effect of
BDNF was prevented by cycloheximide (10mmol/L) but
not by ActD (5mmol/L).
Discussion
In recent years, BDNF has emerged as a major
regulator of synaptic transmission and plasticity at
adult synapses in many regions of the central
nervous system (Bramham and Messaoudi, 2005).
Among the mechanisms subserving synaptic plasti-
city, enhancement of localized protein synthesis
constitutes a critical process for long-term adaptation
of synaptic efficacy. Brain-derived neurotrophic
factor is one of the major activity-dependent mod-
ulators of dendritic protein synthesis and it is known
to activate specific components of the translational
machinery in neurons (Bramham and Messaoudi,
2005; Steward and Schuman, 2003). Previously, it
has been shown that the rapid induction of protein
synthesis by BDNF is mediated both through the
PI3K pathway, as it involves the activation of PI3K
and mTOR (Bramham and Messaoudi, 2005; Schratt
et al, 2004; Yoshii and Constantine-Paton, 2007), as
well as through the MAPK signaling pathway
(Kelleher et al, 2004). Interestingly, BDNF was
shown in this study to enhance MCT2 protein
expression in cultured cortical neurons through a
stimulation of translation. This is supported by the
observations that no changes in MCT2 mRNA levels
were detected, whereas MCT2 protein expression
was enhanced by BDNF in synaptoneurosomes, a
preparation that can sustain translation but not
transcriptional activation. The observation that the
mRNA synthesis inhibitor ActD can prevent BDNF-
induced enhancement of MCT2 protein expression
in intact cells but not in synaptoneurosomes is
intriguing. It cannot be excluded that as a general
transcription inhibitor, ActD indirectly interferes
with the translation process in intact cells by
reducing the expression of some essential compo-
nents. The effect of BDNF on MCT2 protein expres-
sion was shown to involve the activation of three
distinct signaling pathways, all classically impli-
cated in the regulation of translation initiation (Hay
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Figure 5 Effect of BDNF on the phosphorylation levels of ERK
and p38 MAPK in cultured mouse cortical neurons. Western blot
analysis of phospho-ERK (A) and phospho-p38 MAPK (B) levels
in cultures of mouse cortical neurons treated with BDNF 100ng/
mL for the indicated times as compared with untreated cells
(ctrl). (Panel A) PD98058, a specific MEK inhibitor, was added
to the culture medium at a concentration of 50 mmol/L, 30mins
before incubation with BDNF 100ng/mL during 5mins,
30mins, and 1 h. (Panel B) SB202190, a specific p38 MAPK
inhibitor, was added to the culture medium at a concentration of
10 mmol/L, 30mins before incubation with BDNF 100ng/mL.
Western blots were quantified using Odyssey software (LI-COR
Biosciences, Lincoln, NE, USA). Results are expressed as
percentage of control after the values had been normalized
using b-actin signal as reference. Statistical analysis was
performed using ANOVA followed by Bonferroni’s test. ***
indicates phospho-ERK or phospho-p38 MAPK levels signifi-
cantly different from control with P<0.001. ##, ### indicates
phospho-ERK or phospho-p38 MAPK levels significantly differ-
ent from BDNF-treated condition with P<0.01 and P<0.001,
respectively. Numbers in the graph bars represent the number of
independent experiments for each condition.
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and Sonenberg, 2004). Thus, a concomitant activa-
tion of PI3K/Akt/mTOR, p38 MAPK as well as MEK/
ERK kinases was found to be necessary for the
enhancement of MCT2 protein expression by BDNF
(Figure 7). Such an observation suggests a putative
cross talk between the different signaling pathways
activated by BDNF to regulate translational activa-
tion, a possibility previously proposed by others
(Almeida et al, 2005; Bramham and Messaoudi,
2005). It is noted that noradrenaline (a neurotrans-
mitter), insulin (a hormone), and IGF-1 (a neuro-
trophic factor) were also previously shown to
regulate MCT2 protein expression at the translational
level, notably by activating the PI3K/Akt/mTOR/S6
kinase pathway in cultured cortical neurons (Chenal
and Pellerin, 2007; Chenal et al, 2008). As each of
these neuroactive substances, similar to BDNF,
has been implicated in different forms of synaptic
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Figure 6 Synaptic regulation of MCT2 protein synthesis by BDNF. (A) Primary cultures of mouse cortical neurons were treated with
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before the application of 100ng/mL BDNF for 6 h. (C) Western blot analysis of MCT2 expression in synaptoneurosomes treated with
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different from BDNF-treated condition with P<0.05 and P<0.01, respectively. Numbers in the graph bars represent the number of
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plasticity, it suggests that MCT2 represents
a common target for such signals, pointing to a
putatively important role of MCT2 in relation to
synaptic modifications.
In view of the current results, it appears that MCT2
belongs to a group of neuronal proteins specifically
regulated at the translational level. Until now, more
than 100 different mRNAs coding for proteins
involved in neurotransmission and in the modula-
tion of synaptic activity have been identified in
dendrites. Local protein synthesis from these
mRNAs is postulated to provide the basic mechan-
ism of long-term changes in the strength of neuronal
connections (Skup, 2008). Postsynaptic proteins that
undergo enhancement of their synthesis locally
include calmodulin kinase II (Ouyang et al, 1999;
Wu and Cline, 1998), MAP2 (Blichenberg et al,
1999), Arc/Arg 3.1 (Steward and Schuman, 2001),
and GluR1, as well as GluR2 AMPA receptor
subunits (Ju et al, 2004). Although the presence of
MCT2 mRNA has not been described yet in den-
drites, it seems likely that the translational regula-
tion of MCT2 expression would occur locally. Our
results obtained with synaptoneurosomes support
this conclusion. The MCT2 protein is not only
present in dendrites but it is also specifically
associated with spines, where it was found to be
expressed in the postsynaptic density as well as on
vesicle-like structures forming an intracellular pool
(Bergersen et al, 2005). MCT2 was recently found to
interact with a specific subset of postsynaptic
proteins (Pierre et al, 2009). This is particularly the
case with GluR2, a subunit of the glutamatergic
AMPA receptor subtype. It was shown that MCT2
seems not only to determine the subcellular localiza-
tion of GluR2 in neural cells but also to regulate its
expression levels (Maekawa et al, 2009). In addition,
it was observed that MCT2 together with GluR2
undergoes a trafficking process between the plasma
membrane and an intracellular pool under condi-
tions inducing synaptic plasticity (Pierre et al, 2009).
Translocation of GluR2 to and from the plasma
membrane has been implicated in synaptic plasticity
mechanisms, such as long-term potentiation and
long-term depression (Kessels and Malinow, 2009;
Malenka, 2003; Sheng and Kim, 2002). Thus, MCT2
localization and interaction with specific synaptic
proteins involved in plasticity mechanisms strength-
en the view that its expression may be regulated in a
manner similar to its partners. In this regard,
increased MCT2 protein expression by BDNF may
be part of a coordinated mechanism of local synth-
esis for various postsynaptic proteins involved in the
long-term regulation of glutamatergic transmission.
Although a major effort has been devoted to
decipher the molecular events involved in synaptic
plasticity, including those induced by BDNF, few
studies have explored the concomitant changes in
neuroenergetics that could take place with altera-
tions in synaptic transmission. Recently, the concept
that energy metabolism might be coupled to synaptic
plasticity has been proposed together with the
implication of BDNF in such interactions (Vaynman
et al, 2006). Indeed, BDNF was shown to enhance
mitochondrial activity (El Idrissi and Trenkner,
1999). Regarding the energy substrates that might
be concerned, lactate has attracted much attention
recently. Lactate has been shown to be a preferential
oxidative substrate for neurons both in vitro (McKen-
na et al, 1993, 1994) and in vivo (Hyder et al, 2006;
Serres et al, 2005). Lactate is not only able to sustain
synaptic vesicle turnover and synaptic transmission
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Figure 7 Putative signaling pathways leading to translational
activation and enhanced MCT2 protein synthesis after BDNF
treatment in cultured cortical neurons. BDNF and TrkB can
activate distinct signal transduction pathways involving specific
kinases leading to translation initiation. Two pathways investi-
gated in this study are illustrated herein (PI3K/Akt/mTOR/S6 and
MAPK signaling pathways). The surrounding proteins were
directly investigated for their level of phosphorylation. First,
phosphorylation of PI3K can cause the phosphorylation and
activation of Akt, which then directly phosphorylates mTOR,
which in turn phosphorylates p70S6K. The target of p70S6K,
the ribosomal S6 protein, once phosphorylated, participates in
the translational machinery as part of the 40S complex. Second,
the MAPK cascade is also activated by BDNF requiring the
activation of MEK. MEK phosphorylates the p44 and p42
MAPK, which can activate, among others, MNK1. When
activated, MNK1 phosphorylates eIF4E on Ser209 that corre-
lates with enhanced rates of translation of capped mRNA.
Specific inhibitors for some kinases have been used to
distinguish the implication of each pathway in the effect of
BDNF: LY294002, PI3K inhibitor; rapamycin, mTOR inhibitor;
PD98058, MEK inhibitor; SB202190 and SB203580, p38
MAPK inhibitors.
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(Morgenthaler et al, 2006; Rouach et al, 2008; Schurr
et al, 1988) but it is also shown to allow, at least in
part, the establishment of long-term potentiation
(Izumi et al, 1997; Yang et al, 2003). In addition,
glutamatergic activity increases the production and
release of lactate by astrocytes (Pellerin and Magis-
tretti, 1994), and it has been purported that such an
effect participates in a mechanism to provide lactate
as an additional energy substrate to neurons to
sustain their activity (Pellerin et al, 2007). As the
primary role of MCT2 is to supply neurons with
nonglucose energy substrates, e.g., lactate, changes
in MCT2 expression might facilitate the utilization of
alternative substrates. Indeed, overexpression of
MCT2 in neurons was shown to enhance lactate
consumption by neurons stimulated with kainate
(Bliss et al, 2004). Our observation that MCT2 can be
upregulated by BDNF is consistent with the possibi-
lity of a coupling between lactate utilization and
synaptic plasticity. It is hypothesized that to meet
higher energy demands caused by enhanced synaptic
transmission after synaptic plasticity, MCT2 expres-
sion is increased to facilitate lactate supply at
potentiated synapses.
In conclusion, we have shown that BDNF
enhances the expression of the monocarboxylate
transporter MCT2 in cultured cortical neurons
through a translational regulation. A possible role
for such an effect could be to enlarge the local lactate
transporter pool to allow potentiated synapses to
meet higher energy demands on activation.
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Abstract—Brain-derived neurotrophic factor (BDNF) pro-
motes synaptic plasticity via an enhancement in expression
of specific synaptic proteins. Recent results suggest that the
neuronal monocarboxylate transporter MCT2 is a postsynap-
tic protein critically involved in synaptic plasticity and long-
term memory. To investigate in vivo whether BDNF can mod-
late the expression of MCT2 as well as other proteins in-
olved in synaptic plasticity, acute injection of BDNF was
erformed in mouse dorsal hippocampal CA1 area. Using
mmunohistochemistry, it was found that MCT2 expression
as enhanced in part of the CA1 area and in the dentate
yrus 6 h after a single intrahippocampal injection of BDNF.
imilarly, expression of the immediate early genes Arc and
Zif268 was enhanced in the same hippocampal areas, in ac-
cordance with their role in synaptic plasticity. Immunoblot
analysis confirmed the significant enhancement in MCT2 pro-
tein expression. In contrast, no changes were observed for
the glial monocarboxylate transporters MCT1 and MCT4.
When other synaptic proteins were investigated, it was found
that postsynaptic density 95 (PSD95) and glutamate receptor
2 (GluR2) protein levels were significantly enhanced while no
effect could be detected for synaptophysin, synaptosomal-
associated protein 25 (SNAP25), CaMKII and GluR1. These
results demonstrate that MCT2 expression can be upregu-
lated together with other key postsynaptic proteins in vivo
under conditions related to synaptic plasticity, further sug-
gesting the importance of energetics for memory formation.
© 2011 IBRO. Published by Elsevier Ltd. All rights reserved.
Key words: energy metabolism, hippocampus, lactate, syn-
apses/dendrites, trophic factors.
The neurotrophin brain-derived neurotrophic factor (BDNF)
plays an important role in activity-dependent synaptic plastic-
ity mechanisms such as long-term potentiation (LTP) (Bram-
ham and Messaoudi, 2005). Moreover, it has been proposed
to participate in processes leading to memory formation
(Yamada and Nabeshima, 2003). Indeed, several studies
have shown an increase in BDNF mRNA expression and
TrkB activation during memory acquisition and consolidation
*Corresponding author. Tel: 41-21-692-5547; fax: 41-21-692-5505.
-mail address: Luc.Pellerin@unil.ch (L. Pellerin).
bbreviations: Arc, activity-regulated cytoskeleton-associated protein;
DNF, brain derived neurotrophic factor; GluR, glutamate receptors;
EGs, immediate early genes; LTP, long-term potentiation; MCTs, mono-
arboxylate transporters; PBS, phosphate buffered saline; PSD95, post-
ynaptic density 95; SNAP25, synaptosomal-associated protein 25;
BST, Tris-buffered saline supplemented with Tween-20; Zif268, zinc-
nger proteins; CamKII, acalmodulin kinase II.
0306-4522/11 $ - see front matter © 2011 IBRO. Published by Elsevier Ltd. All righ
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155(reviewed in Yamada and Nabeshima, 2003). Application of
BDNF to hippocampal slices facilitates the induction of syn-
aptic potentiation and enhances basal synaptic transmission
in CA1 pyramidal neurons (Ji et al., 2010). Similarly, acute
intrahippocampal infusion of BDNF leads to a long-lasting
enhancement of synaptic transmission in the rat dentate
gyrus (Messaoudi et al., 1998) and induces LTP in intact
adult hippocampus (Ying et al., 2002). The BDNF-induced
long-lasting potentiation requires extracellular signal-regu-
lated protein kinase (ERK) pathway activation and the up-
regulation of Arc and Zif268 synthesis (Rosenblum et al.,
2002; Ying et al., 2002). Arc and Zif268 are two immediate
early genes (IEGs) transiently and rapidly activated during
LTP as well as along the process of learning and memory
formation (Davis et al., 2003; Plath et al., 2006; Lonergan et
al., 2010). Ultimately, it is purported that BDNF exerts its
effect on synaptic function by regulating local translation of a
specific subset of synaptic proteins (Santos et al., 2010).
While a few of these proteins have been described, more
remain to be identified. Moreover, BDNF-induced enhance-
ment in expression of several key synaptic proteins still
awaits confirmation in vivo.
Apart from classical proteins involved in synaptic trans-
ission, BDNF possibly regulates the expression of proteins
nvolved in other cellular functions. In this regard, putative
hanges in energetics occurring upon synaptic plasticity and
ossible regulation of associated proteins have not been
xplored. Recently, the role of monocarboxylates, and par-
icularly lactate, as additional energy substrates for neurons
as attracted attention (Pellerin, 2003). Release and uptake
f these substrates are dependent on the presence of spe-
ific carriers known as monocarboxylate transporters (MCTs)
hat are expressed by both neurons and glial cells (Pierre and
Pellerin, 2005). Possible BDNF-mediated alteration in ex-
pression of these transporters in vivo has never been inves-
tigated. In the present study, the level of expression of six
synaptic proteins, two IEGs, as well as three monocarboxy-
late transporters were determined inmouse hippocampus 6 h
after a single intrahippocampal infusion of BDNF. Results
clearly indicate that the neuronal monocarboxylate trans-
porter MCT2 is one of the key postsynaptic proteins upregu-
lated as part of the synaptic changes induced by BDNF.
EXPERIMENTAL PROCEDURES
Animals
Seven-week-old C57Bl/6Rj male mice (20 g) were obtained from
the Janvier Breeding Center (Le Genest Saint-Isle, France) and
received 1 week prior to the experiments to acclimatize them to
ts reserved.
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C. Robinet and L. Pellerin / Neuroscience 192 (2011) 155–163156the animal facility. They were housed in a temperature-controlled
environment with 12:12 h. light-dark cycle and given free access
to food and water. Animal experiments were performed in accor-
dance with the Animal Care and Use Committee guidelines (Ser-
vice vétérinaire du Canton de Vaud, Switzerland).
Surgery and intrahippocampal injection of BDNF
Mice were weighed and anesthetized by i.p. injection with a mix-
ture of ketamine (24 l) and xylazine (10 l) diluted in 100 l NaCl
0.9%, and positioned in a stereotaxic apparatus (Stoelting, Wood
Dale, IL, USA). Rectal temperature was maintained at 36 °C with
a thermostatically controlled electric heating pad. Stereotaxic co-
ordinates relative to bregma were anteroposterior (AP): 1.85;
mediolateral (ML): 1.25; dorsoventral (DV): 1.4. A single intra-
hippocampal injection was performed using a 5 l Hamilton sy-
ringe with a 33-gauge needle. The needle was inserted into the
dorsal hippocampal CA1 area and 2 l of phosphate buffered
aline (PBS) or 2 g of BDNF in 2 l PBS were injected slowly
during 20 min (brain-derived neurotrophic factor human, recom-
binant expressed in E. coli, Sigma, Buchs, Switzerland). Mice
completely recovered 1 h after the surgery. Mice were sacrificed
6 h after the end of surgery.
Western blotting and related quantification
Once mice had been sacrificed, the brain was rapidly removed
and put into a cold solution of phosphate buffered saline (PBS
1). Hippocampi were rapidly dissected on ice, directly freezed in
liquid nitrogen and stored at 80 °C.
For Western blotting, hippocampal tissue was homogenized
and sonicated in a 0.32 M sucrose solution containing HEPES 1
mM, MgCl2 1 mM, NaHCO3 1 mM, phenyl-methyl-sulfonyl fluoride
0.1 mM, pH 7.4, in presence of a complete set of protease
inhibitors (Complete; Roche, Mannheim, Germany). Protein con-
centrations were determined by the BCAmethod. Ten micrograms
of protein were heated at 95 °C in SDS-PAGE sample buffer (62.5
mM Tris–HCl, 50 mM DTT, 2% SDS, 10% glycerol and 0.1%
Bromophenol Blue) and loaded onto 10% polyacrylamide gels.
After electrophoresis, samples were transferred on nitrocellulose
membranes (Bio-Rad Laboratories, Reinach, Switzerland). For
protein detection, membranes were incubated in a blocking solu-
tion of Tris-buffered saline supplemented with Tween-20 (TBST;
Tris–HCl 50 mM pH 7.5, NaCl 150 mM, and Tween-20, 0.1%)
containing 5% nonfat milk for 1 h at room temperature. Mem-
branes were incubated overnight at 4 °C with a mixture containing
the primary antibodies: anti-MCT4 (Santa Cruz Biotechnology,
Heidelberg, Germany), anti-GluR1 and anti-GluR2/3 (Chemicon,
CA, USA) diluted 1:500; anti-MCT1 and anti-MCT2 antibodies
(developed and characterized by our group, as described in Pierre
et al., 2000), anti-synaptophysin (Sigma, Buchs, Switzerland),
anti-SNAP25 (Alomone Labs, Jerusalem, Israel), anti-PSD95 and
anti-CamKII (Cell Signaling, Allschwil, Switzerland) diluted
:1000; anti-actin (Sigma, Buchs, Switzerland), diluted 1:10000;
nti-tubulin (Sigma, Buchs, Switzerland), diluted 1:1000. These
ntibodies were diluted in TBS, 0.1% Tween, 5% bovine serum
lbumin (BSA). After three washes in TBST, membranes were
ncubated with the secondary antibodies Alexa Fluor 680 goat anti
gG (Juro, Luzern, Switzerland) and IRDye_800 antimouse IgG
BioConcept, Allschwil, Switzerland), diluted at 1:5000 in TBST
ontaining 1% nonfat milk, for 2 h at room temperature, and
rotected from light. For anti-MCT1, peroxydase-conjugated don-
ey anti-rabbit IgG was used as secondary antibodies (Amer-
ham, Piscataway, NJ, USA) diluted 1:10000. After three washes
n TBST, membranes were scanned and quantified with the
dyssey®Infrared Imaging System (LI-COR® Biosciences, Lin-
oln, NE, USA). For MCT1 detection, Enhanced Chemilumines-
ence (ECL) was required for detection and ImageJ softwarehttp://rsbweb.nih.gov/ij/) was used for the quantification. -actin
or -tubulin was used for normalization of proteins of interest.
Immunohistochemistry
Under urethane anaesthesia (1.5 g/kg, i.p.), animals were per-
fused intracardially with a heparinized solution of saline (25 IU/ml
in 0.9% NaCl, during 2 min) followed by a freshly prepared solu-
tion of 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.4,
for 15 min). Brains were removed and fixed in 4% paraformalde-
hyde for 2 h, then cut on a vibratome (Leica VT1000M; Leica
Microsystems, Heerbrugg, Switzerland) to obtain coronal sections
(40 m thick), which were collected in PBS. Sections were rinsed
everal times in PBS and incubated with casein (0.5% in PBS) for
h to block non-specific sites. They were incubated overnight at
°C in freshly prepared primary antibody solution diluted in PBS
ontaining 0.25% BSA: anti-MCT2 (1:500), anti-MAP2 (1:200;
igma, Buchs, Switzerland), anti-Arc (1:200; Santa Cruz Biotech-
ology, Heidelberg, Germany), anti-EGR1 (1:500; Cell Signaling,
llschwil, Switzerland).
After careful rinsing in PBS, sections were incubated in a
olution containing Cy3-conjugated anti-rabbit Igs (diluted 1:500,
h, room temperature; Jackson Immunoresearch, West Grove,
A, USA) and/or anti-mouse FITC-conjugated Igs (diluted 1:200,
h, room temperature; Jackson Immnoresearch, West Grove, PA,
SA). After rinsing in PBS twice and a final rinsing in water, slices
ere mounted with Vectashield-DAPI (Reactolab SA, Servion,
witzerland).
Microscopy
Brain slices were examined and photographed with an Eclipse 80i
microscope (Nikon, Kingston, England) using epifluorescence
with an appropriate filter together with the NIS-Elements Micro-
scope Imaging 5.1 software (Nikon, Kingston, England). They
were also examined under a Zeiss LSM 710 Quasar confocal
microscope using the DPSS 561-10, 561 nm laser illumination.
Stacks were made of images taken with 0.5–0.8 m step size.
ictures were treated with Imaris software, version 7.0.0.
Statistical analysis
All values are presented as meanSEM. Mann–Whitney’s test, or
one-way ANOVA followed by Dunnett’s post hoc test were used
for data analysis with GraphPad Prism® software, version 5.0 (La
Jolla, CA, USA). P-values 0.05 were considered as statistically
significant.
RESULTS
Intrahippocampal injections of BDNF (or PBS) were made
in the right (or left) hippocampus of 7 week-old C57/Bl6
mice. Six hours later, hippocampal expression of MCT2
was examined by immunohistochemistry on coronal sec-
tions taken at different levels along the anteroposterior
axis. Results showed that MCT2 immunofluorescence was
stronger in a portion of the pyramidal cell layer of the CA1
area as well as in the granule cell layer of the dentate gyrus
for the BDNF-injected hippocampus compared to the con-
tralateral, PBS-injected structure, as indicated by arrows
(Fig. 1). No sign of lesion was detected in the surroundings
of the needle tract. Confocal microscopy showed at high
magnification a visible increase of MCT2 staining in neu-
rons after BDNF treatment compared to PBS control (Fig.
2). Under the same conditions, the expression of two im-
mediate early genes, Arc and Zif268, known to be impli-
t
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tochemistry. Double immunostainings for Arc or Zif268
proteins with the neuronal marker MAP2 revealed an en-
hancement in neuronal expression of these two immediate
early gene products after BDNF injection compared to PBS
control in the same hippocampal area as for MCT2 (Fig. 3).
Based on the comparison of all immunostainings per-
formed in the present study, BDNF did not systematically
and significantly altered the level of MAP2 expression (nor
its co-localization with MCT2), in agreement with observa-
tions reported in the literature (Labelle and Leclerc, 2000;
Schäbitz et al., 2004).
In order to further characterize the extent and nature of
the changes induced by BDNF, expression levels of sev-
eral synaptic and extra-synaptic proteins, including MCT2,
were determined by immunoblot on hippocampal extracts.
Fig. 1. Effect of acute intrahippocampal injection of BDNF in vivo on
hree different hippocampal levels 6 h after injection of either PBS (left
immunolabelling is visible in portions of the hippocampus injected with
Magnification, 10; calibration bar, 100 m. Numbers at the bottom rWestern blot analysis of hippocampal extracts from BDNF-injected tissue showed a significant increase (12512%
vs. control) of MCT2 expression compared to control (no
injection, contralateral side) or PBS-injected animals (Fig.
4A). Basal hippocampal MCT2 expression levels were not
different between anesthetized (Keta/Xyla) and unanes-
thetized (Keta/Xyla) mice, excluding a confounding effect
of anesthesia (Fig. 4B). Expression levels of MCT1 and
MCT4, two other monocarboxylate transporters present in
the brain but predominantly on glial cells, were not altered
(Fig. 4C, D, respectively).
In parallel to monocarboxylate transporters, the effect of
BNDF on the hippocampal expression of several pre- and
postsynaptic proteins was determined by Western blot (Fig.
5A). Quantitative analysis of immunoblots for synaptophysin
and synaptosomal-associated protein 25 (SNAP25), two pre-
synaptic proteins, showed no expression change 6 h after
otein expression. MCT2 immunolabelling in coronal brain sections at
or 2 g BDNF (right column). As pointed out by white arrows, stronger
mpared to PBS, particularly in the CA1 area and in the dentate gyrus.
ight column images refer to position from bregma.MCT2 pr
column)BDNF injection (Fig. 5B, C, respectively). A similar analysis
o
6
n
o
C. Robinet and L. Pellerin / Neuroscience 192 (2011) 155–163158on some postsynaptic proteins gave differential results. No
expression change was observed for the protein kinase
CamKII and the glutamate receptor subunit GluR1 (Fig. 5D,
F). In contrast, a significant increase of the postsynaptic
density scaffold protein postsynaptic density 95 (PSD95)
(1189%) and of the glutamate receptor subunit GluR2/3
(1247%) compared to control (no injection) was observed
6 h after BDNF injection (Fig. 5E, G).
DISCUSSION
As it is proposed to provide the underlying mechanism
subserving learning and memory processes, synaptic plas-
ticity is the subject of intense attention. Brain-derived neu-
rotrophic factor represents an essential signal released
under learning-associated conditions that contributes to
the modifications of synaptic transmission taking place in
this context (Gottmann et al., 2009; Yoshii and Constan-
tine-Paton, 2010). Then, activation of TrkB receptors by
BDNF leads to a cascade of events including transcrip-
tional and translational steps that will result in the synthesis
of a specific subset of synaptic proteins (Santos et al.,
2010). However, relatively few informations exist in vivo
about the specific proteins that are subject to regulation by
BDNF. Moreover, evidence for a possible modulation of
proteins essential in energy metabolism are scarce and
limited to in vitro (Burkhalter et al., 2007; Robinet and
Pellerin, 2010). This question was addressed here by in-
vestigating the putative changes in expression of several
key synaptic proteins including monocarboxylate trans-
porters, a group of proteins involved in energy substrate
transfer and supply to neurons, following an intrahip-
Fig. 2. Effect of acute intrahippocampal injection of BDNF in vivo on
rescent labellings for the neuronal marker MAP2 (green) and MCT2
h from animals injected with either PBS (top row) or 2 g BDNF (bot
eurons after BDNF injection compared to control (PBS). Pictures we
f 18 sections of 0.5 m. Magnification, 63; calibration bar, 15 m.pocampal BDNF injection.MCT2 is the predominant monocarboxylate transporter
expressed by neurons whereas MCT1 and MCT4 are ex-
pressed by glial cells (Pellerin et al., 2005). At the subcel-
lular level, MCT2 is expressed on axons and dendrites
(Pierre et al., 2002, 2009). Moreover, MCT2 is present at
glutamatergic synapses and exclusively on postsynaptic
elements (Bergersen et al., 2002; Pierre et al., 2009). It is
particularly enriched in the postsynaptic density of asym-
metric synapses as well as in an intracellular pool within
spines (Bergersen et al., 2005). Recently, it was demon-
strated in cultured neocortical neurons that BDNF induces
the expression of MCT2 via a regulation of local translation
(Robinet and Pellerin, 2010). Data obtained in the present
study showing increased MCT2 protein levels after BDNF
injection further extend this observation to the hippocam-
pus in vivo.
Interestingly, this increased neuronal expression of
MCT2 in the hippocampus following BDNF injection is
matched in terms of distribution by a similar enhancement
in neuronal expression of both Arc and Zif268 proteins.
Induction of the IEGs Arc (also known as Arg3.1) and
Zif268 (also known as EGR1) is required for late long-term
potentiation (l-LTP) and long-term memory formation (Gu-
zowski et al., 2000; Jones et al., 2001). In parallel, BDNF-
induced long-lasting potentiation leads to an upregulation
of Arc and Zif268 synthesis (Rosenblum et al., 2002; Ying
et al., 2002). Arc mRNA is rapidly transported to dendrites
and translated locally where it plays a critical role in local
translation as well as in trafficking of AMPA receptors
(Bramham et al., 2008). In parallel, Zif268 regulates the
transcription of some late response genes and is involved
MCT2 expression in the hippocampal CA1 area. Double immunoflu-
oronal hippocampal sections (2.06 mm from bregma) obtained after
. A stronger MCT2 immunolabelling is clearly visible in CA1 pyramidal
d with a confocal microscope and images correspond to a projectionneuronal
(red) in c
tom row)
re obtainein the degradation of synaptic proteins as well as in recep-
compared
nification
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spatially and timely related appearance, it is not excluded
that Arc and Zif268 could be involved in the regulation of
MCT2 expression and subcellular distribution induced by
BDNF. Indeed, it was previously shown that BDNF-in-
duced upregulation of MCT2 protein expression in cultured
neurons requires a transcriptional step although MCT2
mRNA levels were not affected (Robinet and Pellerin,
2010). Thus, transcriptional activation of Arc and Zif268
might be critical to allow a translationally regulated en-
hancement of MCT2 protein levels. Such a possibility will
Fig. 3. Effect of acute intrahippocampal injection of BDNF in vivo o
immunofluorescent labellings for the neuronal marker MAP2 (green) a
bregma) obtained after 6 h from animals injected with either PBS (top
Zif268 is observed in CA1 hippocampal neurons after BDNF injection
and images correspond to a projection of 18 sections of 0.5 m. Magrequire to be further investigated both in vitro and in vivo.BDNF was shown previously in vitro to enhance the
expression of a few synaptic proteins. PSD95 is a scaffold
protein of the postsynaptic density that plays an important
role in synaptic plasticity (Gardoni et al., 2009). BDNF can
induce the transport of PSD95 to dendrites and it was
suggested that activation of the PI3K–Akt pathway by
BDNF could lead to enhanced PSD95 synthesis (Yoshii
and Constantine-Paton, 2007). Indeed, it was reported that
activation of the PI3K–Akt pathway causes an increase of
PSD95 expression in hippocampal slices (Lee et al.,
2005). In cultured cortical neurons, BDNF was shown to
al Arc and Zif268 expression in the hippocampal CA1 area. Double
Arc or Zif268 (red) in coronal hippocampal sections (2.06 mm from
2 g BDNF (bottom rows). A strong immunolabelling for both Arc and
to control (PBS). Pictures were obtained with a confocal microscope
, 40; calibration bar, 20 m.n neuron
nd either
rows) orenhance PSD95 protein expression (Matsumoto et al.,
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C. Robinet and L. Pellerin / Neuroscience 192 (2011) 155–1631602006). Our data provide a confirmation that BDNF can
enhance PSD95 protein levels in vivo, supporting the idea
that more PSD95 proteins are necessary to sustain BDNF-
induced synaptic modifications. PSD95 colocalizes with
MCT2 both in vitro and in vivo (Pierre et al., 2009). As
SD95 is a necessary component of the postsynaptic
ensity, it might be required to ensure proper insertion of
ewly formed MCT2 in the postsynaptic membrane.
AMPA-type glutamate receptors are composed of distinct
ubunits known as GluR1 to GluR4. The synaptic distribution
nd levels of GluR1 and GluR2 subunits have been shown to
e modulated as part of the mechanism of synaptic plasticity
Sprengel, 2006; Keifer and Zheng, 2010). It was demon-
trated in both neocortical and hippocampal neurons in cul-
ure that BDNF treatment causes an enhancement of GluR1
nd GluR2 protein expression levels (Narisawa-Saito et al.,
999; Matsumoto et al., 2006). Our observations in vivo that
DNF raises GluR2/3 protein levels partly confirm these
ata. It also emphasizes the important role that the GluR2
ubunit appears to play in synaptic plasticity (Isaac et
l., 2007; Bassani et al., 2009). MCT2 was shown pre-
iously to not only colocalize but also directly interact
Fig. 4. Effect of intrahippocampal injection of BDNF in vivo on MCT1,
), MCT1 (C) and MCT4 (D) expression in hippocampal protein extrac
ippocampi were used as control. Effect of anesthesia (Ketamine/xyla
B). Western blots were quantified using Odyssey software (LI-COR Bio
s percentage of control (meanSEM) after the values were norma
performed using one-way ANOVA followed by Dunnett’s test (A) or pe
levels significantly different from control (Ctrl) with P0.05. n6 miceith GluR2 (Pierre et al., 2009). Moreover, changes in the expression levels of MCT2 have been shown to
odify both the expression levels and the subcellular
istribution of GluR2 subunits (Maekawa et al., 2009).
hus, it appears that MCT2 and GluR2 must be concom-
tantly regulated in order to fulfill their respective roles in
he adaptation to changes in synaptic transmission.
In contrast to PSD95 and GluR2, no change could be
etected in the expression of several other proteins. This is
he case for the other monocarboxylate transporters MCT1
nd MCT4. Since these transporters are rather expressed
y glial cells, regulation of their expression might be under
he control of other signals that remain to be identified. The
rotein kinase calmodulin kinase II (CamKII) is a post-
synaptic protein that has been involved in the process of
synaptic plasticity (Miyamoto, 2006). BDNF has been re-
ported to enhance CamKII protein levels, notably in syn-
aptosomes (Schratt et al., 2004). Surprisingly, no change
in CamKII protein levels could be evidenced in vivo under
our experimental conditions. Similarly, the expression of
the GluR1 subunit was not modified despite being en-
hanced by BDNF in vitro (Matsumoto et al., 2006). A
ossible explanation for these differences could be related
d MCT4 protein expression levels. Western blot analysis of MCT2 (A,
ippocampi were injected with 2 g BDNF and collected after 6 h. Left
hippocampal MCT2 protein expression was also performed as control
) or ImageJ software (http://rsbweb.nih.gov/ij/). Results are expressed
ng -actin or -tubulin signal as reference. Statistical analysis was
using a Mann–Whitney’s test (B–D). Asterisk indicates MCT2 protein
condition.MCT2 an
ts. Right h
zine) on
sciences
lized usio our experimental protocol. Since a single dose of BDNF
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using -
M levels dif
C. Robinet and L. Pellerin / Neuroscience 192 (2011) 155–163 161was used and observation was made at only one time-
point, possible changes in GluR1 and CamKII protein
xpression might have been overlooked. Moreover, since
ippocampal extracts were prepared from the entire hip-
ocampus while the effect of injected BDNF was restricted
o only portions of the tissue, putative differences might
ave been diluted in Western blot analyses. Further ex-
eriments investigating changes in expression at different
imes after BNDF injection (and at different doses), as well
s using more restricted portions of the hippocampus, will
Fig. 5. Effect of intrahippocampal injection of BDNF in vivo on expr
analysis of synaptophysin, SNAP25, CamKII, PSD95, GluR1 and Gl
njected with 2 g BDNF and collected after 6 h. Left hippocampi wer
C), CamKII (D), PSD95 (E), GluR1 (F) and GluR2/3 (G), perform
percentage of control (meanSEM) after the values were normalized
ann–Whitney’s test. Asterisk indicates PSD95 and GluR2/3 proteine needed to clarify this point. (The presynaptic proteins synaptophysin and SNAP25
re involved in the mechanism of vesicle-dependent neu-
otransmitter release (Valtorta et al., 2004). BDNF was re-
orted to enhance the expression of synaptophysin but not
NAP25 in neocortical neuronal cultures (Matsumoto et al.,
006). In our study, protein levels of synaptophysin and
NAP25 were not altered by intrahippocampal infusion of
DNF. The difference between in vitro and in vivo results
ight come from the developmental stage of each prepara-
ion. Since BDNF is known to promote synaptic maturation
vels of several presynaptic and postsynaptic proteins. Western blot
pression on hippocampal protein extracts (A). Right hippocampi were
s control. Western blot quantification for synaptophysin (B), SNAP25
dyssey software (LI-COR Biosciences). Results are expressed as
actin signal as reference. Statistical analysis was performed using a
ferent from control (Ctrl) with P0.05. n6 mice for each condition.ession le
uR2/3 ex
e used a
ed with OGottmann et al., 2009), involving synthesis of pre- and post-
r
o
b
I
p
t
a
s
M
z
e
e
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c
C. Robinet and L. Pellerin / Neuroscience 192 (2011) 155–163162synaptic proteins, such an effect might be more prominent in
cultured cells prepared from embryonic animals than in adult
mice.
Our data emphasize the fact that neuronal expression
of MCT2, in parallel with other proteins known or highly
suspected to participate in the mechanism of synaptic
plasticity such as the immediate early genes Arc and
Zif268, the postsynaptic scaffold protein PSD95 as well as
the AMPA receptor GluR2 subunit, is upregulated by
BDNF in the hippocampus in vivo. Considering the critical
ole of MCT2 in lactate uptake and utilization by neurons,
ur results point to the intriguing possibility of a coupling
etween neuronal lactate utilization and synaptic plasticity.
ndeed, the concept that energy metabolism might be cou-
led to synaptic plasticity has been proposed together with
he implication of BDNF in such interactions (Vaynman et
l., 2006; Gomez-Pinilla et al., 2008). In addition, a recent
tudy has shown that lactate import into neurons through
CT2 is necessary for long-term memory formation (Su-
uki et al., 2011). In this context, it is tempting to hypoth-
size that to meet higher energy demands caused by
nhanced synaptic transmission after synaptic plasticity,
ncreased MCT2 expression induced by BDNF would fa-
ilitate lactate supply at potentiated synapses.
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